Document:

EX-10.4

 Exhibit 10.4 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED 

BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE 

THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. 

OYSTER POINT MARINA PLAZA 

OFFICE LEASE 
 of

 SUITE 217 
 to

 DAY ONE THERAPEUTICS, INC., 

a Delaware corporation 

395 OYSTER POINT BOULEVARD 

SOUTH SAN FRANCISCO, CA 94080 

 OYSTER POINT MARINA PLAZA 

OFFICE LEASE 
 THIS OFFICE
LEASE (the “Lease”) is entered into as of February 8, 2020, by and between KASHIWA FUDOSAN AMERICA, INC., a California corporation (“Landlord”) and DAY ONE THERAPEUTICS, INC., a Delaware corporation (“Tenant”).

 1 BASIC LEASE TERMS 
 1.1
LEASE OF PREMISES. Landlord leases to Tenant, and Tenant rents and hires from Landlord, the premises described in § 1.3 below, in the building known by the street address 395 Oyster Point Boulevard (the “Building”) in the City
of South San Francisco, County of San Mateo, State of California, on the property described in § 1.6 below, in the business park commonly known as Oyster Point Marina Plaza (the “Complex”), for the term stated in § 1.4 below, for
the rents hereinafter reserved, and upon and subject to the terms, conditions (including limitations, restrictions, and reservations), and covenants hereinafter provided. The Building and the Complex are more particularly described and depicted in
Exhibit A which is attached hereto. Each party hereby expressly covenants and agrees to observe and perform all of the conditions and covenants herein contained on its part to be observed and performed.

 1.2 SUMMARY TABLE. The parties agree that the following table (the “Table”) sets forth in summary form the basic terms of this
Lease, including the specific space comprising the Premises and, with respect to such space, the Term of the Lease, the usable and rentable square footage, the Base Rent, Base Year, and Tenant’s Share, as all of such terms are defined below:

  

																													
	 PERIOD
	  	SUITE NO.	 	  	RSF	 	  	USF	 	  	MONTHLY
BASE RENT	 	  	T’s SHARE
BLDG	 	 	T’s SHARE
COMPLEX	 	 	BASE
YEAR	 
	 March 1, 2020 through February 28, 2021
	  	 	217	 	  	 	4,759	 	  	 	3,965	 	  	$	16,656.50	 	  	 	2.035	% 	 	 	1.018	% 	 	 	2020	 
	 March 1, 2021 through February 28, 2022
	  	 	217	 	  	 	4,759	 	  	 	3,965	 	  	$	17,156.20	 	  	 	2.035	% 	 	 	1.018	% 	 	 	2020	 
	 March 1, 2022 through February 28, 2023
	  	 	217	 	  	 	4,759	 	  	 	3,965	 	  	$	17,670.88	 	  	 	2.035	% 	 	 	1.018	% 	 	 	2020	 

 In the event of any conflict between the terms contained in the Table and the terms contained in subsequent sections of the
Lease, the terms of the Table shall control, except that any dates stated in the Table are subject to adjustment as appropriate to the extent any other provisions of the Lease provide for adjustments to the Commencement Date and/ or the Expiration
Date. 
 1.3 PREMISES. The premises leased to Tenant comprise approximately 4,759 rentable square feet of space on the second (2nd) floor of
the Building and are commonly known as Suite 217 (the “Premises”), as outlined on the floor plan annexed hereto as Exhibit B (the “Space Plan”) together with details of improvements described on the Space
Plan to be constructed in accordance with the provisions of § 3.2 below. The Premises also include all fixtures and equipment which are attached thereto, except items not deemed to be included therein and which are removable by Tenant as
provided in Article 10 below. Landlord and Tenant agree that the usable and rentable area of the Premises, and the respective rentable areas of the Property (as defined in § 1.6 below) and Complex, for all purposes under this Lease, are as
follows and as specified in the Table: 
 Property’s Rentable Area:         233,914 rsf 

Complex’s Rentable Area:        467,360 rsf 

 Tenant acknowledges that it has caused its architect to verify the numbers stated in the Table and herein
relating to the measurements of such spaces prior to the Commencement Date of this Lease or has had an opportunity to do so. 
 1.4 TERM;
COMMENCEMENT DATE. The term (the “Term”) for which the Premises are hereby leased shall extend for a period of three (3) years, shall commence on March 1, 2020 (the “Commencement Date”), and shall end at noon on
February 28, 2023, (the “Expiration Date”) or any earlier date upon which the Term may expire or be cancelled or terminated pursuant to any of the conditions or covenants of this Lease or pursuant to law. Promptly following the
Commencement Date the parties hereto shall, if required by Landlord, enter into a supplementary agreement fixing the dates of the Commencement Date and the Expiration Date in the form which is attached hereto as Exhibit E and
incorporated herein by reference. 
 1.4.1 Option to Renew. Tenant is hereby granted one (1) option to extend (the
“Extension Option”) the Term of the Lease for one (1) additional period of three (3) years (the “Extension Period”). The Extension Period term shall begin the first day following the Expiration Date and shall take
effect on the same terms and conditions in effect under the Lease immediately prior to the Extension Period, except that (i) Tenant shall have no further right to extend and (ii) monthly Base Rent shall be the rate which is Fair Market
Value (as defined below). The Fair Market Value shall be the effective rent (face rate less free rent) being charged for comparable space in comparable buildings in the vicinity of the Building leased on comparable terms and shall be limited to the
rates charged in such comparable transactions for tenants renewing or extending their leases. 
 (a) Exercise of Option. The
Extension Option may be exercised only by (i) delivering in person to Landlord’s Building Manager in the Building Office written notice of Tenant’s irrevocable election to exercise no earlier than nine (9) months and no later
than six (6) months prior to the commencement of the Extension Period, and (ii) collecting and retaining in exchange for such notice of exercise an original written receipt therefor signed and dated by Landlord’s Building Manager.
Tenant’s exercise of its Extension Option shall not be effective or valid if there is any deviation in the timing or manner of exercise prescribed herein. 

(b) Failure to Exercise. If Tenant shall fail validly and timely to exercise the Option herein granted, said Option shall
terminate and shall be null and void and of no further force and effect. 
 (c) Fair Market Value. Provided that Tenant has
validly exercised its Option when and as required hereunder, not less than one hundred and eighty (180) days prior to the commencement of the Extension Period, Landlord shall provide written notice to Tenant of its determination of the Fair
Market Value. Within ten (10) days after receiving such determination (“Tenant’s Review Period”), Tenant shall irrevocably elect, in writing, to do one of the following: (i) accept Landlord’s determination; or
(ii) object to Landlord’s determination and with such objection set forth in writing Tenant’s determination of the Fair Market Value. If Tenant so objects, Landlord and Tenant shall attempt in good faith to agree upon such Fair Market
Value using their best good-faith efforts. If Landlord and Tenant fail to reach agreement within fifteen (15) days following Tenant’s Review Period (the “Outside Agreement Date”), then each party’s determination shall be
submitted to arbitration in accordance with the then-current rules and procedures of the American Arbitration Association, but subject to the instructions set forth in this§ 1.4.1 et seq.. If Tenant objects to Landlord’s determination of
Fair Market Value, Tenant shall pay Rent at the Fair Market Value determined by Landlord until the matter is resolved by binding arbitration as provided below subject to retroactive adjustment after the matter is so resolved. If Tenant fails so to
accept or object to Landlord’s determination of Fair Market Value in writing within Tenant’s Review Period, Tenant shall conclusively be deemed to have approved of the Fair Market Value as determined by Landlord. The determination of the
arbitrators shall be limited solely to the issue of whether Landlord’s or Tenant’s submitted Fair Market Value for the Premises is the more accurate as determined by the arbitrators, taking into account the requirements of this§ 1.4.1
et seq. 

  
 2 

 (d) Appointment of Arbitrators. Not later than fifteen (15) days
following the Outside Agreement Date, Landlord and Tenant shall each appoint one arbitrator who shall by profession be a real estate broker who shall have been active over the ten-year period ending on the
date of such appointment in the leasing of commercial properties within northern San Mateo County. The determination of the arbitrators shall be limited solely to the issue of whether Landlord’s or Tenant’s submitted Fair Market Value for
the Premises is the more accurate as determined by the arbitrators, taking into account the requirements of this§ 1.4.1 et seq. 

(e) Appointment of Third Arbitrator. The two (2) arbitrators so appointed shall within fifteen (15) days of the date
of the appointment of the last-appointed arbitrator agree upon and appoint a third arbitrator, who shall be qualified under the same criteria as set forth hereinabove for qualification of the initial two arbitrators. 

(f) Arbitrators’ Decision. The three (3) arbitrators shall, within thirty (30) days of the appointment of the
third arbitrator, reach a decision as to whether the parties shall use Landlord’s or Tenant’s submitted Fair Market Value, and shall notify Landlord and Tenant thereof. The decision of the majority of the three (3) arbitrators shall
be binding upon Landlord and Tenant. The arbitrators shall not be permitted to set Fair Market Value to any level other than either Landlord’s or Tenant’s submitted Fair Market Value. 

(g) Failure to Appoint. If either Landlord or Tenant fails to appoint an arbitrator within fifteen (15) days after the
Outside Agreement Date, the arbitrator timely appointed by one of the parties shall reach a decision, notify Landlord and Tenant thereof, and such arbitrator’s decision shall be binding upon Landlord and Tenant. If the two (2) arbitrators
fail to agree upon and appoint a third arbitrator, both arbitrators shall be dismissed and the matter to be decided shall be forthwith submitted to arbitration under the Commercial Arbitration Rules of the American Arbitration Association then in
effect, but subject to the instructions set forth in this§ 1.4.1 et seq.. 
 (h) Cost of Arbitration. The cost of
arbitration shall be paid by Landlord and Tenant equally. 
 (i) Default. Tenant’s exercise of the Option shall, at
Landlord’s election, be null and void if Tenant is in Default on the date of Tenant’s notice of exercise or at any time thereafter and prior to commencement of the Extension Period. Tenant’s exercise of the Extension Option shall not
operate to cure any Default by Tenant nor to extinguish or impair any rights or remedies of Landlord arising by virtue of such Default. If the Lease or Tenant’s right to possession of the Premises shall terminate before Tenant shall have
exercised the Extension Option, then immediately upon such termination the Extension Option shall simultaneously terminate and become null and void. 

(j) Time. Time is of the essence of the Extension Option granted hereunder. 

1.5 RENT. The “Rent” reserved under this Lease, for the Term thereof, shall consist of the following: 

(a) “Base Rent” as set forth in the Table for the various spaces and periods described therein per month, which shall be
payable in advance on the first day of each and every calendar month during the Term of this Lease, except that Tenant shall pay the first month’s Base Rent due under the Lease upon the execution and delivery of this Lease by Tenant; and 

  
 3 

 (b) “Additional Rent” consisting of any and all other sums of money as
shall become payable by Tenant to Landlord hereunder; and Landlord shall have the same remedies for default in the payment of Additional Rent as for a default in payment of Base Rent). 

1.5.1 Payment of Rent. Tenant shall pay the Base Rent and Additional Rent promptly when due, without demand therefor and without
any abatement, deduction, or setoff whatsoever, except as may be expressly provided in this Lease. Tenant shall pay the Rent to Landlord, in lawful money of the United States of America, at Landlord’s office at the Complex or at such other
place, or to such agent and at such place, as Landlord may designate by notice to Tenant. If the Commencement Date occurs on a day other than the first day of a calendar month, the Base Rent for such calendar month shall be prorated based on a 30-day month, and the balance of the first month’s Base Rent theretofore paid shall be credited against the next monthly installment of Base Rent. Notwithstanding anything to the contrary in this Lease, Tenant
shall pay the first month’s Base Rent due hereunder, together with the Security Deposit due under§ 5.1 below, upon Tenant’s execution and delivery of this Lease to Landlord. 

1.5.2 Interest and Late Charges. If Tenant fails to pay any Rent when due, the unpaid amounts shall bear interest from the due
date until paid at a rate per annum equal to the Prime Rate plus five percent (5%) or, if less, at the highest rate of interest permitted by applicable law. As used herein, “Prime Rate” means the prime rate published in the Money Rates
section of the Wall Street Journal (Western edition) as the same may change from time to time or in a similar publication if the Wall Street Journal ceases publication or ceases publication of its Money Rates section during the Term. Tenant
acknowledges that the late payment of any monthly Rent will cause Landlord to lose the use of that money and incur costs and expenses not contemplated under this Lease, including administrative and collection costs and processing and account
expenses, the exact amount of which it is difficult to ascertain. Therefore, in addition to interest, if any such installment is not received by Landlord within five (5) days from the date it is due, Tenant shall pay Landlord a late charge
equal to ten percent (10%) of such installment. Landlord and Tenant agree that this late charge represents a reasonable estimate of such costs and expenses and is fair compensation to Landlord for the loss suffered from such nonpayment by Tenant. In
addition, any check returned by the bank for any reason will be considered late and will be subject to all late charges plus an additional returned check fee of Twenty Dollars ($20.00). After two such occasions upon which checks have been returned
in any twelve-month period, Landlord will have the right to require payment by a cashier’s check or money order. Acceptance of any interest or late charge shall not constitute a waiver of Tenant’s default with respect to such nonpayment by
Tenant nor prevent Landlord from exercising any other rights or remedies available to Landlord under this Lease or at law or in equity, unless the payment of such interest and late charges is accompanied by all rentals then due and owning
(notwithstanding anything to the contrary in§ 20.2.1 below). 
 1.6 PROPERTY. For the purposes of this Lease, the “Property”
shall mean the Building and any common or public areas or facilities, easements, corridors, lobbies, sidewalks, loading areas, driveways, landscaped areas, skywalk, parking garages and lots, and any and all other structures or facilities operated or
maintained in connection with or for the benefit of the Building, and all parcels or tracts of land on which all or any portion of the Building or any of the other foregoing items are located, and any fixtures, machinery, equipment, apparatus,
Systems and Equipment (as defined in § 1.6.5 below), furniture and other personal property located thereon or therein and used in connection therewith, whether title is held by Landlord or its affiliates. The Property shall also be deemed to
include such other of the Complex’s buildings or structures (and related facilities and parcels on which the same are located) as Landlord shall have incorporated by reference to the total square footage of the Building stated in § 1.3
above. 
 1.6.1 Common Areas. Tenant and its agents, employees, and invitees shall have the
non-exclusive right with others designated by Landlord to the free use of the common areas in the Property and the Complex for the common areas’ intended and normal purpose. The term common areas shall
mean elevators, sidewalks, parking areas, driveways, hallways, stairways, public restrooms, common entrances, lobbies, and other similar public areas and access ways. 

  
 4 

 1.6.2 Athletic Facility. Notwithstanding the foregoing, the common areas do
not include the Building’s athletic facility (the “Athletic Facility”), which is an unsupervised and unattended weight and exercise room and shower facility. Tenant acknowledges that Landlord presently makes available (but is not
obligated under this Lease to make available) the Athletic Facility for the general use of all tenants and their officers and employees, subject to such rules and regulations as Landlord may impose from time to time in its sole and absolute
discretion regarding the use thereof. Tenant shall cause each of its officers and employees using the Athletic Facility to sign and deliver to Landlord an “Athletic Facility Use Agreement” in the form attached hereto as Exhibit
D, as such form may be revised by Landlord from time to time in its sole and absolute discretion. Tenant understands and agrees that no individual shall be permitted use of or access to the Athletic Facility unless and until such individual
shall have first signed and delivered the Athletic Facility Use Agreement to Landlord. Landlord shall have the right to limit the use of the Athletic Facility in any manner it may deem necessary, or to discontinue the Athletic Facility altogether,
at any time, in its sole and absolute discretion, and neither Tenant nor its officers or employees shall be entitled to any compensation, credit, allowance, or offset of expenses or Rent as a result of any such limitation or discontinuance. 

1.6.3 Reservation to Landlord. Notwithstanding anything to the contrary herein, possession of areas necessary for utilities,
services, safety, and operation of the Property, including the Systems and Equipment, telephone closets (whether located in the common areas or in the Premises), fire exits and stairways, perimeter walls, space between the finished ceiling of the
Premises and the slab of the floor or roof of the Property thereabove, and the use thereof, together with the right to install, maintain, operate, repair, and replace any part of the Systems and Equipment in, through, under, or above the Premises in
locations that will not materially interfere with Tenant’s use of the Premises, are hereby excepted from both the Premises and the common areas and are reserved by Landlord and not demised to Tenant. Tenant’s access to the telephone
closets on each floor and the Building’s main telephone room shall be subject to the Rules (as defined in§ 13.1 below) and shall be permitted only with Landlord’s written consent and under the supervision of Landlord’s Building
Engineer on each occasion that such access is sought. 
 1.6.4 Changes and Alterations of the Property. Landlord reserves the
right to make repairs, alterations, additions, or improvements, structural or otherwise, in or to the Property or Complex as deemed necessary or desirable in Landlord’s sole and absolute discretion, so long as such repairs or alterations do not
materially and unreasonably interfere with Tenant’s access to or beneficial use of the Premises for their intended purposes. Landlord reserves the right hereunder to do the following: (i) install, use, maintain, repair, and replace pipes,
ducts, conduits, wires, and appurtenant meters and equipment for service to the various parts of the Property above the ceiling surfaces, below the floor surfaces, within the walls, and in the central core areas; (ii) to relocate any pipes,
ducts, conduits, wires, and appurtenant meters and equipment which are located in the Premises or located elsewhere outside the Premises; (iii) expand the Building or the Complex; (iv) make changes to the Property or the Complex, including
changes, expansions, and reductions in the location, size, shape, and number of driveways, entrances, loading and unloading areas, ingress, egress, direction of traffic, landscaped areas, walkways, parking spaces, and parking areas; (v) close
any of the common areas, so long as reasonable access to the Premises remains available; (vi) use the common areas while engaged in making additional improvements, repairs, or alterations to the Property, Complex, or any portion thereof; and
(vii) do and perform such other acts and make such other changes in, to, or with respect to the Property, Complex, common areas, and Building as Landlord may deem appropriate . The exercise of any of the foregoing rights shall not subject
Landlord to claims for constructive eviction, abatement of Rent, damages, or other claims of any kind, except as otherwise expressly provided in this Lease. If Landlord enters the Premises to exercise any of the foregoing rights, Landlord shall
provide reasonable advance written or oral notice to Tenant’s on-site manager. 

  
 5 

 1.6.5 Systems and Equipment. As used in this Lease, “Systems and
Equipment” means collectively any existing plant, machinery, transformers, duct work, intrabuilding network cables and wires that transmit voice, data, and other telecommunications signals (“INC”), and other equipment, facilities, and
systems designed to supply water, heat, ventilation, air conditioning and humidity or any other services or utilities, or comprising or serving as any component or portion of the electrical, gas, steam, plumbing, sprinkler, communications, alarm,
security, or fire/life/ safety systems or equipment, or any other mechanical, electrical, electronic, computer or other systems or equipment for the Property. 

2 USE 
 2.1 USE AND ENJOYMENT OF
PREMISES. Tenant shall use and occupy the Premises for executive and general offices and for no other purpose. Notwithstanding anything contained herein to the contrary, Tenant may use portions of the Premises not to exceed one hundred fifty
(150) usable square feet for the preparation and reheating of food and beverages, including the use of refrigerators, ice makers, coffee machines, hot plates, microwave ovens, or similar heating devices (but not for the actual cooking of food)
for service only to Tenant’s employees and business invitees. 
 2.1.1 Suitability. Tenant acknowledges that neither
Landlord nor any agent of Landlord has made any representation or warranty with respect to the Premises, the Property, or the Complex, or with respect to the suitability of same for the conduct of Tenant’s business, except as expressly provided
in this Lease. Tenant’s acceptance of possession of the Premises shall conclusively establish that the foregoing were at such time in satisfactory condition. Landlord makes no representation to Tenant regarding the installation, ownership,
location, or suitability for Tenant’s purposes of the INC in the Building. 
 2.1.2 Insurance Rates. Tenant shall not do
or suffer anything to be done in or about the Premises, nor shall Tenant bring or allow anything to be brought into the Premises, which will in any way increase the rate of any fire insurance or other insurance upon the Property or its contents,
cause a cancellation of said insurance, or otherwise affect said insurance in any manner. 
 2.1.3 Use to Comply with Laws.
Tenant shall use the Premises in conformity with all applicable Laws, as specified in Article 6 below. 
 2.1.4 Floor Loading.
Tenant shall not place or permit to be placed on any floor a load exceeding eighty (80) pounds per square foot or such lower floor load as such floor was designed to carry. 

2.2 NUISANCE AND WASTE. Tenant also shall not do or suffer anything to be done in or about the Premises which will in any way obstruct or
interfere with the rights of other tenants or occupants of the Property or injure or annoy said tenants or occupants, nor shall Tenant use or suffer the Premises to be used for any unlawful purposes. In no event shall Tenant cause or permit any
nuisance in or about the Premises, and no loudspeakers or similar devices shall be used without the prior written approval of Landlord, which approval may be withheld in Landlord’s sole and absolute discretion. Tenant shall not commit or suffer
to be committed any waste in or upon the Premises. The provisions of this section are for the benefit of Landlord only and shall not be construed to be for the benefit of any tenant or occupant of the Building. If any governmental license or permit,
other than a Certificate of Occupancy, shall be required for the proper and lawful conduct of Tenant’s business in the Premises, or any part thereof, and if failure to secure such license or permit would in any way affect Landlord, Tenant, at
its sole expense, shall procure and thereafter maintain such license or permit and submit the same for inspection by Landlord. Tenant shall at all times comply with the terms and conditions of each such license or permit. 

  
 6 

 2.3 COMPLIANCE WITH CERTIFICATE OF OCCUPANCY Tenant shall not at any time use or occupy the
Premises, or suffer or permit anyone to use or occupy, the Premises, or do or permit anything to be done in the Premises, in violation of the Certificate of Occupancy for the Premises or for the Building. 

3 PREPARATION OF THE PREMISES 
 3.1
CONDITION OF PREMISES. Except as otherwise expressly provided in § 3.2 below, Tenant shall accept the Premises, any existing Improvements in the Premises (as defined in§ 10.1 below), and the Systems and Equipment serving the same in
an “as is” condition on the date the Term commences, and Landlord shall have no obligation to improve, alter, remodel, or otherwise modify the Premises prior to Tenant’s occupancy or thereafter under this Lease. 

3.2 LANDLORD’S PREPARATION. Landlord shall use reasonable diligence in completing and preparing the Premises for Tenant’s occupancy in
the manner and subject to the terms, conditions, and covenants set forth in this Article 3 on or before the Commencement Date specified in § 1.4 above. 

3.2.1 Effect of Delay. If the Occupancy Conditions specified in § 3.2.2 below are not met by the Commencement Date
specified in § 1.4 above, the Commencement Date shall be delayed by one day for each day that the date on which the Occupancy Conditions are met extends beyond the Commencement Date specified in § 1.4 above; and in any such case, Tenant
shall not have the right to terminate the Lease, but Tenant’s obligation to pay Rent shall be delayed until the occurrence of the Commencement Date. 

3.2.2 Landlord’s Work. The facilities, materials, and work to be furnished, installed, and performed in the Premises by
Landlord hereunder at Landlord’s sole cost and expense are referred to as the “Work.” Any other installations, materials, and work which may be undertaken by or for the account of Tenant to prepare, equip, decorate, and furnish the
Premises for Tenant’s occupancy are referred to as the “Tenant’s Work,” which shall be undertaken or installed by Tenant at Tenant’s sole cost and expense and which shall include the installation of Tenant’s furniture,
fixtures, office systems, and Tenant’s data and telecommunications cables and wiring. The parties agree that Landlord’s Work, to be completed by Landlord at Landlord’s sole cost and expense in preparation for Tenant’s Work, shall
consist of the following items only: 
 (a) repair or replacement of any stained or damaged ceiling tiles throughout the Premises; and

 (b) delivery of the Premises with all Systems and Equipment serving the same in good working order. 

3.2.3 Tenant’s Work. Tenant shall have the right to improve the Premises as delineated in§§ 3.2.3 through 3.2.11
below setting forth the scope of Tenant’s Work and payment for the cost thereof. 
 3.2.4 Completion of Plans. On or
before February 29, 2020 (the “Date To Complete Planning”), Tenant shall (a) provide Landlord’s Space Planner with all information concerning Tenant’s requirements in order for Space Planner to prepare the final plans
for the Work (the “Plans”), (b) arrange for Space Planner to prepare the Plans, and (c) obtain Landlord’s written approval of the Plans. 

3.2.5 Cost of the Work and Tenant Improvement Allowance. Landlord shall bear the cost of the Work (including the cost of
architectural and engineering, combining the energy-management and life-safety systems, demolition, building permits, Landlord’s construction supervision fee as required for Tenant’s Changes under the Lease, and sales tax) as shown on the
final approved Plans up to the maximum amount of Ten Thousand Dollars ($10,000.00) (the “Improvement Allowance”); and Tenant shall bear any 

  
 7 

 
costs which exceed such Improvement Allowance or incurred in connection with any work it may desire in addition to the Work shown on the final approved Plans (referred to collectively as
“Tenant’s Costs” and defined in§ 3.2.6 below). Landlord shall have the right to charge against the Improvement Allowance specified above a construction management fee of five percent (5%) of the aggregate cost of (a) the
Landlord’s Work and (b) Tenant’s Work (if any). 
 3.2.6 Cost of the Plans. The cost of the Plans (including
any engineering reports or other studies or tests in connection therewith) may be paid with the Improvement Allowance, subject to its aggregate maximum specified in § 3.2.5 above, and Tenant shall bear any costs of the Plans which exceed the
Improvement Allowance. 
 3.2.7 Landlord’s Approval of Plans. Landlord shall either approve any Plans or revisions
submitted hereunder or disapprove the same with suggestions for making the same acceptable within the shortest time reasonably practicable. Landlord shall not unreasonably withhold approval, if the Plans provide for a customary office layout, with
finishes and materials generally conforming to Building-standard materials currently being used by Landlord at the Building, are compatible with the Building’s shell and core construction, and if no modifications will be required for the base
Building electrical, heating, air-conditioning, ventilation, plumbing, fire protection, life safety, or other systems or equipment, and will not require any structural modifications to the Building, whether
required by heavy loads or otherwise. Landlord may request that Tenant approve Landlord’s suggested changes in writing (such approval shall not be unreasonably withheld), or Landlord may arrange directly with Space Planner for revised Plans to
be prepared incorporating such suggestions; and in any such case, Tenant shall sign or initial the revised Plans and/ or Landlord’s notice concerning the suggested changes, if requested by Landlord. Landlord’s approval of the Plans shall
not be deemed a warranty as to the adequacy or legality of the design, and Landlord hereby disclaims any responsibility or liability for the same. Tenant & Landlord agree that Tenant’s Work may include any or all of the following
items: 
 (a) design, architectural, construction, engineering, life safety, MEPs, permitting, and related construction; 

(b) installation of an approved dishwasher; 

(c) application of fresh paint to two (2) accents walls; and 

(d) installation of Mecho shades. 

3.2.8 Delays in Planning. The Commencement Date under the Lease shall be postponed for each day that final Plans are not
prepared and approved by the Date to Complete Planning described above, including any revisions reasonably required by Landlord pursuant to § 3.2.7 above and revisions by Tenant to reduce Tenant’s Cost pursuant to § 3.2.5 above
(collectively called “Delays in Planning”). Notwithstanding anything to the contrary herein, the commencement of Rent shall be postponed only to the extent that substantial completion of the Work is delayed beyond the Commencement Date as
a result of one or more of the following events (collectively called “Landlord Delays”): 
 (A) Delay in Approval of
Plans. Landlord takes more than seven (7) business days to approve or disapprove the Plans or revisions thereof after receiving the same (or such longer time as may be reasonably required in order to obtain any engineering or HVAC report or
due to other special or unusual features of the Work or Plans); 
 (B) Delay of Space Planner. Landlord’s Space Planner
takes more than five (5) business days to meet with Tenant after receiving a written request for a meeting or takes more than five (5) business days to prepare or revise the Plans after meeting with Tenant and receiving all information
from Tenant required in order to do so; or 

  
 8 

 (C) Delay of Cost Estimates. Landlord takes more than thirty (30) days
to provide Tenant with cost estimates after receiving Plans sufficiently detailed for such purposes. 
 3.2.9 Changes After Plans
Are Approved. If Tenant shall desire any changes, alternations, or additions to the final Plans after they have been approved by Landlord, Tenant shall submit a detailed written request or revised Plans (the “Change Order”) to the
Landlord for approval. If reasonable and practicable and generally consistent with the Plans theretofore approved, Landlord shall not unreasonably withhold approval; but all costs in connection therewith, including construction costs, permit fees,
and any additional plans, drawings, engineering reports, or other studies or tests, or revisions of such existing items, shall be paid for by Tenant as a Tenant’s Cost under § 3.2.10 below. 

3.2.10 Tenant’s Cost; Estimates (If Applicable). Any amounts that Tenant is required to pay hereunder shall be referred to
as “Tenant’s Cost” herein. Tenant’s Cost shall be deemed additional “Rent” under the Lease. Landlord may at any time reasonably estimate Tenant’s Cost in advance, in which case, Tenant shall deposit such estimated
amount with Landlord within ten (10) days after requested by Landlord. If such estimated amount exceeds the actual amount of Tenant’s Cost, Tenant shall receive a prompt refund of the difference; and if the actual amount shall exceed the
estimated amount, Tenant shall pay the difference to Landlord within ten (10) days after requested by Landlord. 
 3.2.11
Construction Management Services. Notwithstanding anything to the contrary in this Lease, at the completion of Landlord’s Work, Tenant shall pay to Landlord promptly upon receipt of invoice a construction management fee in the amount of
five percent (5%) of the total cost of Landlord’s Work (the “CM Fee”) to cover the cost of Landlord’s personnel providing construction management services in connection with Landlord’s Work in the Premises. 

3.2.12 Readiness for Occupancy. The Premises shall be deemed ready for occupancy on the earliest date on which all of the
following conditions (the “Occupancy Conditions”) have first been met: 
 (a) Substantial Completion of Work. The
Work has been substantially completed as determined by Landlord its reasonable discretion and, if applicable, Landlord’s architect has issued a certificate of substantial completion; and it shall be so deemed notwithstanding the fact that minor
or insubstantial details of construction, mechanical adjustment, or decoration remain to be performed, the noncompletion of which does not materially interfere with Tenant’s beneficial use of the Premises for their intended purposes; 

(b) Access and Services. Reasonable means of access and facilities necessary to Tenant’s use and occupancy of the Premises,
including corridors, elevators, stairways, heating, ventilating, air-conditioning, sanitary, water, and electrical facilities (but exclusive of parking facilities) have been installed and are in reasonably
good operating order and available to Tenant; and 
 (c) Required Governmental Approval. If a building permit for the Work is
required, a final inspection card or similar governmental approval (temporary or final) has been issued by the City of South San Francisco permitting use of the Premises for office purposes. 

  
 9 

 3.2.13 Tenant Delays. If the occurrence of any of the Occupancy Conditions and
Landlord’s preparation of the Premises for occupancy shall be delayed owing to either (a) any act, omission, or failure of Tenant or any of its employees, agents, or contractors which shall continue after Landlord shall have given Tenant
reasonable notice that such act, omission, or failure would result in delay, and such delay shall have been unavoidable by Landlord in the exercise of reasonable diligence and prudence; or (b) the nature of any items of additional work or
change orders that Landlord undertakes to perform for the account of Tenant (including any delays incurred by Landlord, after making reasonable efforts, in procuring any materials, equipment, or fixtures of a kind or nature not used by Landlord as
part of its standard construction) (collectively “Tenant Delays”), then the Premises shall be deemed ready for occupancy on the date when they would have been ready but for such Tenant Delays. 

3.3 EARLY ENTRY. During any period that Tenant shall be permitted to enter the Premises prior to the Commencement Date other than to occupy the
same (e.g., to perform alterations or improvements), Tenant shall comply with all terms and provisions of this Lease, except those provisions requiring the payment of Rent. If Tenant shall be permitted to enter the Premises prior to the Commencement
Date for the purpose of occupying the same, Rent shall commence on such date at the rate specified in the Table for the first period during which Rent is payable after the Commencement Date; and if Tenant shall commence occupying only a portion of
the Premises prior to the Commencement Date, Rent shall be prorated based on the number of rentable square feet occupied by Tenant. Landlord shall permit early entry, provided the Premises are legally available and Landlord has completed any Work
required under this Lease. In no event shall Tenant’s early entry extend or shorten the Term of the Lease set forth in§ 1.2 above. Notwithstanding anything to the contrary herein, Tenant shall have the right enter the Premises free from
the obligation to pay Rent for the period commencing two (2) weeks prior to the Commencement Date for the limited purposes of installing Tenant’s furniture and fixtures and telephone and data equipment, lines, and cabling, provided that
Tenant’s does not interfere with Landlord’s completion of the Work and that Tenant has delivered to Landlord the insurance certificates and the Security Deposit required hereunder. 

3.4 NOTICE OF DEFECTS. It shall be conclusively presumed upon Tenant’s taking actual possession of the Premises that the same were in
satisfactory condition (except for latent defects) as of the date of such taking of possession, unless within thirty (30) days after the Commencement Date Tenant shall give Landlord notice in writing specifying the respects in which the
Premises were not in satisfactory condition. 
 4 ADJUSTMENTS OF RENT 

4.1 TAXES AND OPERATING EXPENSES. In addition to the Base Rent and all other payments due under this Lease, Tenant shall pay to Landlord, in the
manner set forth in this Article 4, as Additional Rent, the following amounts: 
 (a) Increased Operating Expenses. An amount
equal to Tenant’s Pro Rata Share of that portion of Operating Expenses paid by Landlord during each Adjustment Period which exceeds the amount of Base Operating Expenses (as all of such terms are defined in § 4.2 below); and 

(b) Increased Taxes. An amount equal to Tenant’s Pro Rata Share of that portion of Real Estate Taxes paid by Landlord
during each Adjustment Period which exceeds the amount of Base Real Estate Taxes (as all of such terms are defined in § 4.2 below). 
 Tenant’s
Pro Rata Share of (i) such increase in Operating Expenses over the Base Operating Expenses and (ii) such increase in Real Estate Taxes over the Base Real Estate Taxes is sometimes referred to collectively herein as the “Rental
Adjustment.” 

  
 10 

 4.2 DEFINITIONS. For the purposes of this Lease, the following definitions shall apply: 

(a) Base Operating Expenses. “Base Operating Expenses” means the total of Operating Expenses paid by Landlord during
calendar year 2020 (the “Base Expense Year”), as adjusted under § 4.5 below. 
 (b) Base Real Estate
Taxes. “Base Real Estate Taxes” means the total of Real Estate Taxes paid by Landlord during calendar year 2020 (the “Base Tax Year”). 

(c) Tenant’s Pro Rata Share. “Tenant’s Pro Rata Share” as to the Building is the percentage labeled as such
in the Table in § 1.2 and is calculated by dividing the agreed rentable area of the Premises (numerator) by the agreed rentable area of the Property (denominator) and expressing the resulting quotient as a percentage. “Tenant’s Pro
Rata Share” as to the Complex is the percentage labeled as such in the Table in§ 1.2 as is calculated by dividing the agreed rentable area of the Premises (numerator) by the agreed rentable area of the Complex (denominator) and expressing
the resulting quotient as a percentage. Tenant’s Pro Rata Share shall be increased during the Term in proportion to any increase in the area of the Premises in accordance with the formula stated herein. 

(d) Adjustment Period. “Adjustment Period” as to Operating Expenses and Real Estate Taxes means each calendar year of
which any portion occurs during the Term, excluding the Base Year and beginning with the first calendar year immediately following the Base Year. 

(e) Real Estate Taxes. “Real Estate Taxes” means all of the following charges, whether or not now customary or in the
contemplation of the parties hereto, and whether or not general, special, ordinary, or extraordinary, which Landlord shall pay during any Adjustment Period because of or in connection with the ownership, leasing, or operation of the Property: 

(1) ad valorem real property taxes; 

(2) any form of assessment, license fee, license tax, business license fee, commercial rental tax, levy, charge, fee, tax, or other
imposition imposed by any authority, including any city, county, state, or federal governmental agency, or any school, agricultural, lighting, transportation, housing, drainage, or other improvement or special assessment district thereof; 

(3) any tax on Landlord’s ‘right’ to rent or ‘right’ to other income from the Building or as against
Landlord’s business of leasing the Building; 
 (4) any assessment, tax, fee, levy, or charge in substitution, partially or
totally, of any assessment tax, fee, levy or charge previously included within the definition of Real Estate Taxes, it being acknowledged by Tenant and Landlord that Proposition 13 was adopted by the voters of the State of California in the Election
of June, 1978, and that assessments, taxes, fees, levies, and charges may be imposed by governmental agencies for such services as fire protection, street, sidewalk, and road maintenance, refuse removal, and for other governmental services formerly
provided without charge to property owners or occupants, and it being the intention of Tenant and Landlord that all such new and increased assessments, taxes, fees, levies, and charges be included within the definition of Real Estate Taxes for the
purposes of this Lease; 
 (5) any assessment, tax, fee, levy, or charge allocable to or measured by the area of the Building or
Property or the Rent payable hereunder, including any gross income tax or excise tax levied by any city, county, state, or federal governmental agency or any political subdivision thereof with respect to the receipt of such Rent, or upon or with
respect to the possession, leasing, operating, management, maintenance, alteration, repair, use, or occupancy by Tenant of the Property or any portion thereof; 

  
 11 

 (6) any assessment, tax, fee, levy, or charge upon this transaction or any document
to which Tenant is a party, creating or transferring an interest or an estate in the Building or Property; 
 (7) any assessment,
tax, fee, levy, or charge by any governmental agency related to any transportation plan, fund, or system instituted within the geographic area of which the Building is a part; or 

(8) reasonable legal and other professional fees, costs and disbursements incurred in connection with proceedings to contest,
determine or reduce Real Estate Taxes. 
 Exclusions. Notwithstanding the foregoing, Real Estate Taxes shall not include (A) federal, state, or
local income taxes; (B) franchise, gift, transfer, excise, capital stock, estate, succession, or inheritance taxes; or (C) penalties or interest for late payment of Real Estate Taxes. 

(f) Operating Expenses. “Operating Expenses” means all expenses, costs, and amounts (other than Real Estate Taxes) of
every kind and nature which Landlord shall pay during any Adjustment Period of which any portion occurs during the Term, because of or in connection with the ownership, management, repair, maintenance, restoration, and/or operation of the Property,
including costs of the following: 
 (1) all expenses, costs, and amounts of every kind and nature which Landlord shall pay during
any Adjustment Period of which any portion occurs during the Term, because of or in connection with the electricity, power, gas, steam, oil or other fuel, water, sewer, lighting, heating, air conditioning, and ventilating delivered to or consumed or
used in or on the Property, but excluding the cost of any utilities provided by a public utility directly to any tenant in the Complex and/ or billed directly and separately by such utility or Landlord to such tenant by means of separate metering or
otherwise; 
 (2) permits, licenses, and certificates necessary to operate, manage, and lease the Property; 

(3) supplies, tools, equipment, and materials used in the operation, repair, and maintenance of the Property; 

(4) all insurance premiums for any insurance policies deemed necessary or desirable by Landlord (including workers’ compensation,
health, accident, group life, public liability, property damage, earthquake, and fire and extended coverage insurance for the full replacement cost of the Property as required by Landlord or its lenders for the Property); 

(5) the deductible portion of any claim paid under any insurance policy maintained by Landlord in connection with its management and
operation of the Property; 
 (6) accounting, legal, inspection, consulting, concierge, and other services; 

(7) services of independent contractors; 

(8) compensation (including employment taxes and fringe benefits) of all persons who perform duties in connection with the operation,
maintenance, repair, or overhaul of the Building or Property, and equipment, improvements, and facilities located within the Property, including engineers, janitors, painters, floor waxers, window washers, security, parking personnel, and gardeners;

  
 12 

 (9) operation and maintenance of a room for delivery and distribution of mail to
tenants of the Building as required by the U.S. Postal Service (including an amount equal to the fair market rental value of the mail room premises); 

(10) management of the Building or Property, whether managed by Landlord or an independent contractor (including an amount equal to
the fair market value of any on-site manager’s office); 
 (11) rental expenses for (or
a reasonable depreciation allowance on) personal property used in maintenance, operation, or repair of the Property and installment equipment purchase or equipment financing agreements for such personal property; 

(12) costs, expenditures, or charges (whether capitalized or not) required by any governmental or quasi-governmental authority after
the Commencement Date; 
 (13) payments under any easement, operating agreement, declaration, restrictive covenant, or instrument
pertaining to the sharing of costs in any planned development; 
 (14) amortization of capital expenses (including financing costs)
incurred by Landlord after the Commencement Date in order to (A) comply with Laws enacted after the Commencement Date, (B) reduce Property Operating Expenses, or (C) upgrade the utility, efficiency, or capacity of any Utility or
telecommunication systems serving tenants of the Property; 
 (15) operation, repair, and maintenance of all Systems and Equipment
and components thereof (including replacement of components); janitorial service; alarm and security service; window cleaning; trash removal; elevator maintenance; cleaning of walks, parking facilities, and building walls; removal of ice and snow;
replacement of wall and floor coverings, ceiling tiles, and fixtures in lobbies, corridors, restrooms and other common or public areas or facilities; maintenance and repair of the roof and exterior fabric of the Building, including replacement of
glazing as needed; maintenance and replacement of shrubs, trees, grass, sod, and other landscaped items, irrigation systems, drainage facilities, fences, curbs, and walkways; repaving and restriping parking facilities; and roof repairs; 

(16) the operation of any on-site maintenance shop(s) and the operation and maintenance of the
Athletic Facility, any other fitness center, conference rooms, and all other common areas and amenities in the Property; 
 (17)
provision of shuttle busses, shuttle services, and drivers between the Complex and BART and SFO airport, as required by the Bay Area Regional Transportation Act and deed covenants and restrictions applicable to the Complex; and 

(18) any other costs or expenses incurred by Landlord which are reasonably necessary to operate, repair, manage, and maintain the
Building and Property in a first-class manner and condition and which are not otherwise reimbursed by tenants of the Building. 
 Exclusions.
Notwithstanding the foregoing, Operating Expenses shall not include (A) depreciation, interest, and amortization on Superior Mortgages (as defined in§ 18.1 below), and other debt costs or ground lease payments, if any; (B) legal fees
in connection with leasing, tenant disputes, or enforcement of leases; (C) real estate brokers’ leasing commissions or other marketing costs; (D) improvements or alterations to tenant spaces; (E) the cost of providing any service
directly to, and reimbursed or paid directly by, any tenant; (F) any costs expressly excluded from Operating Expenses elsewhere in this Lease; (G) costs of any items to the extent Landlord receives reimbursement from insurance proceeds,
warranties, or from a third 

  
 13 

 
party (such proceeds to be deducted from Operating Expenses in the year in which received); (H) capital expenditures, except those expressly permitted above; provided, all such permitted capital
expenditures (together with reasonable financing charges) shall be amortized for purposes of this Lease over the shorter of (x) their useful lives or (y) the period during which the reasonably estimated savings in Operating Expenses equals
the expenditures, or (z) three (3) years. 
 4.3 MANNER OF PAYMENT. To provide for current payments of the Rental Adjustment, Tenant
shall pay as Additional Rent during each Adjustment Period an amount equal to Landlord’s estimate of the Rental Adjustment which will be payable by Tenant for such Adjustment Period. Such payments shall be made in monthly installments,
commencing on the first day of the month following the month in which Landlord notifies Tenant of the amount it is to pay hereunder and continuing until the first day of the month following the month in which Landlord gives Tenant a new notice of
the estimated Rental Adjustment. It is the intention hereunder to estimate from time to time the amount of Tenant’s Rental Adjustment for each Adjustment Period and then to effect a reconciliation in the following year based on the actual
expenses incurred for the preceding Adjustment Period, as provided in 4.4 below. 
 4.4 RECONCILIATION. On or before the first day of April of
each year after the first Adjustment Period (or as soon thereafter as is practical), Landlord shall deliver to Tenant a statement (the “Statement”) setting forth the Rental Adjustment for the preceding year. If the actual Rental Adjustment
for the preceding Adjustment Period exceeds the total of the estimated monthly payments made by Tenant for such Adjustment Period, Tenant shall pay Landlord the amount of the deficiency within ten (10) days of the receipt of the Statement. If
such total of estimated payments made exceeds the actual Rental Adjustment for such Adjustment Period, then Tenant shall receive a credit for the difference against payments of Rent next due. If the credit is due from Landlord on the Expiration
Date, Landlord promptly shall pay Tenant the amount of the credit, less any Rent then due. The obligations of Tenant and Landlord to make payments required under this § 4.4 shall survive the expiration or earlier termination of the Term of this
Lease. 
 4.4.1 Changes in Method. So long as Tenant’s obligations hereunder are not materially adversely affected
thereby, Landlord reserves the right reasonably to change from time to time the manner or timing of the foregoing payments. In lieu of providing one Statement covering Real Estate Taxes and Operating Expenses, Landlord may provide separate
statements, at the same or different times. No delay by Landlord in providing the Statement (or separate statements) shall be deemed a default by Landlord or a waiver of Landlord’s right to require payment of Tenant’s obligations for
actual or estimated Real Estate Taxes or Operating Expenses. In no event shall a decrease in Real Estate Taxes or Operating Expenses below the Base Operating Expenses or Base Real Estate Taxes ever decrease the monthly Base Rent or give rise to a
credit in favor of Tenant. 
 4.4.2 Proration of Rental Adjustment. If the Term does not commence on January 1 or does
not end on December 31, Tenant’s obligations to pay estimated and actual amounts towards Real Estate Taxes and Operating Expenses for such first or final calendar year shall be prorated to reflect the portion of such year(s) included in
the Term. Such proration shall be made by multiplying the total estimated or actual (as the case may be) Real Estate Taxes and Operating Expenses for such calendar year(s), as well as the Base Real Estate Taxes and Base Operating Expenses, by a
fraction, the numerator of which shall be the number of days of the Term during such calendar year, and the denominator of which shall be three hundred sixty-five (365). 

4.5 GROSS-UP. If the Building is less than ninety-five percent (95%) occupied during the Base Period or
any Adjustment Period, then Operating Expenses and Real Estate Taxes for the Base Period and/or such Adjustment Period shall be “grossed up” to that amount of Operating Expenses and Real Estate Taxes that, using reasonable projections,
would normally have been incurred during the Base Period and/or such Adjustment Period if the Building had been ninety-five percent (95%) occupied during the Base Period and/or such Adjustment Period, as determined in accordance with sound
accounting and management practices, consistently applied. Only those component elements or items of expense of Operating Expenses and Real Estate Taxes that are affected by variations in occupancy levels shall be grossed up. 

  
 14 

 4.6 ADJUSTMENT OF BASE OPERATING EXPENSES. Notwithstanding anything to the contrary contained
in the Lease, the parties agree that Base Operating Expenses and Operating Expenses for any subsequent Adjustment Period (herein called “Subsequent Operating Expenses”) shall be subject to further adjustment by Landlord as follows: 

(a) Exclusion of Capital Expenditures. Landlord may exclude from Base Operating Expenses capital expenditures otherwise
permitted, provided Landlord shall also exclude any amortization of such expenditures from Subsequent Operating Expenses. 
 (b)
Elimination of Recurring Expenses. If Landlord eliminates from any Subsequent Operating Expenses a category of recurring expenses previously included in Base Operating Expenses, Landlord may subtract such category from Base Operating Expenses
commencing with such subsequent Adjustment Period. 
 (c) New Recurring Expenses. If Landlord includes a new category of
recurring Subsequent Operating Expenses not previously included in Base Operating Expenses, Landlord shall also include an amount (the “Assumed Base Amount”) for such category in Base Operating Expenses commencing in such subsequent
Adjustment Period. 
 (d) Assumed Base Amount. The “Assumed Base Amount” under§ 4.6(c) above shall be the
annualized amount of expenses for such new category in the first Adjustment Period it is included, reduced by an amount determined in Landlord’s sole good faith discretion (but in no event by an amount less than five percent (5% )) for each
full or partial Adjustment Period that has elapsed during the Term of the Lease before such Adjustment Period. 
 4.7 ADJUSTMENT OF REAL ESTATE
TAXES. If Base Real Estate Taxes are reduced as the result of protest, by means of agreement, as the result of legal proceedings, or otherwise, Landlord may adjust Tenant’s obligations for Real Estate Taxes in all years affected by any
refund of taxes following the Base Tax Year; and Tenant shall pay Landlord within thirty (30)days after notice any additional amount required by such adjustment for any Adjustment Periods that have theretofore occurred. Tenant shall be entitled to
receive a share of any refund or abatement of Real Estate Taxes received by Landlord to the extent of and in proportion to Tenant’s actual contribution to the amount of Real Estate Taxes paid by Landlord during the period to which such refund
or abatement relates, but in no event shall Tenant be entitled to any refund with respect to Real Estate Taxes paid by Landlord during Tenant’s Base Tax Year. If Real Estate Taxes for any Adjustment Period during the Term or any extension
thereof shall be increased after payment thereof by Landlord for any reason, including error or reassessment by applicable governmental authorities, Tenant shall pay Landlord upon demand Tenant’s Pro Rata Share of such increased Real Estate
Taxes. Tenant shall pay increased Real Estate Taxes whether Real Estate Taxes are increased as a result of increases in the assessment or valuation of the Property (whether based on a sale, change in ownership, refinancing of the Property, or
otherwise), increases in the tax rates, reduction or elimination of any rollbacks or other deductions available under current law, scheduled reductions of any tax abatement, as a result of the elimination, invalidity, or withdrawal of any tax
abatement, or for any other cause whatsoever. Notwithstanding the foregoing, if any Real Estate Taxes shall be paid based on assessments or bills by a governmental authority using a fiscal year other than a calendar year, Landlord may elect to
average the assessments or bills for the subject calendar year, based on the number of months of such calendar year included in each such assessment or bill. 

  
 15 

 4.8 ALLOCATION WTIHIN COMPLEX. So long as the Property shall be part of the Complex
collectively owned or managed by Landlord or its affiliates or collectively managed by Landlord’s managing agent, Landlord may allocate Real Estate Taxes and Operating Expenses within the Complex and between the buildings and structures
comprising the Complex and the parcels on which they are located, in accordance with sound accounting and management principles. In the alternative, Landlord shall have the right to determine, in accordance with sound accounting and management
principles, Tenant’s Pro Rata Share of Real Estate Taxes and Operating Expenses based upon the totals of each of the same for all such buildings and structures, the land constituting parcels on which the same are located, and all related
facilities, including common areas and easements, corridors, lobbies, sidewalks, elevators, loading areas, parking facilities, driveways, and other appurtenances and public areas, in which event Tenant’s Pro Rata Share shall be based on the
ratio of the rentable area of the Premises to the rentable area of all buildings in the Complex. 
 4.9 LANDLORD’S RECORDS. Landlord
shall maintain records with respect to Real Estate Taxes and Operating Expenses and determine the same in accordance with sound accounting and management practices, consistently applied. Although this Lease contemplates the computation of Real
Estate Taxes and Operating Expenses on a cash basis, Landlord shall make reasonable and appropriate accrual adjustments to ensure that each Adjustment Period includes substantially the same recurring items. Landlord reserves the right to change to a
full accrual system of accounting so long as the same is consistently applied and Tenant’s obligations are not materially adversely affected. Tenant or its representative shall have the right to examine such records, upon reasonable prior
written notice specifying such records Tenant desires to examine, during normal business hours at the place or places where such records are normally kept, by sending such notice no later than forty-five (45) days following the furnishing of
the Statement. 
 4.10 OTHER TAXES PAYABLE BY TENANT. In addition to the Base Rent and any other charges to be paid by Tenant hereunder,
Tenant shall, as an element of Rent, reimburse Landlord upon demand for any and all taxes payable by Landlord (other than net income taxes) which are not otherwise reimbursable under this Lease, whether or not now customary or within the
contemplation of the parties, where such taxes are upon, measured by, or reasonably attributable to (A) the cost or value of Tenant’s equipment, furniture, fixtures, and other personal property located at the Premises, or the cost or value
of any improvements made in or to the Premises by or for Tenant, regardless of whether title to such improvements is held by Tenant or Landlord; (B) the gross or net Rent payable under this Lease, including any rental or gross receipts tax
levied by any taxing authority with respect to the receipt of the Rent hereunder; (C) the possession, leasing, operation, management, maintenance, alteration, repair, use, or occupancy by Tenant of the Premises or any portion thereof; or
(D) this transaction or any document to which Tenant is a party creating or transferring an interest or an estate in the Premises. Tenant shall pay any rent tax, sales tax, service tax, transfer tax, value-added tax, or any other applicable tax
on the Rent or services herein or otherwise respecting this Lease. 
 4.11 RENT CONTROL. If the amount of Rent or any other payment due under
this Lease violates the terms of any governmental restrictions on such Rent or payment, then the Rent or payment due during the period of such restrictions shall be the maximum amount allowable under those restrictions. Upon termination of the
restrictions, Landlord shall, to the extent it is legally permitted, recover from Tenant the difference between the amounts received during the period of the restrictions and the amounts Landlord would have received had there been no restrictions.

  
 16 

 5 SECURITY DEPOSIT 

5.1 DEPOSIT FOR SECURITY. Tenant shall deposit with Landlord the amount of Seventy Thousand Six Hundred Eighty-Three Dollars and Fifty-Two Cents ($70,683.52) (the “Security Deposit”) upon Tenant’s execution and delivery of this Lease to Landlord. The Security Deposit shall serve as security for the prompt, full, and faithful
performance by Tenant of the terms and provisions of this Lease, including the value of future rents as damages in accordance with California Civil Code § 1951.2, as set forth in§ 20.3 below. Landlord shall not be required to keep the
Security Deposit separate from Landlord’s general funds or pay interest on the Security Deposit. 
 5.1.1 Application of
Deposit. In the event that Tenant is in Default hereunder and fails to cure within any applicable time permitted under this Lease, or in the event that Tenant owes any amounts to Landlord upon the expiration of this Lease, Landlord may use or
apply the whole or any part of the Security Deposit for the payment of Tenant’s obligations hereunder. The use or application of the Security Deposit or any portion thereof shall not prevent Landlord from exercising any other right or remedy
provided hereunder or under any Law and shall not be construed as liquidated damages. 
 5.1.2 Restoration of Full Deposit. In
the event the Security Deposit is reduced by such use or application, Tenant shall deposit with Landlord, within ten (10) days after written notice, an amount sufficient to restore the full amount of the Security Deposit. If the Premises shall
be expanded at any time, or if the Term shall be extended at any increased rate of Rent, the Security Deposit shall thereupon be proportionately increased. 

5.1.3 Disposition of Security Deposit. After the Expiration Date or any earlier termination of the Lease, any remaining portion
of the Security Deposit shall be returned to Tenant after deduction of all amounts due as Rent or otherwise. Tenant expressly waives the provisions of § 1950.7 of the California Civil Code. 

6 COMPLIANCE WITH LAWS 
 6.1
TENANT’S COMPLIANCE WITH LAWS. Tenant shall use the Premises in compliance with all applicable federal, state, county, and local governmental and municipal laws, statutes, ordinances, rules, regulations, codes, decrees, orders, and other
such requirements, and decisions by courts in cases where such decisions are considered binding precedents in the State of California (the “State”), and decisions of federal courts applying the laws of the State (collectively
“Laws”). Tenant shall, at its sole cost and expense, promptly comply with each and all of such Laws, and also with the requirements of any board of fire underwriters or other similar body now or hereafter constituted to deal with the
condition, use, or occupancy of the Premises, except in the case of required structural changes not triggered by Tenant’s change in use of the Premises or Tenant’s alterations, additions, or improvements therein. Tenant shall comply with
all applicable Laws regarding the physical condition of the Premises, but only to the extent that the applicable Laws pertain to the particular manner in which Tenant uses the Premises or the particular use to which Tenant puts the Premises, if
different from that permitted under Article 2 of this Lease. Tenant shall also comply with all applicable Laws which do not relate to the physical condition of the Premises and with which only the occupant can comply, such as laws governing maximum
occupancy, workplace smoking, VDT regulations, and illegal business operations, such as gambling. The judgement of any court of competent jurisdiction or the admission of Tenant in any judicial action, regardless of whether Landlord is a party
thereto, that Tenant has violated any of such Laws shall be conclusive of that fact as between Landlord and Tenant. 
 6.1.1 Code
Costs. Notwithstanding anything to the contrary in this Article 6, if the requirement of any public authority obligates either Landlord or Tenant to expend money in order to bring the Premises and/or any area of the Property into compliance with
Laws as a result of (a) Tenant’s particular use or alteration of the Premises; (b) Tenant’s change in the use of the Premises; (c) the manner of conduct of Tenant’s business or operation of its installations, equipment,
or other property therein; (d) any cause or condition created by or at the instance of Tenant, other than by Landlord’s performance of any work for or on behalf of Tenant; or (e) breach of any of Tenant’s obligations hereunder,
then Tenant shall bear all costs (“Code Costs”) of bringing the Premises and/or Property into compliance with Laws, whether such Code Costs are related to structural or nonstructural elements of the Premises or Property. 

  
 17 

 6.2 LANDLORD’S COMPLIANCE WITH LAWS. Landlord represents that on the Commencement Date
Landlord has no actual knowledge of any violation of any applicable Laws respecting the Premises. During the Term Landlord shall comply with all applicable Laws regarding the Premises and Property, except to the extent Tenant must comply under§
6.1 above. 
 7 HAZARDOUS MATERIALS 

7.1 REGULATION OF HAZARDOUS MATERIALS. Tenant shall not transport, use, store, maintain, generate, manufacture, handle, dispose, release, or
discharge any “Hazardous Material” (as defined below) upon or about the Property, nor permit Tenant’s employees, agents, contractors, and other occupants of the Premises to engage in such activities upon or about the Property.
However, the foregoing provisions shall not prohibit the transportation to and from, and use, storage, maintenance, and handling within, the Premises of substances customarily used in offices, provided all of the following conditions are met: 

(a) such substances shall be used and maintained only in such quantities as are reasonably necessary for such permitted use of the
Premises, strictly in accordance with applicable Laws and the manufacturers’ instructions therefor; 
 (b) such substances shall
not be disposed of, released, or discharged on the Property and shall be transported to and from the Premises in compliance with all applicable Laws, and as Landlord shall reasonably require; 

(c) if any applicable Laws or Landlord’s trash removal contractor requires that any such substances be disposed of separately from
ordinary trash, Tenant shall make arrangements at Tenant’s expense for such disposal directly with a qualified and licensed disposal company at a lawful disposal site (subject to scheduling and approval by Landlord), and shall ensure that
disposal occurs frequently enough to prevent unnecessary storage of such substances in the Premises; and 
 (d) any remaining such
substances shall be completely, properly, and lawfully removed from the Property upon expiration or earlier termination of this Lease. 
 7.2
DEFINITION OF HAZARDOUS MATERIAL. The term “Hazardous Material” for purposes hereof shall mean any chemical, substance, material, or waste or component thereof which is now or hereafter listed, defined, or regulated as a hazardous
or toxic chemical, substance, material, or waste or component thereof by any federal, state, or local governing or regulatory body having jurisdiction, or which would trigger any employee or community “right-to-know” requirements adopted by any such body, or for which any such body has adopted any requirements for the preparation or distribution of an MSDS. 

7.3 NOTIFICATION OF LANDLORD. Tenant shall promptly notify Landlord of (A) any enforcement, cleanup, or other regulatory action taken or
threatened by any governmental or regulatory authority with respect to the presence of any Hazardous Material on the Premises or the migration thereof from or to other property; (B) any demands or claims made or threatened by any party against
Tenant or the Premises relating to any loss or injury resulting from any Hazardous Material on or from the Premises; and (C) any matters where Tenant is required by law to give a notice to any governmental or regulatory authority respecting any
Hazardous Material on the Premises. Landlord shall have the right (but not the obligation) to join and participate, as a party, in any legal proceedings or actions affecting the Premises initiated in connection with any environmental, health, or
safety law. 

  
 18 

 7.4 LIST OF HAZARDOUS MATERIALS. At such times as Landlord may reasonably request, Tenant
shall provide Landlord with a written list identifying any Hazardous Material then used, stored, or maintained upon the Premises, the use and approximate quantity of each such material, a copy of any material safety data sheet (“MSDS”)
issued by the manufacturer thereof, written information concerning the removal, transportation, and disposal of the same, and such other information as Landlord may reasonably require or as may be required by law. 

7.5 CLEANUP. If any Hazardous Material is released, discharged or disposed of by Tenant or any other occupant of the Premises, or their
employees, agents, or contractors, on or about the Property in violation of the foregoing provisions, Tenant shall immediately, properly, and in compliance with applicable Laws clean up and remove the Hazardous Material from the Property and any
other affected property and clean or replace any affected personal property (whether or not owned by Landlord), at Tenant’s expense. Such clean up and removal work shall be subject to Landlord’s prior written approval (except in
emergencies), and shall include any testing, investigation, and the preparation and implementation of any remedial action plan required by any governmental body having jurisdiction or reasonably required by Landlord. If Tenant shall fail to comply
with the provisions of this § 7.2 within five (5) days after written notice by Landlord, or such shorter time as may be required by Laws or in order to minimize any hazard to persons or property, Landlord may (but shall not be obligated
to) arrange for such compliance directly or as Tenant’s agent through contractors or other parties selected by Landlord, at Tenant’s expense (without limiting Landlord’s other remedies under this Lease or applicable Laws). 

7.6 CASUALTY DAMAGE. If any Hazardous Material is released, discharged, or disposed of on or about the Property and such release, discharge, or
disposal is not caused by Tenant or other occupants of the Premises, or their employees, agents, or contractors, such release, discharge, or disposal shall be deemed casualty damage under Article 15 to the extent that the Premises or common areas
serving the Premises are affected thereby; in such case, Landlord and Tenant shall have the obligations and rights respecting such casualty damage provided under Article 15 of this Lease. 

7.7 REFRIGERANT. Tenant shall not install any refrigerant-containing systems or equipment, including refrigerators, freezers, supplemental HVAC
systems or self-contained air conditioners, without Landlord’s prior approval, which Landlord may withhold in its sole discretion. Unless Tenant shall have obtained Landlord’s prior written approval to install existing equipment after an
inspection, at Tenant’s sole cost and expense, by Landlord’s engineer for defects and proper proposed installation in the Premises, all refrigerant-containing equipment and/or systems which Tenant installs in the Premises shall be new.
Whether Tenant’s refrigerant-containing equipment or systems are defective and are properly installed shall be determined at the sole discretion of Landlord’s engineer. If Tenant wishes to install any refrigerant-containing equipment or
systems, Tenant shall obtain and provide Landlord with copies of all required permits associated with such equipment or systems. Notwithstanding the foregoing, Tenant shall have the right, subject to Landlord’s reasonable approval, to install
one or more standard food refrigerators in the Premises. 
 7.7.1 Removal of Refrigerant. Notwithstanding anything to the
contrary in this Lease, Tenant shall remove all refrigerant and refrigerant-containing equipment and/or systems installed in the Premises by or on behalf of Tenant prior to the Expiration Date of this Lease. Prior to the removal of any such
refrigerant or refrigerant-containing equipment and/ or systems, Tenant shall submit to Landlord for Landlord’s approval, the names of Tenant’s contractors and all plans and specifications for such removal. Tenant and Tenant’s
contractors shall comply with all legal requirements, industry practices and rules established by Landlord in performing such removal work. Tenant shall repair any damage to the Property or the Systems and Equipment associated with such removal, and
Tenant shall be responsible for the costs associated with restoring the Property to the condition which existed immediately prior to any modification undertaken by Landlord in order to accommodate Tenant’s refrigerant-containing equipment or
systems. 

  
 19 

 8 SERVICES AND UTILITIES 

8.1 LANDLORD’S SERVICES. Landlord agrees to provide, on the terms and conditions specified herein, the following services and Utilities for
Tenant’s use and consumption in the Premises, the cost of which shall be included in Operating Expenses and reimbursed to Landlord in accordance with§ 4.1 above: 

(a) Electricity. Electricity for standard office lighting fixtures and for equipment and accessories customary for offices,
provided (i) the connected electrical load of all the same does not exceed an average of four (4) watts per usable square foot of the Premises (or such lesser amount as may be available, based on the safe and lawful capacity of the
existing electrical circuit(s) and facilities serving the Premises); (ii) the electricity will be at nominal 120 volts, single phase (or 110 volts, depending on available service in the Building); and (iii) the safe and lawful capacity of the
existing electrical circuit(s) serving the Premises is not exceeded. Landlord will permit its electric feeders, risers, and wiring servicing the Premises to be used by Tenant to the extent available and safely capable of being used for such purpose.

 (b) Telecommunications Interface. Interface with the telephone network at the demarcation point or minimum point of entry
(“MPOE”) supplied by the local regulated public utility by means of Landlord’s INC consisting of cable pairs with a capacity consistent with the engineering standards to which the Building was designed. 

(c) HVAC. Heat, ventilation, and air-conditioning (“HVAC”) to provide a
temperature required, in Landlord’s reasonable opinion and in accordance with applicable Laws, for the comfortable occupancy of the Premises during business hours (as defined in§ 8.1.1 below). Landlord shall not be responsible for
inadequate air-conditioning or ventilation to the extent the same occurs because Tenant uses any item of equipment consuming more than 500 watts at rated capacity without providing adequate air-conditioning and ventilation therefor. 
 (d) Water. Water for drinking, lavatory and
toilet purposes at those points of supply provided for nonexclusive general use of other tenants at the Property. 
 (e)
Janitorial Services. Customary office cleaning and trash removal service Monday through Friday or Sunday through Thursday in and about the Premises. 

(f) Elevator Services. Operatorless passenger elevator service and freight elevator service (if the Property has such equipment
serving the Premises, and subject to scheduling by Landlord) in common with Landlord and other tenants and their contractors, agents, and visitors. 

8.1.1 Business Hours. The term business hours in this Lease shall mean the hours from 8:00 a.m. until 6:00 p.m. on Monday
through Friday and from 9:00 a.m. until 1:00 p.m. on Saturday throughout the year, except for New Year’s Day, Presidents’ Day, Memorial Day, Independence Day, Labor Day, Thanksgiving Day, Christmas Day, and any other federally-observed
holiday which may be created during the Term (“Holidays”). 
 8.2 ADDITIONAL ELECTRICAL CAPACITY. Any additional risers, feeders, or
other equipment or service proper or necessary to supply Tenant’s electrical requirements will be installed by Landlord, upon written request of Tenant, at the sole cost and expense of Tenant, if, in Landlord’s sole judgement, the same are
necessary and will not cause permanent damage or injury to the Property, the Premises, or the Systems and Equipment or cause or create a dangerous or hazardous condition or entail excessive or unreasonable alterations, repairs, or expense or
interfere with or disturb other tenants or occupants. Rigid conduit only will be allowed. 

  
 20 

 8.2.1 Approved Electrical Load. Tenant agrees not to connect any additional
electrical equipment of any type to the building electric distribution system, beyond that on Tenant’s approved plans for initial occupancy, other than lamps, typewriters, and other office machines which consume comparable amounts of
electricity or other electrical equipment which in the aggregate consumes the same amount of electricity as those approved for initial occupancy and will not result in any overload of electrical circuits, lines, or wiring, without Landlord’s
prior written consent. In no event shall Tenant use or install any fixtures, equipment, or machines the use of which in conjunction with other fixtures, equipment, and machines in the Premises would result in an overload or the electrical circuits
servicing the Premises. Tenant covenants and agrees that at all times its use of electric current shall never exceed the capacity of the feeders to the Building or the risers or wiring installation existing at the time in question. 

8.3 ADDITIONAL TELECOMMUNICATIONS CAPACITY. If Tenant desires any telecommunications capacity in excess of that available as of the Commencement
Date in the form of the INC between the MPOE and the telephone closet nearest the Premises and provided pursuant to§ 8.1 above, Tenant shall bear the cost of installing additional risers or INC or replacing existing INC serving the Premises
pursuant to Article 9 below. 
 8.4 REPLACEMENT BULBS AND TUBES. Tenant shall furnish, install, and replace, as required, all non-Building-standard lighting tubes, lamps, bulbs, and ballasts required in the Premises, at Tenant’s sole cost and expense. All lighting tubes, lamps, bulbs, and ballasts so installed become Landlord’s
property upon the expiration or sooner termination of this Lease. 
 8.5 TWENTY-FOUR HOURS ACCESS. Subject to the provisions of § 8.8,
Tenant, its employees, agents, and invitees shall have access to the Premises twenty-four (24) hours a day, seven (7) days a week. Landlord may restrict access outside of business hours by requiring persons to show a badge or
identification card issued by Landlord. Landlord shall not be liable for denying entry to any person unable to show the proper identification. Landlord may without liability temporarily close the Building if required because of a life-threatening or
Building-threatening situation. 
 8.6 EXTRA SERVICES. Landlord shall, subject to all applicable Laws, seek to provide such utilities or
services in excess of those Landlord is required to provide under§ 8.1 above as Tenant may from time to time request, if the same are reasonable and feasible for Landlord to provide and do not involve modifications or additions to the Property
or the Systems and Equipment and if Landlord shall receive Tenant’s request within a reasonable period prior to the time such extra utilities or services are required. Landlord may comply with written or oral requests by any officer or employee
of Tenant, unless Tenant shall notify Landlord of, or Landlord shall request, the names of authorized individuals (up to three (3) for each floor on which the Premises are located) and procedures for written requests. Tenant shall, for such
extra utilities or services, pay such charges as Landlord shall from time to time establish. 
 8.6.1 Extraordinary Service
Usage. If Tenant shall utilize Building services for the Premises at any time other than during business hours, Landlord shall furnish such extraordinary services (excluding air-conditioning, except as
provided below) at Landlord’s then-current prevailing rate for such services. In addition to the foregoing services, if Tenant shall require air-conditioning service for the Premises at any time other
than during business hours, Landlord shall, upon reasonable advance notice from Tenant, furnish such after-hours air-conditioning service at Landlord’s then-current prevailing rate for such services as a
separate charge; provided, however, in the event Tenant requests such after-hours air-conditioning service at a time not immediately preceding or immediately succeeding times when “regular hours”
service is being furnished hereunder, then Tenant must request not less than five (5) hours of after-hours air-conditioning service. Notwithstanding anything contained herein to the contrary,
Landlord’s prevailing rate for the extraordinary services described herein shall be subject to increase from time to time as Landlord may reasonably determine. 

  
 21 

 8.6.2 Payment for Excess Usage. All charges for extra utilities or services or
those requested outside business hours shall be due at the same time as the installment of Base Rent with which the same are billed, or if billed separately, shall be due within twenty (20) days after such billing. 

8.6.3 Changes in HVAC System. Use of the Premises, or any part thereof, in a manner exceeding the design conditions (including
occupancy and connected electrical load) for the heating or cooling units in the Premises, or rearrangement of partitioning which interferes with normal operation of the HVAC system in the Premises, may require changes in the HVAC system servicing
the Premises. Such changes shall be made by Tenant, at its expense, as Tenant’s Changes pursuant to Article 9. Tenant shall not change or adjust any closed or sealed thermostat or other element of the HVAC system without Landlord’s express
prior written consent. 
 8.6.4 Separate Metering. Landlord may install and operate meters or any other reasonable system for
monitoring or estimating any services or utilities used by Tenant in excess of those required to be provided by Landlord under this Article 8 (including a system for Landlord’s engineer reasonably to estimate any such excess usage). If such
system indicates such excess services or utilities, Tenant shall pay Landlord’s reasonable charges for installing and operating such system and any supplementary air-conditioning, ventilation, heat,
electrical, or other systems or equipment (or adjustments or modifications to the existing Systems and Equipment), and Landlord’s reasonable charges for such amount of excess services or utilities used by Tenant. If Tenant’s use of extra
utilities or services causes Landlord’s regulated baseline quantities of water, gas, electricity, or any other utility or service to be exceeded, Tenant shall pay for such excess quantities of such utilities or services at the rate which is
imposed upon Landlord for quantities in excess of the regulated baseline. In addition, Tenant shall pay prior to delinquency any fine or penalty which may be imposed upon or assessed against Landlord or the Building or the Property by virtue of
Tenant’s excess usage of any services or utilities, including water, gas, and electricity. 
 8.6.5 Supplemental HVAC. If
Tenant operates a supplemental HVAC unit in the Premises for cooling of a dedicated server room or otherwise, whether such unit is was existing on the Commencement Date, installed by Landlord as part of Landlord’s Work to prepare the Premises
for Tenant’s occupancy, or installed later by Tenant as a Tenant’s Change, Tenant shall pay to Landlord as an extra service charge all costs of operating such supplementary HVAC unit in accordance with the provisions of § 8.6.4 above
as determined by separate metering or the reasonable estimate of Landlord’s engineer. 
 8.7 INTERRUPTION OF SERVICES. Landlord does not
warrant that any services or utilities provided hereunder for Tenant’s use in the Premises will be free from shortages, failures, variations, or interruptions caused by repairs, maintenance, replacements, improvements, alterations, changes of
service, strikes, lockouts, labor controversies, accidents, inability to obtain services, fuel, steam, water or supplies, governmental requirements or requests, or other causes beyond Landlord’s reasonable control, including interference with
light or other incorporeal hereditaments and any interruption in services or any failure to provide services to Landlord by a designated utility company at the demarcation point at which Landlord accepts responsibility for such service or at any
point prior thereto, which interference impedes Landlord in furnishing plumbing, HVAC, electrical, sanitary, life safety, elevator, telecommunications, or other Building services, utilities, or the Systems and Equipment. None of the same shall be
deemed an eviction or disturbance of Tenant’s use and possession of the Premises or any part thereof, shall render Landlord liable to Tenant for abatement of Rent, or shall relieve Tenant from performance of Tenant’s obligations under this
Lease. Landlord in no event shall be liable for damages by reason of loss of profits, business interruption, or other compensatory or consequential damages. 

  
 22 

 8.8 SAFETY AND SECURITY DEVICES, SERVICES, AND PROGRAMS. The parties acknowledge that safety
and security devices, services, and programs provided by Landlord, if any, while intended to deter crime and ensure safety, may not in given instances prevent theft or other criminal acts or ensure safety of persons or property, and such devices,
services and programs shall not under any circumstances be deemed to be a guaranty, representation, or warranty by Landlord to Tenant or any third parties as to the safety or protection of person or property. The risk that any safety or security
device, service, or program may not be effective, or may malfunction, or be circumvented by a criminal, is assumed by Tenant with respect to Tenant’s property and interests; and Tenant shall obtain insurance coverage to the extent Tenant
desires protection against such criminal acts and other losses, as further described in Article 14. Tenant agrees to cooperate in any reasonable safety or security program developed by Landlord or required by Law. 

9 TENANT’S CHANGES 
 9.1
TENANTS REQUESTED CHANGES. Tenant may, subject to § 9.2 below, from time to time during the Term of this Lease, at its expense, make such alterations, additions, installations, substitutions, improvements, and decorations (collectively
“Tenant’s Changes”) in and to the Premises as Tenant may reasonably consider necessary for the conduct of its business in the Premises (except for changes which would require modification of the Property outside the Premises), on the
following conditions: 
 (a) the outside appearance or the strength of the Building or of any of its structural parts shall not be
affected, and Tenant shall cause no penetration of the roof or the exterior fabric of the Building; 
 (b) no part of the Building
outside of the Premises shall be physically affected; 
 (c) the proper functioning of any of the Systems and Equipment shall not be
adversely affected, and the usage of such systems by Tenant shall not be increased; 
 (d) no such change shall require the addition
of new INC riser cable or expand the number of telephone pairs dedicated to the Premises by the Buildings’ telecommunications engineering design; 

(e) in performing the work involved in making such changes, Tenant shall be bound by and observe all of the conditions and covenants
contained in the following sections of this Article 9; and 
 (f) with respect to Tenant’s Changes, Tenant shall make all
arrangements for, and pay all expenses incurred in connection with, use of the freight elevators servicing the Premises. 
 9.2 PLANS AND
APPROVAL. Before proceeding with any Tenant’s Changes, Tenant shall advise Landlord thereof and arrange a meeting with the Building Manager, the Building Architect, and/ or the Building Contractor, as required by Landlord in relation to the
scope of the proposed Changes. Except in extraordinary circumstances which would reasonably require an exception, all work to be performed in the Building shall be performed by the Building Contractor on the basis of plans and drawings prepared by
the Building Architect. If Landlord grants permission for Tenant to utilize another contractor and/or architect for its Changes, before proceeding with any Tenant’s Changes, Tenant shall submit to Landlord plans and specifications and all
changes and revisions thereto for the work to be done for Landlord’s reasonable approval; and Tenant shall, upon demand of Landlord, pay to Landlord the reasonable costs incurred and paid to third parties by Landlord for the review of such
plans and specifications and all changes and revisions thereto by its architect, engineer, and other consultants. Landlord may as a condition of its approval require Tenant to make reasonable revisions in and to the plans and specifications.
Landlord may require Tenant to post a bond or other security reasonably satisfactory to Landlord to insure the completion of such change. If Landlord consents to any Tenant’s Changes or supervises the work of constructing any

  
 23 

 
Tenant’s Changes, such consent or supervision shall not be deemed a warranty as to the adequacy of the design, workmanship, or quality of materials, and Landlord hereby expressly disclaims
any responsibility or liability for the same. Landlord shall under no circumstances have any obligation to repair, maintain, or replace any portion of such work. 

9.2.1 As-Built Plans. Within thirty (30) days after completion of Tenant’s
Changes requiring the submission of plans to Landlord, Tenant shall furnish to Landlord a complete set of “as-built” plans and specifications. 

9.3 PERMITS AND PERFORMANCE. Tenant, at its expense, shall obtain all necessary governmental permits and certificates for the commencement and
prosecution of Tenant’s Changes and for final approval thereof upon completion and shall furnish copies thereof to Landlord. Tenant shall cause Tenant’s Changes to be performed in compliance therewith and with all applicable Laws and
requirements of public authorities and with all applicable requirements of insurance bodies, and in good and workmanlike manner, using new materials and equipment at least equal in quality and class to the original installations in the Property.
Tenant’s Changes shall be performed in such manner as not unreasonably to interfere with, delay, or impose any additional expense upon Landlord in the renovation, maintenance, or operation of the Property or any portion thereof, unless Tenant
shall indemnify Landlord therefor to the latter’s reasonable satisfaction. 
 9.4 CONTRACTORS. All electrical, mechanical, and plumbing
work in connection with Tenant’s Changes shall be performed by Landlord’s contractors at Tenant’s expense. If Tenant shall request any electrical, mechanical, or plumbing work in connection with Tenant’s Changes, Landlord shall
request Landlord’s contractors to furnish Tenant with prices to perform the same prior to prosecuting same. In addition to the foregoing, and notwithstanding anything to the contrary in this Article 9, Landlord may, at Landlord’s option,
require that the work of constructing any Tenant’s Changes be performed by Landlord’s contractor, in which case the cost of such work shall be paid for before commencement of the work. 

9.5 SUPERVISION AND FEE. Landlord may require that all work of constructing Tenant’s Changes be performed under Landlord’s
supervision. If Landlord does not elect to require that Tenant use Landlord’s contractor, and if Tenant chooses to use its own contractor for the work of constructing Tenant’s Changes, Tenant shall pay to Landlord upon completion of any
such work by Tenant’s contractor an administrative fee of fifteen percent (15%) of the cost of the work, to cover Landlord’s overhead in reviewing Tenant’s plans and specifications and performing any supervision of the work of
Tenant’s Changes. If Tenant chooses to use Landlord’s contractor for such work, Tenant shall pay to Landlord upon completion an administrative fee equal to five percent (5%) of the cost of the work. 

9.6 RESTORATION OF FIXTURES. If any of Tenant’s Changes shall involve the removal of any fixtures, equipment, or other property in the
Premises which are not Tenant’s Property (as defined in Article 10), such fixtures, equipment, or other property shall be promptly replaced, at Tenant’s expense, with new fixtures, equipment, or other property (as the case may be) of like
utility and at least equal value, unless Landlord shall otherwise expressly consent in writing; and Tenant shall, upon Landlord’s request, store and preserve, at Tenant’s sole cost and expense, any such fixtures, equipment or property so
removed and shall return same to Landlord upon the expiration or sooner termination of this Lease. 
 9.7 MECHANIC’S LIENS. Tenant shall
keep the Property and Premises free from any mechanic’s, materialman’ s, or similar liens or other such encumbrances, including the liens of any security interest in, conditional sales of, or chattel mortgages upon, any materials,
fixtures, or articles so installed in and constituting part of the Premises, in connection with any Tenant’s Changes on or respecting the Premises not performed by or at the request of Landlord and shall indemnify, defend, protect, and hold
Landlord harmless from and against any claims, liabilities, judgements, or costs (including attorneys’ fees) arising 

  
 24 

 
out of the same or in connection with any such lien, security interest, conditional sale or chattel mortgage or any action or proceeding brought thereon. Tenant shall give Landlord written notice
at least twenty (20) days prior to the commencement of work on any Tenant’s Change in the Premises (or such additional time as may be necessary under applicable Laws), in order to afford Landlord the opportunity of posting and recording
appropriate notices of nonresponsibility. Tenant shall remove any such lien or encumbrance by bond or otherwise within thirty (30) days after written notice by Landlord; and if Tenant shall fail to do so, Landlord may pay the amount necessary
to remove such lien or encumbrance, without being responsible for investigating the validity thereof. The amount so paid shall be deemed Additional Rent under this Lease payable upon demand, without limitation as to other remedies available to
Landlord under this Lease. Nothing contained in this Lease shall authorize Tenant to do any act which shall subject Landlord’s title to the Property or Premises to any liens or encumbrances, whether claimed by operation of law or express or
implied contract. Any claim to a lien or encumbrance upon the Property or Premises arising in connection with any Work on or respecting the Premises not performed by or at the request of Landlord shall be null and void, or, at Landlord’s
option, shall attach only against Tenant’s interest in the Premises and shall in all respects be subordinate to Landlord’s title to the Property and Premises. 

9.8 NOTICES OF VIOLATION. Tenant, at its expense, and with diligence and dispatch, shall procure the cancellation or discharge of all notices of
violation arising from or otherwise connected with Tenant’s Changes which shall be issued by any governmental, public, or quasi-public authority having or asserting jurisdiction. However, nothing herein contained shall prevent Tenant from
contesting, in good faith and at its own expense, any such notice of violation, provided that Landlord’s rights hereunder are in no way compromised or diminished thereby. 

9.9 INDUSTRIAL RELATIONS. Tenant agrees that the exercise of its rights pursuant to the provisions of this Article 9 or any other provision of
this Lease shall not be done in a manner which would create any work stoppage, picketing, labor disruption, or dispute or violate Landlord’s union contracts affecting the Property and/or Complex or interfere with the business of Landlord or any
Tenant or occupant of the Building. Tenant shall, immediately upon notice from Landlord, cease any activity, whether or not permitted by this Lease, giving rise to such condition. If Tenant fails to do so, Landlord, in addition to any rights
available to it under this Lease and pursuant to Law, shall have the right to an ex parte injunction without notice. 
 10 TENANT’S
PROPERTY 
 10.1 FIXTURES AND IMPROVEMENTS. All fixtures, equipment, improvements, alterations, and appurtenances attached to or built
into the Premises at the commencement of or during the Term of this Lease, including cabinets, sinks, faucets, appliances, hot water heaters, etc. (collectively “Improvements”), whether or not by or at the expense of Tenant, shall be and
remain a part of the Premises, shall be deemed the property of Landlord, and shall not be removed by Tenant, except as expressly provided in Article 11 below. 

10.2 TENANT’S PROPERTY AND TRADE FIXTURES. All movable partitions, trade fixtures, office machinery and equipment, communications
equipment, and computer equipment (whether or not attached to or built into the Premises) which are installed in the Premises by or for the account of Tenant, without expense to Landlord and which can be removed without structural damage to the
Property, and all furniture, furnishings, and other articles of movable personal property owned by Tenant and located in the Premises (collectively “Tenant’s Property”) shall be and shall remain the property of Tenant and may be
removed by it at any time during the Term of this Lease; provided that if any of Tenant’s Property is removed, Tenant or any party or person entitled to remove same shall repair or pay the cost of repairing any damage to the Premises or to the
Property resulting from such removal. Any equipment or other property for which Landlord shall have granted any allowance or credit to Tenant or which has replaced such items originally provided by Landlord at Landlord’s expense shall not be
deemed to have been installed by or for the account of Tenant, without expense to Landlord, and shall not be considered Tenant’s Property. 

  
 25 

 11 CONDITION UPON SURRENDER 

11.1 CONDITION AND RESTORATION. At or before the Expiration Date or the date of any earlier termination of this Lease, or as promptly as
practicable using Tenant’s best efforts after such an earlier termination date, Tenant, at its expense, shall do all of the following: 

(a) surrender possession of the Premises in the condition required under§ 12.1 below, ordinary wear and tear excepted; 

(b) surrender all keys, any key cards, and any parking stickers or cards to Landlord and give Landlord in writing the combinations of
any locks or vaults then remaining in the Premises; 
 (c) remove from the Premises all of Tenant’s Property, including any data
wiring and cabling that Tenant has installed, except such items thereof as Tenant shall have expressly agreed in writing with Landlord were to remain and to become the property of Landlord; and 

(d) fully repair any damage to the Premises or the Property resulting from such removal. 

Tenant’s obligations herein shall survive the expiration or earlier termination of the Lease, unless expressly provided to the contrary herein. All
Improvements and other items in or upon the Premises (except Tenant’s Property), whether installed by Tenant or Landlord, shall be Landlord’s property and shall remain upon the Premises, all without compensation, setoff, allowance, or
credit to Tenant; provided, however, that if prior to such expiration or earlier termination Landlord so directs by notice, Tenant shall promptly remove such of the Improvements in the Premises as are designated in such notice and shall restore the
Premises to their condition prior to the installation of such Improvements. Notwithstanding the foregoing, Landlord shall not require removal of customary office improvements installed as part of Landlord’s Work under § 3.2 above (except
as expressly provided to the contrary therein), or installed by Tenant with Landlord’s written approval (except as expressly required by Landlord in connection with granting such approval). 

11.2 TENANT’S FAILURE TO REMOVE OR RESTORE. If Tenant shall fail to perform any repairs or restoration or fail to remove any items from the
Premises as required under this Article 11, Landlord may do so, and Tenant shall pay Landlord the cost thereof upon demand. All property removed from the Premises by Landlord pursuant to any provisions of this Lease or any Law may be handled or
stored by Landlord at Tenant’s expense, and Landlord shall in no event be responsible for the value, preservation, or safekeeping thereof. All property not removed from the Premises or retaken from storage by Tenant within thirty (30) days
after expiration or earlier termination of this Lease or Tenant’s right to possession shall at Landlord’s option be conclusively deemed to have been conveyed by Tenant to Landlord as if by bill of sale without payment by Landlord. Unless
prohibited by applicable Laws, Landlord shall have a lien against such property for the costs incurred in removing and storing the same. 

  
 26 

 12 REPAIRS AND MAINTENANCE 

12.1 TENANT’S CARE OF PREMISES. Except for customary cleaning and trash removal provided by Landlord under § 8.1 above and damage
covered under Article 15, Tenant shall keep the Premises in good and sanitary condition, working order, and repair, including carpet, wall-covering, doors pertinent to and within the Premises, plumbing, all telecommunications cables and wiring
within Tenant’s Premises (“IW”) from the interface of such IW with the INC, and other fixtures, equipment, alterations, and improvements, whether installed by Landlord or Tenant. In addition, Tenant, at its expense, shall promptly
make all repairs, ordinary or extraordinary, interior or exterior, structural or otherwise, in and about the Premises and the Property, as shall be required by reason of (a) the performance or existence of Tenant’s Work or Tenant’s
Changes; (b) the installation, use, or operation of Tenant’s Property in the Premises; (c) the moving of Tenant’s Property in or out of the Building; or (d) the misuse or neglect of Tenant or any of its employees, agents, or
contractors. Tenant, at its expense, shall replace all scratched, damaged, or broken doors or other glass in or about the Premises and shall be responsible for all repairs, maintenance, and replacement of wall and floor coverings in the Premises and
for the repair and maintenance of all lighting fixtures therein. All repairs except for emergency repairs made by Tenant as provided herein shall be performed by contractors or subcontractors approved in writing by Landlord prior to commencement of
such repairs, which approval shall not be unreasonably withheld or delayed. If Tenant does not promptly make such arrangements, Landlord may, but need not, make such repairs, maintenance, and replacements, and the costs paid or incurred by Landlord
therefor shall be reimbursed by Tenant promptly after request by Landlord. 
 12.2 LANDLORD’S CARE OF PROPERTY. Landlord, at its expense,
shall keep and maintain the structural elements of the Building, the common areas of the Property, and the Systems and Equipment serving the Premises in good working order, condition, and repair and shall make all repairs, structural and otherwise,
interior and exterior, as and when needed in or about the Premises, except for those repairs for which Tenant is responsible pursuant to § 12.1 above or any other provisions of this Lease. Landlord shall maintain and repair all INC in the
Building, and Tenant shall have no right to make repairs to INC. The cost of Landlord’s maintenance and repairs pursuant to this Article 12 shall be reimbursed to Landlord to the extent provided in Article 4 above. 

12.3 WAIVER BY TENANT. Tenant waives the benefits of any statute now or hereafter in effect which would otherwise afford Tenant the right to
make repairs at Landlord’s expense or to terminate this Lease because of Landlord’s failure to keep the Premises in good order, condition, and repair. 

13 RULES AND REGULATIONS 
 13.1
OBSERVANCE AND MODIFICATION. Tenant and its employees and agents shall faithfully observe and comply with the Rules and Regulations attached hereto as Exhibit C (the “Rules”) and such reasonable changes therein
(whether by modification, elimination, or addition) as Landlord at any time or times hereafter may make and communicate in writing to Tenant, so long as such changes do not unreasonably affect the conduct of Tenant’s business in the Premises,
except as required by any applicable Law; provided, however, that in case of any conflict or inconsistency between the provisions of this Lease and any of the Rules as originally promulgated or as changed, the provisions of this Lease shall control.

 13.2 APPLICATION TO TENANT. Nothing in this Lease shall be construed to impose upon Landlord any obligation to Tenant to enforce the Rules
or the terms, covenants, or conditions in any other lease, as against any other tenant, and Landlord shall not be liable to Tenant for violation of the same by any other tenant or its employees, agents, or visitors. 

  
 27 

 14 INSURANCE AND INDEMNIFICATION 

14.1 TENANT’S INSURANCE. Tenant shall obtain and maintain in effect at all times during Tenant’s possession of the Premises the
following insurance coverages and policies: 
 14.1.1 Liability Insurance. Tenant shall maintain a policy of commercial general
liability insurance, which shall include coverages for (a) personal injury; (b) broad-form contractual liability; and (c) broad-form property damage liability. The minimum limits of liability shall be a combined single limit with
respect to each occurrence of not less than Two Million Dollars ($2,000,000) and an aggregate limit of not less than Three Million Dollars ($3,000,000). Such limits may be met through any combination of primary and excess liability policies,
provided that any umbrella or excess liability policy shall be in following form. The policy shall contain a cross-liability endorsement and a severability of interest clause. Tenant shall increase the insurance coverage as required by
Landlord’s lender or if Landlord’s insurance consultant believes that the coverage is not adequate. 
 14.1.2
Tenant’s Business Auto Liability Insurance. Tenant shall maintain business auto liability insurance with an “any auto, owned, non-owned, and hired” endorsement in an amount not less than
Two Million Dollars ($2,000,000) combined single limit. 
 14.1.3 Tenant’s Business Personal Property Insurance. Tenant
shall maintain on all of its business personal property, including valuable business papers and accounts receivable; operating supplies; inventory; and furniture, fixtures, and equipment (whether owned, leased, or rented) (collectively
“Business Personal Property”) an “all risk” property damage insurance policy including coverages for sprinkler leakage and containing an agreed amount endorsement (or, if applicable, a business owner’s policy with a no-coinsurance provision) in an amount not less than one hundred percent (100%) of the full replacement cost valuation of such Business Personal Property. The proceeds from any such policy shall be used by Tenant
for the replacement of such Business Personal property. 
 14.1.4 Workers’ Compensation Insurance. Tenant shall maintain
workers’ compensation insurance as required by law and employer’s liability insurance in an amount not less than Five Hundred Thousand Dollars ($500,000). 

14.1.5 Business Interruption/Extra Expense Insurance. Tenant shall maintain business interruption or (if applicable) contingent
business interruption and extra expense insurance in such amounts as will reimburse Tenant for direct or indirect loss of earnings and incurred costs attributable to the perils commonly covered by Tenant’s property insurance described in §
14.1.3 above but in no event less than the average total of Tenant’s annual net profits plus annual continuing business expenses during the three-year period immediately preceding such interruption or loss. Such insurance will be carried with
the same insurer that issues the insurance for Tenant’s Business Personal Property pursuant to§ 14.1.2 above. 
 14.1.6
Other Coverage. Tenant, at its cost, shall maintain such other insurance as Landlord may reasonably require from time to time, but in no event may Landlord require any other insurance which is not then available at commercially reasonable
rates. 
 14.2 TENANT’S INSURANCE CRITERIA. All insurance required to be maintained by Tenant under this Lease shall conform to the
following criteria: 
 (i) Tenant’s insurance shall be issued by insurance companies authorized to do business in the State of
California with a financial rating of at least A-:VIII for any property insurance and at least A-:Vlll for any liability insurance, as rated in the most recent edition
of Best’s Insurance Reports. 
 (ii) Tenant’s commercial general liability insurance shall be issued as primary and
noncontributory to any insurance maintained by Landlord. 

  
 28 

 (iii) Tenant’s liability insurance policies shall name Tenant as the insured
and Landlord, Landlord’s agents, and any Lessors and Holders (as such terms are defined in § 18.1 below) whose names shall have been furnished to Tenant as additional insureds. 

(iv) Should Tenant receive a notice of cancellation from the insurer of any of the insurance required in this Lease, Tenant shall
notify Landlord in writing within five (5) business days of receipt of such notice. Tenant will take all reasonable steps to remedy the cause of any such cancellation or shall find replacement insurance meeting the requirements of this Lease,
such that no lapse in the required insurance shall occur. Tenant shall provide written notice to Landlord that the pending cancellation has been rescinded or shall provide a certificate of insurance evidencing the replacement insurance, by the date
the pending cancellation was to become effective. 
 (v) with respect to damage to or loss of Tenant’s Business Personal
Property, a waiver of subrogation must be obtained, as required under § 14.4 below. 
 14.2.2 Blanket Coverage. All of
the insurance requirements set forth herein on the part of Tenant to be observed shall be deemed satisfied if the Premises are covered by a blanket insurance policy complying with the limits, requirements, and criteria contained in this Article 14
insuring all or most of Tenant’s facilities in California. 
 14.2.3 Evidence of Coverage. A duplicate original policy or
a certificate of insurance shall be deposited with Landlord at the commencement of the Term or, if earlier, upon Tenant’s taking possession of the Premises; and on renewal of the policy a certificate of insurance listing the insurance coverages
required hereunder and naming the appropriate additional insureds shall be deposited with Landlord not less than seven (7) days before expiration of the policy. 

14.3 LANDLORD’S INSURANCE. Landlord shall maintain “all risk” property damage insurance containing an agreed amount endorsement
covering not less than one hundred percent (100%) of the full insurable replacement cost valuation of (y) the Building and the tenant improvements, betterments, and the alterations thereto; and (z) Landlord’s personal property,
business papers, furniture, fixtures, and equipment (collectively “Landlord’s Property”), exclusive of the costs of excavation, foundations and footings, and risks required to be covered by Tenant’s insurance, and subject to
commercially reasonable deductibles. Landlord shall also obtain and keep in full force the following policies of insurance: (a) commercial general liability insurance; (b) loss of rent insurance (also known as rent continuation insurance);
(c) workers’ compensation insurance, if required by applicable Law; and (d) such other insurance as Landlord deems appropriate or as may be required by any Holder or Lessor. 

14.4 RELEASES AND WAIVERS OF SUBROGATION. The purpose of this provision is to allow Landlord and Tenant to allocate and assume certain risks to
coincide with insurance coverages required to be maintained pursuant to the terms to this Lease. Landlord and Tenant recognize the benefit that each will receive from the waivers of subrogation each is required to obtain pursuant to this § 14.4
and that there are significant advantages to each in connection with minimizing duplication of insurance coverages. Accordingly, Landlord and Tenant agree to accept and place the limitations which follow on each other’s respective liabilities
and responsibility for damages in order to coincide with required insurance coverages; provided, however, that the provisions of§§ 14.4.1 through 14.4.5 below shall be applicable only to the extent that the injured party in each case
actually receives compensation from its insurer with respect to the damage caused by the other party, and otherwise the provisions of§ 14.5 below shall apply. 

  
 29 

 14.4.1 Tenant’s Property Agreement. In light of Tenant’s agreement
to insure Tenant’s Business Personal Property in accordance with § 14.1.3 above, Tenant agrees that Landlord will have no liability to Tenant in the event Landlord negligently damages or destroys all or any part of Tenant’s Business
Personal Property. Tenant will cause to be placed in its insurance policies covering Tenant’s Business Personal Property a waiver of subrogation so that its insurance company will not become subrogated to Tenant’s rights and will not be
able to proceed against Landlord in connection with any such damage or destruction. 
 14.4.2 Landlord’s Property
Agreement. In light of Landlord’s agreement to insure Landlord’s Property in accordance with § 14.3 above, Landlord agrees that Tenant will have no liability to Landlord in the event that Tenant negligently damages or destroys all
or any part of Landlord’s Property. Landlord will cause to be placed in its insurance policies covering Landlord’s Property a waiver of subrogation so that its insurance company will not become subrogated to Landlord’s rights and will
not be able to proceed against Tenant in connection with any such damage or destruction. 
 14.4.3 Tenant’s Release.
Landlord shall not be responsible or liable to Tenant for any damages or destruction to Tenant’s Business Personal Property caused by Landlord’s employees, agents, visitors, invitees, guests, or independent contractors (collectively
“Landlord’s Associates”), and Tenant hereby releases Landlord from any claims, liabilities, demands, losses, damages, consequential damages, and the like, including reasonable attorneys’ fees and court costs (collectively
“Claims”) resulting from damage or destruction to Tenant’s Business Personal Property caused directly or indirectly by Landlord and/ or Landlord’s Associates; provided, however, that nothing herein shall be deemed to release
Landlord’s independent contractors from any such Claims Tenant may have against Landlord’s independent contractors. 

14.4.4 Landlord’s Release. Tenant shall not be responsible or liable to Landlord for any damages or destruction to
Landlord’s Property caused by Tenant’s employees, agents, visitors, invitees, guests, or independent contractors (collectively “Tenant’s Associates”), and Landlord hereby releases Tenant from any Claims resulting from damage
or destruction to Landlord’s Property caused directly or indirectly by Tenant and/ or Tenant’s Associates; provided, however, that nothing herein shall be deemed to release Tenant’s independent contractors from any such Claims
Landlord may have against Tenant’s independent contractors. 
 14.4.5 Damage to Business and Loss of Rents. In light of
Landlord’s agreement to carry continuation of rent insurance pursuant to § 14.3 above and Tenant’s agreement to carry business interruption insurance (extra expense insurance) in accordance with§ 14.1.5 above, in the event that
Landlord’s Property is damaged or destroyed because of any act or conduct, negligent or otherwise, by Tenant and/ or by Tenant’s Associates, Landlord shall have no rights against Tenant by virtue of such damage or destruction, and Landlord
hereby releases Tenant from all Claims, including claims for loss of rent or profits, by Landlord directly or indirectly resulting from the damage or destruction of Landlord’s Property by conduct by Tenant and/or by Tenant’s Associates.
Likewise, in the event that Tenant’s Business Personal Property is damaged or destroyed because of any act or conduct, negligent or otherwise, by Landlord and/ or by Landlord’s Associates, Tenant shall have no rights against Landlord by
virtue of such damage or destruction, and Tenant hereby releases Landlord from all Claims by Tenant directly or indirectly resulting from the damage or destruction to Tenant’s Business Personal Property by the conduct of Landlord and/or
Landlord’s Associates, including Claims for loss of business or loss of profits. Notwithstanding the foregoing, nothing herein shall be deemed to release Tenant’s or Landlord’s independent contractors from any liability to Tenant
and/or Landlord. 
 14.4.6 Injury and Death to Individuals. Landlord and Tenant understand that waivers of subrogation do not
apply to injury to and death of individuals. Landlord and Tenant shall each carry insurance, as provided by this Article 14, in connection with injury and death to individuals. Landlord hereby agrees to indemnify and hold Tenant harmless from any
Claims which Tenant may otherwise have with respect to injury or death to individuals occurring within the Property but outside the Premises, except 

  
 30 

 
to the extent that such injury or death is caused by Tenant and/or Tenant’s Associates, through negligence or otherwise, and is not covered by the insurance Landlord is required to carry
under this Lease. Likewise, Tenant agrees to indemnify, defend, protect, and hold Landlord harmless from any Claims for injury or death to persons occurring within the Premises or caused, directly or indirectly, by Tenant or Tenant’s Associates
outside the Premises, except to the extent such injuries or death are caused by Landlord and/ or Landlord’s Associates, through negligence or otherwise, and are not covered by the insurance Tenant is required to carry under this Lease. 

14.4.7 Abatement of Rent. Except as may be expressly provided elsewhere in this Lease, Tenant shall not be entitled to Rent
abatement and shall not otherwise have, and hereby releases Landlord from, any Claims resulting from Tenant’s inability to utilize all or any part of the Premises, except to the extent that Tenant is unable to use all or any part of the
Premises and does not use all or any part of the Premises as a result of Landlord’s intentional decision to refuse to provide access to the Building and/or the Premises and/or to provide services and/ or utilities to Tenant as required to be
provided by Landlord to Tenant pursuant to this Lease, where such refusal is not caused by a Force Majeure occurrence. 
 14.4.8
Availability of Waiver of Subrogation. If an insurance policy cannot be obtained with a waiver of subrogation or is obtainable only by the payment of an additional premium charge above that charged by insurance companies issuing policies
without waiver of subrogation, the party undertaking to obtain the insurance shall notify the other party of this fact. The other party shall have a period of ten (10) days after receiving the notice either to place the insurance with a company
that is reasonably satisfactory to the other party and that will carry the insurance with a waiver of subrogation at no additional cost or to agree to pay the additional premium if such a policy is obtainable at additional cost. If the insurance
cannot be obtained or the party in whose favor a waiver of subrogation is desired refuses to pay the additional premium charged, the other party is relieved of the obligation to obtain a waiver of subrogation with respect to the particular insurance
involved. 
 14.5 OTHER CASES OF DAMAGE OR INJURY. In all cases not covered by the foregoing provisions of this Article 14, Tenant hereby assumes all
risk of damage to property or injury to persons in, upon, or about the Premises from any cause other than the active negligence or intentional misconduct of Landlord and its agent or employees. Without limiting the generality of the foregoing,
Landlord shall not be liable for injury or damage which may be sustained by the person, goods, wares, merchandise, or property of Tenant or Tenant’s Associates or any other person in or about the Premises caused by or resulting from fire,
steam, electricity, gas, water or rain, which may leak or flow from or into any part of the Premises, or from the breakage, leakage, obstruction, or other defects of the Systems and Equipment, pipes, sprinklers, wires, INC, appliances, plumbing,
heating, air-conditioning, or lighting fixtures of the same, whether the damage or injury results from conditions arising upon the Premises or upon other portions of the Property, the Complex, or from other
sources. Landlord shall not be liable for any damages arising from any act or omission of any other tenant or occupant of the Property or Complex. In all cases not covered by the foregoing provisions of this Article 14, Tenant shall indemnify,
defend, protect, and hold Landlord harmless against (a) any and all Claims arising from any death or injury to any person or damage to any property whatsoever occurring in, on, or about the Premises or any part thereof, and (b) any and all
Claims occurring in, on or about any of the Common Areas, the Property, or the Complex, when such injury or damage is caused in whole or in part by the act, negligence, fault, or omission of any duty with respect to the same by Tenant or
Tenant’s Associates. In all cases not covered by the foregoing provisions of this Article 14, Tenant shall further indemnify, defend, protect, and hold Landlord harmless from and against any and all Claims arising from any breach or default in
the performance of any obligation on Tenant’s part to be performed under this Lease, or arising from any act or negligence of Tenant or Tenant’s Associates, and from and against all costs, attorneys’ fees, expenses, and liabilities
incurred in connection with any such Claim or any action or proceeding brought thereon. In case any action or proceeding be brought against Landlord by reason of any such Claim, Tenant, upon notice from Landlord, shall defend the same at

  
 31 

 
Tenant’s expense by counsel reasonably satisfactory to Landlord; provided, however, that Tenant shall not be liable in any case for damage to property or death or injury to person(s)
occasioned by the active negligence or intentional misconduct of Landlord or Landlord’s Associates, unless covered by insurance Tenant is required to provide. 

15 DAMAGE OR DESTRUCTION 
 15.1
LOSS COVERED BY INSURANCE. If at any time prior to the expiration or termination of this Lease the Premises or the Property is wholly or partially damaged or destroyed by any casualty which results in a loss to Landlord that is fully covered
by insurance maintained by Landlord or for Landlord’s benefit (or required to be maintained by Landlord pursuant to§ 14.3 above), which casualty renders the Premises totally or partially inaccessible or unusable by Tenant in the ordinary
conduct of Tenant’s business, the parties agree that the following provisions shall modify their obligations under this Lease after such damage or destruction. 

15.1.1 Repairs Which Can Be Completed Within Six (6) Months. Within thirty (30) days after Tenant’s
written notice to Landlord of such damage or destruction, Landlord shall provide Tenant with notice of its determination of whether the damage or destruction can be repaired within six (6) months after the commencement of the work of repairing
such damage or destruction without the payment of overtime or other premiums. If all repairs to Premises or Property can, in Landlord’s judgement, be completed within six (6) months following the date of the commencement of the work of
repairing such damage or destruction without the payment of overtime or other premiums, Landlord shall, at Landlord’s expense, repair the same; and this Lease shall remain in full force and effect, except that a proportionate reduction of the
Base Rent shall be allowed Tenant to the extent that the Premises shall be rendered inaccessible or unusable by Tenant and are not used by Tenant during the period of time that such portion is unusable or inaccessible and not used by Tenant. 

15.1.2 Repairs Which Cannot Be Completed Within Six (6) Months. If all such repairs to the Property and
Premises cannot, in Landlord’s judgement, be completed within six (6) months following the commencement of the work of repairing such damage or destruction without the payment of overtime or other premiums, Landlord shall notify Tenant of
such determination; and in such an event, either Landlord or Tenant may, at its option, upon written notice to the other party given within sixty (60) days after the occurrence of such damage or destruction, elect to terminate this Lease as of
the date of the occurrence of such damage or destruction. In the event that neither Landlord nor Tenant elects to terminate the Lease in accordance with the foregoing provisions, then Landlord shall, at Landlord’s expense, repair such damage or
destruction; and in such event, this Lease shall continue in full force and effect, except that the Base Rent shall be proportionately reduced as provided in§ 15.1.1 above; provided, however, that if any such repair is not commenced by Landlord
within ninety (90) days after the occurrence of such damage or destruction or is not substantially completed by Landlord within nine (9) months after the occurrence of such damage or destruction, then in either such event Tenant may, at
its option, upon written notice to Landlord, elect to terminate this Lease as of the date of Landlord’s receipt of such notice. Notwithstanding the foregoing, Tenant shall have no right to terminate this Lease in the situation just described if
all of the following conditions are met: (x) Landlord shall have informed Tenant in its notice of determination that the repair of such damage or destruction could not be substantially completed by Landlord within nine (9) months after the
occurrence of such damage or destruction; (y) Tenant shall not have elected to terminate the Lease by written notice delivered to Landlord within sixty (60) days after the occurrence of such damage or destruction; and (z) Landlord
shall have commenced the work of repairing such damage or destruction. 

  
 32 

 15.2 LOSS NOT COVERED BY INSURANCE. If at any time prior to the expiration or earlier
termination of this Lease the Premises or the Property is totally or partially damaged or destroyed in connection with a casualty, which loss to Landlord is not fully covered by insurance maintained by Landlord or for Landlord’s benefit (or
required to be maintained by Landlord pursuant to § 14.3 above); and if such damage renders the Premises inaccessible or unusable to Tenant for their intended purpose in the ordinary course of its business, Landlord may, at its option, upon
written notice given to Tenant within sixty (60) days after Tenant’s written notice to Landlord of the occurrence of such damage or destruction, either (a) elect to repair or to restore such damage or destruction or (b) elect to
terminate this Lease. If Landlord elects to repair or restore such damage or destruction, this Lease shall continue in full force and effect, except that the Base Rent shall be proportionately reduced as provided in § 15.1.1 above. If Landlord
does not elect by notice to Tenant to repair such damage, the Lease shall terminate as of the date of Tenant’s receipt of Landlord’s notice of election to terminate. Notwithstanding the foregoing, if all repairs to the Premises or the
Building cannot, in Landlord’s reasonable judgement, be completed within six (6) months following the date of the commencement of the work of repairing such damage or destruction without the payment of overtime or other premiums, then
either Landlord or Tenant may at the option of either, upon written notice to the other party given within sixty (60) days after the occurrence of such damage or destruction, elect to terminate this Lease as of the date of such notice. 

15.3 DESTRUCTION DURING FINAL YEAR. Notwithstanding anything to the contrary contained in§§ 15.1 and15.2, if the Premises or the
Building are wholly or partially damaged or destroyed within the final twelve (12) months of the Term of this Lease or, if an applicable renewal option has been exercised, during the last year of any renewal term, in such a way that Tenant
shall be prevented from using the Premises for at least thirty (30) consecutive days as a result of such damage or destruction, then either Landlord or Tenant may, at the option of either, by written notice to the other party delivered within
sixty (60) days after the occurrence of such damage or destruction, elect to terminate the Lease as of the date of such notice. 
 15.4
DESTRUCTION OF TENANTS PROPERTY. Under no circumstances shall Landlord be required to repair any injury or damage to, or make any repairs to or replacements of, Tenant’s Property. However, as part of Operating Expenses, Landlord shall
cause to be insured the Improvements in the Premises which do not consist of Tenant’s Property and shall cause such Improvements to be repaired and restored at Landlord’s sole expense, except that Tenant shall pay any applicable
deductible. Landlord shall have no responsibility for any contents placed or kept in or on the Premises or the Property by Tenant or Tenant’s employees or invitees or any other person claiming through Tenant. 

15.5 EXCLUSIVE REMEDY. Landlord and Tenant agree that their respective rights and obligations in the event of any damage or destruction of the
Premises, Property, or Complex shall be governed exclusively by this Lease. Tenant, as a material inducement to Landlord entering into this Lease, irrevocably waives and releases Tenant’s rights under California Civil Code§§ 1932(2),
1933(4), and 1942, as the same may be modified or replaced hereafter. No damages, compensation, setoff, allowance, or claim shall be payable by Landlord for any inconvenience, interruption, or cessation of Tenant’s business or any annoyance
arising from any damage to or destruction of all or any portion of the Premises, Property, or Complex. 
 16 EMINENT DOMAIN 

16.1 CONDEMNATION. If the whole or any material part of the Premises or Property shall be taken by power of eminent domain or condemned by any
competent authority for any public or quasi-public use or purpose; or if any adjacent property or street shall be so taken, condemned, reconfigured, or vacated by such authority in such manner as to require the use, reconstruction, or remodeling of
any part of the Premises or Property; or if Landlord shall grant a deed or other instrument in lieu of such taking by eminent domain or condemnation (collectively “Takings”), Landlord shall have the option to terminate this Lease upon
ninety (90) days’ notice, provided such notice is given no later than one hundred and eighty (180) days after the date of such Taking. Tenant shall have reciprocal termination rights, on the same terms and conditions and to be
exercised in the same manner as the foregoing sentence provides, if the whole or any material part of the Premises is permanently taken, or if access to the Premises is permanently materially impaired. 

  
 33 

 16.2 RENTAL APPORTIONMENT. All Rent shall be apportioned as of the date of such termination or
the date of such Taking, whichever shall first occur. If any part of the Premises shall be taken, and this Lease shall not be so terminated, the Rent shall be proportionately abated. 

16.3 AWARDS AND DAMAGES. Landlord shall be entitled to receive the entire award or payment in connection with any Taking, except that Tenant
shall have the right to file any separate claim available to Tenant for any taking of Tenant’s personal property and fixtures belonging to Tenant and removable by Tenant upon expiration of the Term, and for moving expenses, so long as such
claim does not diminish the award available to Landlord and such claim is payable separately to Tenant. 
 16.4 TEMPORARY CONDEMNATION. If
part or all of the Premises are condemned for a limited period of time (“Temporary Condemnation”), this Lease shall remain in effect. The Rent and Tenant’s obligations for the part of the Premises taken shall abate during the
Temporary Condemnation in proportion to the part of the Premises that Tenant is unable to use in its business operations as a result of the Temporary Condemnation. Landlord shall receive the entire award for any Temporary Condemnation. 

17 ASSIGNMENT AND SUBLETTING 
 17.1
CONSENT REQUIRED FOR TRANSFER. Tenant agrees that it shall not assign, sublet, mortgage, hypothecate, or encumber this Lease, nor permit or allow the Premises or any part thereof to be used or occupied by others, without the prior written
consent of Landlord in each instance. The actions described in the foregoing sentence are referred to collectively herein as “Transfers” and individually as a “Transfer.” If the Premises or any part thereof be sublet or occupied
by anybody other than Tenant, Landlord may, after default by Tenant, collect rent from the subtenant or occupant and apply the net amount collected to the Rent herein reserved; but no Transfer, occupancy, or collection shall be deemed a waiver of
the provisions hereof, the acceptance of the subtenant or occupant as tenant, or a release of Tenant from the further performance hereunder by Tenant. The consent by Landlord to a Transfer shall not relieve Tenant from obtaining the Landlord’s
express written consent to any further Transfer. In no event shall any permitted sublessee assign or encumber its sublease or further sublet all or any portion of its sublet space, or otherwise suffer or permit the sublet space or any part thereof
to be used or occupied by others, without Landlord’s prior written consent in each instance. 
 17.1.1 Corporate
Transferor. If Tenant is a corporation, the provisions of§ 17.1 shall apply to a transfer (by one or more transfers) of a majority of the stock of Tenant as if such transfer of a majority of the stock of Tenant were an assignment of this
Lease. 
 17.2 NOTICE OF INTENT TO TRANSFER. If Tenant shall at any time or times during the Term of this Lease desire to assign this Lease or
sublet all or part of the Premises, Tenant shall give notice thereof (the “Transfer Notice”) to Landlord, which notice shall set forth all of the following: 

(a) the proposed terms of the assignment or subletting, including (i) the effective or commencement date thereof, which shall be
not less than thirty (30) nor more than one hundred eighty (180) days after the giving of such notice; (ii) in the case of a proposed assignment, the consideration therefor; and (iii) in the case of a proposed subletting, the
rental rate to be paid by the proposed subtenant (including any escalation or Additional Rent payable), the term of the proposed sublease (including any renewal options), any work to be performed or paid for by Tenant, the amount of any security
deposit, the cost and extent of any so-called “take-over” obligations to be assumed by Tenant on behalf of such subtenant, the amount of any rent concessions to be granted by Tenant, and any other
additional monetary or so-called “business” terms or conditions; 

  
 34 

 (b) a statement setting forth in reasonable detail the identity of the proposed
assignee or subtenant, the nature of its business, and its proposed use of the Premises; and 
 (c) current financial information
with respect to the proposed assignee or subtenant, including its most recent financial report, and any other information which may reasonably be required by Landlord. 

17.3 LANDLORD’S RECAPTURE RIGHT. The Transfer Notice shall be deemed an offer from Tenant to Landlord whereby Landlord (or Landlord’s
designee) may, at its option, terminate this Lease as to all or the affected portion of the Premises (as the case may be) as of the effective date of the proposed Transfer. Landlord may exercise its recapture right by notice to Tenant at any time
within thirty (30) days after Landlord’s receipt of Tenant’s Transfer Notice; and during such thirty-day period Tenant shall not assign this Lease nor sublet such space to any person. 

17.3.1 Date of Termination. If Landlord exercises its option to terminate this Lease as provided in§ 17.3 above, this Lease
shall end and expire on the date that such Transfer was to be effective or commence, as the case may be, and the Base Rent and Additional Rent shall be paid and apportioned to such date. 

17.4 CONDITIONS OF CONSENT. If Landlord does not exercise its recapture right pursuant to § 17.3 above, and providing that Tenant is not in
default of any of Tenant’s obligations under this Lease after notice and the expiration of any applicable grace period, Landlord’s consent (which must be in writing and in form reasonably satisfactory to Landlord) to the proposed
assignment or sublease shall not be unreasonably withheld or delayed, provided the following conditions are met: 
 (a) Tenant shall
have complied with the provisions of§ 17.2 above, and Landlord shall not have exercised its recapture right pursuant to § 17.3 above within the time permitted therefor; 

(b) In Landlord’s reasonable judgement the proposed assignee or subtenant is engaged in a business which would use the Premises,
or the relevant part thereof, in a manner which is in keeping with the then-current standards of the Building, is limited to the use expressly permitted under this Lease, and will not violate any negative covenant or other restriction or agreement
as to use contained in any other lease of space in the Complex; 
 (c) The proposed assignee or subtenant is a reputable entity or
person of good character and with reasonably sufficient financial worth considering the responsibility involved, is not subject to any toxic or hazardous materials cleanup order with respect to any other property, and Landlord has been furnished
with reasonable proof thereof; 
 (d) Neither the proposed assignee or sublessee nor any person which, directly or indirectly,
controls, is controlled by, or is under common control with, the proposed assignee or sublessee or any person who controls the proposed assignee or sublessee, is then an occupant of any part of the Complex, provided Landlord then has suitable space
in the Complex available for leasing. For purposes of this Lease control shall be deemed to mean ownership of more than fifty percent (50%) of all the voting stock of a corporation or more than fifty percent (50%) of all the legal and equitable
interest in any other business entity; 

  
 35 

 (e) The proposed assignee or sublessee is not a person or entity with whom Landlord
is then negotiating to lease space in the Building; 
 (f) The form of the proposed lease shall be in form reasonably satisfactory to
Landlord and shall comply with the applicable provisions of this Article 17; 
 (g) There shall not be more than two
(2) subtenants (not including the Permitted Occupant (as defined in§ 17.14 below) of the Premises); 
 (h) The rental and
other terms and conditions of the sublease are the same as those contained in the proposed sublease furnished to Landlord in the Transfer Notice pursuant to § 17.2 above; 

(i) Tenant shall reimburse Landlord on demand for any reasonable costs that may be incurred or paid by Landlord to third persons in
connection with said assignment or sublease, including costs of making investigations as to the acceptability of the proposed assignee or subtenant and legal costs incurred in connection with the granting of any requested consent; and 

(j) Tenant shall not have advertised or publicized in any way the availability of the Premises without prior notice to and approval by
Landlord, nor shall any advertisement state the name (as distinguished from the address) of the Complex or the rental rate; 
 (k)
The sublease shall not allow the use of the Premises or any part thereof for (i) the sale of food for on or off-premises consumption or (ii) use by a foreign or domestic governmental agency. 

Whether or not Landlord shall grant consent, Tenant shall pay $500.00 towards Landlord’s review and processing expenses in connection with any Transfer
request, as well as any reasonable legal fees incurred by Landlord, within thirty (30) days after written request by Landlord 
 17.5
CONTINUATION OF LEASE TERMS. Each subletting pursuant to this Article 17 shall be subject to all of the covenants, agreements, terms, provisions, and conditions contained in this Lease. Notwithstanding any such subletting to any other
subtenant and/or acceptance of Rent by Landlord from any subtenant, Tenant shall remain liable for the payment of the Base Rent and Additional Rent due and to become due hereunder and for the performance of all the covenants, agreements, terms,
provisions, and conditions contained in this Lease on the part of Tenant to be performed and all acts and omissions of any licensee or subtenant or anyone claiming under or through any subtenant which shall be in violation of any of the obligations
of this Lease; and any such violation shall be deemed to be a violation by Tenant. Tenant further agrees that notwithstanding any such subletting, no other and further subletting of the Premises by Tenant or any person or entity claiming through or
under Tenant shall or will be made except upon compliance with and subject to the provisions of this Article 17. If Landlord shall decline to give its consent to any proposed assignment or sublease, or if Landlord shall exercise its recapture right
under § 17.3 above, Tenant shall indemnify, defend, protect, and hold Landlord harmless against and from any and all Claims resulting from any Claims that may be made against Landlord by the proposed assignee or sublessee or by any brokers or
other persons claiming a commission or similar compensation in connection with the proposed assignment or sublease. 
 17.6 LAPSE OF CONSENT.
In the event that Landlord consents to a proposed Transfer described in the Transfer Notice and Tenant fails to execute and deliver the assignment or sublease described in the Transfer Notice to which Landlord consented within one hundred twenty
(120) days after the giving of such consent, then Tenant shall again comply with all of the provisions and conditions of § 17.2 above before assigning this Lease or subletting all or part of the Premises. 

  
 36 

 17.7 TRANSFER DOCUMENTATION. With respect to each and every Transfer authorized by Landlord
under the provisions of this Lease, it is further agreed as follows: 
 (a) no subletting shall be for a term ending later than one
day prior to the Expiration Date of this Lease; 
 (b) no sublease shall be valid, and no subtenant shall take possession of the
Premises or any part thereof, until an executed counterpart of such sublease has been delivered to Landlord; 
 (c) each sublease
shall provide that it is subject and subordinate to this Lease and to the matters to which this Lease is or shall be subordinate, and that in the event of termination (whether by voluntary surrender or otherwise),
re-entry, or dispossession by Landlord under this Lease, Landlord may, at its option, take over all of the right, title, and interest of Tenant, as sublessor, under such sublease, and such subtenant shall, at
Landlord’s option, attorn to Landlord pursuant to the then-executory provisions of such sublease, except that Landlord shall not be (i) liable for any previous act or omission of Tenant under such sublease; (ii) subject to any offset,
credit, or allowance not expressly provided in such sublease which theretofore accrued to such subtenant against Tenant or (iii) bound by any previous modification of such sublease or by any previous prepayment of more than one month’s
rentals; and 
 (d) each assignment or sublease document must provide that the assignee or subtenant expressly assumes all
obligations of the Tenant under the Lease as joint and several obligations without any release of Tenant. 
 17.8 TRANSFER PREMIUM. If
Landlord shall give its consent to any assignment of this Lease or to any sublease, Tenant shall in consideration therefor pay to Landlord, as Additional Rent, the following amounts (collectively the “Transfer Premium”): 

(a) in the case of an assignment, an amount equal to fifty percent (50%) of all sums and other considerations paid to Tenant by the
assignee for or by reason of such assignment, including sums paid for the sale of Tenant’s Property, but excluding the following: (i) in the case of a sale of Tenant’s Property, the then-current net unamortized or undepreciated cost
thereof determined on the basis of Tenant’s federal income tax returns; (ii) then-customary brokerage commissions being paid by Landlord for leasing of space in the Building or, if less, the brokerage commission paid by Tenant in
connection with the assignment; (iii) reasonable legal fees and disbursements; and (iv) reasonable amounts paid by Tenant for tenant improvements constructed for the assignee; and 

(b) in the case of a sublease, fifty percent (50%) of any rents, additional charge, or other consideration payable under the sublease
to Tenant by the subtenant which is in excess of the Base Rent and Additional Rent accruing during the term of the sublease in respect of the subleased space (at the rate per square foot payable by Tenant hereunder) pursuant to the terms hereof,
including sums paid for the sale or rental of Tenant’s Property, but excluding the following: (i) in the case of the sale or lease of Tenant’s Property, the then-current net unamortized or undepreciated cost thereof determined on the
basis of Tenant’s federal income tax returns; (ii) then-customary brokerage commissions being paid by Landlord for leasing of space in the Building or, if less, the brokerage commission paid by Tenant in connection with the sublease;
(iii) reasonable legal fees and disbursements; and (iv) reasonable amounts paid by Tenant for tenant improvements constructed for the subtenant. 

  
 37 

 The sums payable as the Transfer Premium under this § 17.8 shall be paid to Landlord as and when
payable by the subtenant or assignee to Tenant. 
 17.9 ASSUMPTION BY TRANSFEREE Any Transfer, whether made with Landlord’s consent
pursuant to § 17.1 or without Landlord’s consent pursuant to§ 17.1.1, shall be made only if, and shall not be effective until, the assignee or subtenant shall execute, acknowledge, and deliver to Landlord an agreement in form and
substance satisfactory to Landlord under which the assignee or transferee shall assume the obligations of this Lease on the part of Tenant to be performed or observed, from and after the date of Transfer, and whereby the assignee or transferee shall
agree that the provisions in § 17.1 shall, notwithstanding such Transfer, continue to be binding upon it in respect of all future Transfers. The original named Tenant covenants that, notwithstanding any Transfer, whether or not in violation of
the provisions of this Lease, and notwithstanding the acceptance of Base Rent and/or Additional Rent by Landlord from an assignee, transferee, or any other party, the original named Tenant shall remain fully liable for the payment of the Base Rent
and Additional Rent and for the other obligations of this Lease on the part of Tenant to be performed or observed. 
 17.10 NO WAIVER OR
DISCHARGE. The joint and several liability of Tenant and any immediate or remote successor in interest of Tenant and the due performance of the obligations of this Lease on Tenant’s part to be performed or observed shall not be discharged,
released, or impaired in any respect by any agreement or stipulation made by Landlord extending the time of, or modifying any of the obligations of, this Lease, or by any waiver or failure of Landlord to enforce any of the obligations of this Lease.

 17.11 LISTING OF NAME. The listing of any name other than that of Tenant, whether on the doors of the Premises or the Building directory,
or otherwise, shall not operate to vest any right or interest in this Lease or in the Premises, nor shall it be deemed to be the consent of Landlord to any Transfer of this Lease or to any sublease of the Premises or to the use or occupancy of the
Premises by others. 
 17.12 NET PROFITS AGREEMENT. Anything contained in the foregoing provisions of this Article 17 to the contrary
notwithstanding, neither Tenant nor any other person or entity having an interest in the possession, use, occupancy, or utilization of the Premises shall enter into any lease, sublease, license, concession, or other agreement for use, occupancy, or
utilization of space in the Premises which provides for rental or other payment for such use, occupancy, or utilization based, in whole or in part, on the net income or profits derived by any person from the premises leased, used, occupied, or
utilized (other than an amount based on a fixed percentage or percentages of receipts or sales); and any such purported lease, sublease, license, concession, or other agreement shall be absolutely void and ineffective as a conveyance of any right or
interest in the possession, use, occupancy, or utilization of any part of the Premises. 
 17.13 AFFILIATES. Notwithstanding anything to the
contrary in this Article 17, Landlord’s consent shall not be required in the event Tenant desires to assign this Lease or sublet the Premises or any portion thereof to any corporation or entity which (a) controls, is controlled by, or is
under common control with Tenant, (b) acquires all of the assets or equity interest of Tenant, or (c) is the resulting entity in a merger or consolidation of Tenant, subject to the following conditions: 

(a) Tenant shall not be in default of any of the terms, covenants, or conditions on Tenant’s part to observe or perform hereunder;

 (b) such sublet or assignment shall be subject to all of the terms, covenants, and conditions of this Lease; 

  
 38 

 (c) Tenant shall notify Landlord of such sublet or assignment in accordance
with§ 17.2 hereof and furnish Landlord with reasonably satisfactory evidence that such sublessee or assignee controls, is controlled by, or is under common control with Tenant; and 

(d) in the event of such merger, consolidation, or transfer of substantially all of Tenant’s assets, the successor to Tenant has a
net worth, computed in accordance with generally-accepted accounting principles, at least equal to the greater of (i) the net worth of Tenant immediately prior to such merger, consolidation, or transfer or (ii) the net worth of Tenant
herein named on the date of this Lease; and proof satisfactory to Landlord of such net worth shall have been delivered to Landlord at least ten (10) days prior to the effective date of any such transaction. 

As used herein, the terms control and common control shall be deemed to mean the ownership of fifty percent (50%) or more of all of the issued
and outstanding voting shares of such corporation, or fifty percent (50%) or more of all the legal and equitable interest in any such business entities. 

17.14 PERMITIED OCCUPANTS. Landlord hereby agrees that the provisions of this Article 17 shall not apply to the shared occupancy of individual
offices in the Premises with Tenant by individuals renting not more than one (1) such office (the “Permitted Occupant”), provided that the space occupied by the Permitted Occupant shall not be separately demised or contain separate
entrances, demarcations, or reception areas and the occupancy by the Permitted Occupant shall be upon and subject to all of the terms and conditions of this Lease. 

18 SUBORDINATION AND ATTORNMENT 

18.1 SUBORDINATION OF LEASE. This Lease and all rights of Tenant hereunder are and shall be subject and subordinate in all respects to
(a) all ground leases, overriding leases, and underlying leases of the Building, Property, and/ or the Complex now or hereafter existing; (b) all mortgages which may now or hereafter affect the Building, Property, or Complex and any of
such leases, whether or not such mortgages shall also cover other lands and/ or buildings; (c) each and every advance made or hereafter to be made under such mortgages; and (d) to all renewals, modifications, replacements, and extensions
of such leases and such mortgages and spreaders and consolidations of such mortgages. This§ 18.1 shall be self-operative, and no further instrument of subordination shall be required. In confirmation of such subordination, Tenant shall promptly
execute and deliver any instrument that Landlord, the lessor of any such lease or the holder (“Holder”) of any such mortgage or any of their respective successors in interest may reasonably request to evidence such subordination. The
leases to which this Lease is, at the time referred to, subject and subordinate pursuant to this Article 18 are hereinafter sometimes referred to as “Superior Leases”; the mortgages to which this Lease is, at the time referred to, subject
and subordinate are hereinafter sometimes referred to as “Superior Mortgages”; and the lessor of a superior lease or its successor in interest at the time referred to is sometimes hereinafter referred to as a “Lessor.”
Notwithstanding the foregoing, Tenant agrees, upon written request from Landlord or any Holder or Lessor, to reorder the relative priority of the Lease with respect to any particular Superior Mortgage or Superior Lease so as to subordinate the lien
of any such Superior Mortgage or Superior Lease to the Lease. Tenant agrees to execute any instrument which Landlord or any Holder or Lessor may present in order to effect such prioritization of the Lease, provided that such instrument does not
modify any material term of the Lease or increase Tenant’s obligations thereunder. 
 18.2 NOTICE AND CURE RIGHT. In the event of any
action or omission of Landlord which would give Tenant the right, immediately or after lapse of a period of time, to cancel or terminate this Lease, or to claim a partial or total eviction, Tenant shall not exercise such right unless and until
(i) Tenant shall have given written notice of such act or omission to the Holder of each Superior Mortgage and the Lessor of each Superior Lease whose name and address shall previously have been furnished to Tenant in writing; and
(ii) unless such act or omission shall be one which is not capable of being remedied by Landlord or 

  
 39 

 
such mortgage Holder or Lessor within a reasonable period of time, a reasonable period for remedying such act or omission shall have elapsed following the giving of such notice and following the
time when such Holder or Lessor shall have become entitled under such Superior Mortgage or Superior Lease, as the case may be, to remedy the same (which reasonable period shall in no event be less than the period to which Landlord would be entitled
under this Lease or otherwise, after similar notice, to effect such remedy), provided such Holder or Lessor shall with due diligence give Tenant written notice of intention to remedy such act or omission and shall thereafter diligently and
continuously prosecute such cure to completion. 
 18.3 ATTORNMENT. If the Lessor of a Superior Lease or the Holder of a Superior Mortgage
shall succeed to the rights of Landlord under this Lease, whether through possession or foreclosure action or delivery of a new lease or deed, then at the request of such party so succeeding to Landlord’s rights or other person having or
acquiring title by virtue of such foreclosure or termination (herein sometimes referred to as “Successor Landlord”) and upon such Successor Landlord’s written agreement to accept Tenant’s attornment, Tenant shall attorn to and
recognize such Successor Landlord as Tenant’s landlord under this Lease and shall promptly execute and deliver any instrument that such Successor Landlord may reasonably request to evidence such attornment. Upon such attornment this Lease shall
continue in full force and effect as a direct lease between the Successor Landlord and Tenant upon all of the terms, conditions, and covenants in this Lease, except as follows: 

(a) the Successor Landlord shall not be liable for any previous act or omission of Landlord under this Lease; 

(b) the Successor Landlord shall not be subject to any offset (unless expressly provided for in this Lease) which shall have
theretofore accrued to Tenant against Landlord; 
 (c) the Successor Landlord shall not be bound by any previous modification of this
Lease, unless expressly provided for in this Lease, or by any previous prepayment of more than one month’s Base Rent, unless such modification or prepayment shall have been expressly approved in writing by the Lessor of the Superior Lease or
the Holder of the Superior Mortgage through or by reason of which the Successor Landlord shall have succeeded to the rights of Landlord under this Lease. 

19 FINANCING REQUIREMENTS 
 19.1
LENDER-REQUESTED MODIFICATIONS. If, in connection with obtaining financing or refinancing for the Property or Complex a prospective lender shall request reasonable modifications to this Lease as a condition to such financing or refinancing,
Tenant shall not withhold, delay, or unreasonably condition its consent thereto. It is agreed that, among the modifications which shall be deemed reasonable, are modifications to the subordination and attornment provisions of this Lease,
modifications to the notice provisions of this Lease, modifications to the provisions of this Lease which permit the lender to cure any defaults by Landlord, and modifications to the provisions which grant additional time to cure as may be
reasonably required by the lender. 
 19.2 FAILURE TO COMPLY. If Tenant fails or refuses to execute and deliver to Landlord, within fifteen
(15) days after written notice to do so, the amendment(s) to this Lease accomplishing such reasonable modification(s), Landlord, at its sole option, shall have the right either (a) to terminate this Lease or (b) to execute the
amendment for and on behalf of Tenant as its attorney-in-fact. Tenant hereby irrevocably appoints Landlord as its attorney-in-fact solely to execute any documents required to carry out the intent of§ 19.1 above on behalf of Tenant. 

  
 40 

 20 DEFAULT 

20.1 TENANT’S DEFAULT. Tenant’s failure to perform any of its obligations under this Lease when due and in the manner required shall
constitute a material breach and default (“Event of Default”) of this Lease by Tenant, subject to any cure period(s) permitted or available under this Lease or applicable laws or statutes. In addition, the following shall also be deemed
Events of Default hereunder: 
 (a) Tenant’s failure to take possession of the Premises for a period of sixty (60) days or
longer after the Commencement Date; 
 (b) Tenant fails to perform any covenant, condition, or agreement contained in this Lease not
otherwise specified in this § 20.1, where such failure continues for thirty (30) days after written notice from Landlord to Tenant, or such additional period as is reasonably necessary to effect cure, provided Tenant commences cure within
such thirty-(30)-day period and diligently pursues the same to completion within ninety (90) days following Landlord’s notice; 

(c) Tenant’s abandonment or vacation of the Premises; 

(d) any material misrepresentation or omission herein or in any financial statements or other materials provided by Tenant or any
Guarantor in connection with negotiating or entering this Lease or in connection with any Transfer under Article 17; 
 (e)
cancellation of any guaranty of this Lease by any Guarantor; 
 (f) failure by Tenant to cure within any applicable times permitted
thereunder any default under any other lease for space in the Complex or any other buildings owned or managed by Landlord or its affiliates now or hereafter entered by Tenant; and any Default hereunder not cured within the times permitted for cure
herein shall, at Landlord’s election, constitute a default under any other such lease or leases; 
 (g) The levy of a writ of
attachment or execution on this Lease or on any of Tenant’s property; 
 (h) Tenant’s or any Guarantor’s general
assignment for the benefit of creditors or arrangement, composition, extension, or adjustment with its creditors; 
 (i)
Tenant’s or any Guarantor’s filing of a voluntary petition for relief, or the filing of a petition against Tenant or any Guarantor in a proceeding under the Federal Bankruptcy laws or other insolvency laws which is not withdrawn or
dismissed within forty-five (45) days thereafter; or, under the provisions of any law providing for reorganization or winding up of corporations, the assumption by any court of competent jurisdiction of jurisdiction, custody, or control of
Tenant or any substantial part of its property, or of any Guarantor, where such jurisdiction, custody, or control remains in force unrelinquished, unstayed, or unterminated for a period of forty five (45) days; 

(j) In any proceeding or action in which Tenant is a party, the appointment of a trustee, receiver, agent, or custodian to take charge
of the Premises or Tenant’s Property for the purpose of enforcing a lien against the Premises or Tenant’s Property; or 

(k) If Tenant or any Guarantor is a partnership or consists of more than one (1) person or entity, the involvement of any partner
of the partnership or other person or entity in any of the acts or events described in subsections (i) through (l) above. 

  
 41 

 20.2 LANDLORD’S REMEDIES. Upon the occurrence of an Event of Default hereunder, Landlord
shall have the right, in addition to any other rights or remedies Landlord may have under Laws, at Landlord’s option, without further notice or demand of any kind, to elect to do one of the following alternatives: 

(i) Terminate this Lease and Tenant’s right to possession of the Premises, re-enter the
Premises, and take possession thereof; and Tenant shall have no further claim to the Premises or under this Lease; or 
 (ii)
Continue this Lease in effect and collect any unpaid Rent or other charges which have theretofore accrued or which thereafter become due and payable. It is intended hereunder that Landlord have the remedy described in California Civil Code§
1951.4, which provides that a landlord may continue a lease in effect after a tenant’s breach and abandonment and recover rent as it becomes due, if tenant has the right to sublease or assign, subject only to reasonable limitations. 

In the event of any re-entry or retaking of possession by Landlord, Landlord shall have the right, but not the
obligation, to remove all or any part of Tenant’s Property from the Premises and to place such property in storage at a public warehouse at the expense and risk of Tenant. 

20.2.1 No Waiver of Default. The waiver by Landlord of any Event of Default or of any other breach of any term, covenant, or
condition of this Lease shall not be deemed a waiver of such term, covenant, or condition or of any subsequent breach of the same or any other term, covenant, or condition. Acceptance of Rent by Landlord subsequent to any Event of Default or breach
hereof shall not be deemed a waiver of any preceding Event of Default or breach other than the failure to pay the particular Rent so accepted, regardless of Landlord’s knowledge of any breach at the time of such acceptance of Rent. Landlord
shall not be deemed to have waived any term, covenant, or condition of this Lease, unless Landlord gives Tenant written notice of such waiver. Tenant should not rely upon Landlord’s failure or delay in enforcing any right or remedy hereunder.

 20.2.2 Landlord’s Right to Cure. If Tenant defaults in the performance of any of its obligations under this Lease,
Landlord may (but shall not be obligated to), without waiving such default, perform the same for the account and at the expense of Tenant. Tenant shall pay Landlord all costs of such performance promptly upon receipt of a bill therefor. 

20.3 DAMAGES. Should Landlord elect to terminate this Lease under the provisions of§ 20.2 (i) above, Landlord may recover as damages from
Tenant the following: 
 (a) Past Rent: The worth at the time of the award of any unpaid Rent which had been earned at the time
of termination; plus 
 (b) Rent Prior to Award: The worth at the time of the award of the amount by which the unpaid Rent
which would have been earned after termination until the time of award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided; plus 

(c) Rent After Award: The worth at the time of the award of the amount by which the unpaid Rent for the balance of the Term
after the time of award exceeds the amount of the rental loss that Tenant proves could have been reasonably avoided; plus 

  
 42 

 (d) Proximately Caused Damages: Any other amount necessary to compensate
Landlord for all detriment proximately caused by Tenant’s failure to perform its obligations under this Lease or which in the ordinary course of things would be likely to result therefrom, including, but not limited to, any costs or expenses
(including attorneys’ fees), incurred by Landlord in (i) retaking possession of the Premises; (ii) maintaining the Premises after Tenant’s default; (iii) preparing the Premises for reletting to a new tenant, including any
repairs or alterations; and (iv) reletting the Premises, including brokers’ commissions. 
 “The worth at the time of the award” as used
in subsections (a) and (b) above is to be computed by allowing interest at the rate of ten percent (10%) per annum or, if different, the legal rate then applicable in California. “The worth at the time of the award” as used in
subsection (c) above is to be computed by discounting the amount at the discount rate of the Federal Reserve Bank situated nearest to the Premises at the time of the award plus one percent (1%). 

20.4 LANDLORD’S DEFAULT. If Landlord fails to perform any covenant, condition, or agreement contained in this Lease within thirty
(30) days after receipt of written notice from Tenant specifying a default and the relevant Lease provision, or if Landlord fails within that thirty-day period after notice to commence to cure any such
default which cannot reasonably be cured within thirty (30) days, then, subject to§ 21.1 below, Landlord shall be liable to Tenant for any damages sustained by Tenant as a result of Landlord’s breach. Tenant shall not have the right
to terminate this Lease or to withhold, reduce, or offset any amount against any payments of Rent or any other charges due and payable under this Lease, except to the extent that a specific Lease provision permits such termination or withholding,
reduction, or offset of Rent. 
 20.5 HOLDER’S RIGHT TO CURE. Tenant shall give any Holder a copy, by registered mail, of any notice of
default served upon Landlord, provided that Tenant previously has been notified in writing of the address of such Holder. If Landlord fails to cure such default within the time provided in this Lease, any such Holder shall have an additional
forty-five (45) days within which to cure such default by Landlord or, if such default cannot reasonably be cured within that time, such additional time as may be necessary, provided that within such forty-five (45) day period the Holder
has commenced and is pursuing the remedies necessary to cure such default (including commencement of foreclosure proceedings, if necessary to effect such cure), in which event this Lease shall not be terminated while such remedies are being so
pursued. 
 20.6 SURVIVAL OF REMEDIES. The remedies permitted under this Article 20, the parties’ indemnities under§§ 14.4.3,
14.4.4, and14.4.5, and§ 29.5 below shall survive the termination of this Lease. 
 21 LIMITATIONS ON LANDLORD’S LIABILITY

 21.1 PERSONAL LIABILITY. The liability of Landlord to Tenant for any default by Landlord under this Lease or arising in connection
herewith or with Landlord’s operation, management, leasing, repair, renovation, alteration, or any other matter relating to the Property or the Premises shall be limited to the interest of Landlord in the Property (and the rental proceeds
thereof). Under no circumstances shall Landlord ever be liable for consequential or punitive damages, including damages for lost profits or for business interruption. Tenant agrees to look solely to Landlord’s interest in the Property (and the
rental proceeds thereof) for the recovery of any judgement against Landlord, and Landlord shall not be personally liable for any such judgement or deficiency after execution thereon. The limitations of liability contained in this Article 21 shall
apply equally and inure to the benefit of Landlord’s present and future partners, beneficiaries, officers, directors, trustees, shareholders, agents, and employees, and their respective partners, heirs, successors, and assigns. Under no
circumstances shall any present or future general or limited partner of Landlord (if Landlord is a partnership), or trustee or beneficiary (if Landlord or any partner of Landlord is a trust) or corporate officer, director, or shareholder (if
Landlord or any partner of Landlord is a corporation or company) or member (if Landlord is a limited liability company) have any liability for the performance of Landlord’s obligations under this Lease. 

  
 43 

 21.2 LIABILITY UPON TRANSFER. The term Landlord as used in this Lease, so far as
covenants or obligations on the part of the Landlord are concerned, shall be limited to mean and include only the owner or owners, at the time in question, of the fee title to, or a lessee’s interest in a ground lease or master lease of the
Property. In the event of any transfer, assignment, or other conveyance or transfer of any such title or interest, Landlord herein named (and in case of subsequent transfers or conveyances, the current grantor) shall be automatically freed and
relieved from and after the date of such transfer, assignment, or conveyance of all liability with respect to the performance of any covenants or obligations on the part of Landlord contained in this Lease thereafter to be performed; and, without
further agreement, the transferee of such title or interest shall be deemed to have assumed and agreed to observe and perform any and all obligations of Landlord hereunder, during its ownership of the Premises. Landlord may transfer its interest in
the Premises without the consent of Tenant, and such transfer or subsequent transfer shall not be deemed a violation on Landlord’s part of any of the terms and conditions of this Lease. 

22 ESTOPPEL CERTIFICATES 
 22.1
REQUEST AND DELIVERY. Within ten (10) days following any written request Landlord may make from time to time, Tenant without any charge therefor, shall execute, acknowledge, and deliver a statement certifying the following: (a) the
Commencement Date of this Lease; (b) the fact that this Lease is unmodified and in full force and effect or, if there have been modifications hereto, that this Lease is in full force and effect, as modified, and stating the date and nature of
such modifications; (c) the date to which the Rent and other sums payable under this Lease have been paid; (d) the fact that there are no current defaults under this Lease by either Landlord or Tenant except as specified in the statement;
and (e) such other matters as may be reasonably requested by Landlord. Landlord and Tenant intend that any statement delivered pursuant to this Article 22 may be relied upon by any Holder, Lessor, beneficiary, purchaser, or prospective
purchaser of the Building, the Complex, or any interest therein. Tenant’s failure to deliver any such statement within the specified ten-day period shall constitute a material default hereunder, and
Tenant shall indemnify, defend, protect, and hold Landlord harmless from and against any and all Claims which Landlord may sustain or incur as a result of or in connection with Tenant’s failure or delay in delivering such statement. 

22.2 ELECTION TO SELL BUILDING. If Landlord elects to sell the Building or to obtain loans secured by a lien on the Building, Tenant, promptly
after demand, shall include with the estoppel certificate(s) provided to any prospective purchaser or lender as required under this Article 22 any financial statements of Tenant reasonably required by the purchaser or lender. The financial
statements so provided shall be kept confidential as to any parties other than the purchaser or lender. 
 23 NOTICES 

23.1 MANNER OF DELIVERY. Any notice required or permitted under this Lease shall be in writing and shall be delivered in at least one of the
following ways: (a) personally or by private hand-delivery messenger service; (b) by depositing the same in the United States mail, postage prepaid, registered or certified, return receipt requested; (c) by depositing such notice,
postage prepaid, with Federal Express or another nationally-recognized private overnight delivery service; or (d) by any other means permitted or required by applicable California law or statutes relevant in the context in which such notice is
given. Each such notice shall be addressed to the intended recipient at such party’s address set forth as follows, or at such other address as such party has theretofore specified by written notice delivered in accordance with this§ 23.1:

 if to Landlord: 

KASHIWA FUDOSAN AMERICA, INC. 

c/o RiverRock Real Estate Group, Inc. 

Attn: Property Manager 
 400 Oyster
Point Boulevard, Suite 117 
 South San Francisco, CA 94080 

  
 44 

 copy to: 

Metro Properties, LLC, Agent 

Attn: Oyster Point Asset Manager 

11150 West Olympic Boulevard, Suite 1090 

Los Angeles, CA 90064 
 If to
Tenant: 
 DAY ONE THERAPEUTICS, INC. 

Attn: Chief Financial Officer 
 395
Oyster Point Boulevard, Suite 217 
 South San Francisco, CA 94080 

23.2 REQUIRED CONTENTS. Every notice (other than the giving or withholding of consent or approval under the provisions of the Lease) given to a
party shall state the section of the Lease pursuant to which the notice is given; the period of time within which the recipient of the notice must respond (or, if no response is required, a statement to that effect); and if applicable, that the
failure to object to the notice within the stated time period will be deemed to be the equivalent of the recipient’s approval, consent to, or satisfaction with the subject matter of the notice. 

23.3 PRESUMPTION OF RECEIPT. Any notice delivered personally or by private messenger service shall be deemed delivered on the next day following
the deposit of such notice at the recipient’s address. Any notice delivered by Federal Express or another nationally-recognized private overnight delivery service shall be deemed delivered on the earlier of (y) the second day following
deposit thereof with the carrier or (z) the delivery date shown on the carrier’s record of delivery. Any notice delivered by mail in the manner specified in§ 23.1 shall be deemed delivered on the earlier of (a) the third day
following deposit thereof in the United States Mail or (b) the delivery date shown on the return receipt prepared in connection therewith. Refusal by Tenant or Landlord to accept either certified or registered mail shall constitute a waiver of
such notice by the respective party. 
 24 BROKERS 

24.1 TENANT’S REPRESENTATION. Tenant represents and warrants to Landlord that Tenant has dealt with no broker in connection with this Lease
other than Savills Studley and Cushman & Wakefield of California, Inc. Tenant shall be responsible for all foreseeable consequences of damages (including attorneys’ fees and costs) resulting from any claims that may be asserted against
Landlord by any other broker, finder, or other person with whom Tenant has or purportedly has dealt in connection with this Lease, and Tenant agrees to indemnify, defend, protect, and hold Landlord harmless in connection with any such Claims which
may be asserted. 

  
 45 

 25 RIGHTS RESERVED TO LANDLORD 

25.1 ACCESS TO PROPERTY. All of the Property except the inside surfaces of all walls, windows, and doors bounding the Premises (including
exterior Building walls, core corridor walls and doors, and any core corridor entrance) and any space in or adjacent to the Premises used for shafts, stacks, pipes, conduits, fan rooms, ducts, electric, or other utilities, sinks or other Building
facilities, and the use thereof, as well as access thereto through the Premises for the purpose of operation, maintenance, decoration, and repair, are reserved to Landlord . Tenant shall permit Landlord to install, use, replace, and maintain pipes,
ducts, and conduits within the demising walls, bearing columns, and ceilings of the Premises. 
 25.2 CONTROL OF PROPERTY. Except to the
extent expressly limited herein, Landlord reserves full rights to control the Property (which rights may be exercised without subjecting Landlord to claims for constructive eviction, abatement of Rent, damages, or other claims of any kind),
including more particularly the following rights: 
 (a) Name, Address, Access. To change the name or street address of the
Property; install and maintain signs on the exterior and interior of the Property; retain at all times, and use in appropriate instances, keys to all doors within and into the Premises; grant to any Person the right to conduct any business or render
any service at the Property, whether or not it is the same or similar to the use permitted Tenant by this Lease; and have access for Landlord and other tenants of the Property to any mail chutes located on the Premises according to the rules of the
United States Postal Service. 
 (b) Entry into Premises. To enter the Premises at reasonable hours for reasonable purposes,
including inspection and supplying cleaning service or other services to be provided Tenant hereunder, to show the Premises to current and prospective lenders, ground lessors, insurers, and prospective purchasers, tenants and brokers, at reasonable
hours; and if Tenant shall abandon the Premises at any time, or shall vacate the same during the last three (3) months of the Term, to decorate, remodel, repair, or alter the Premises. 

(c) Safety Measures. To limit or prevent access to the Property, shut down elevator service, activate elevator emergency
controls, or otherwise take such action or preventative measures deemed necessary by Landlord for the safety of tenants or other occupants of the Property or the protection of the Property and other property located thereon or therein, in case of
fire, invasion, insurrection, riot, civil disorder, public excitement or other dangerous condition, or threat thereof. 
 (d)
Improvements. To decorate and to make alterations, additions and improvements, structural or otherwise, in or to the Property or any part thereof, and any adjacent building, structure, parking facility, land, street or alley (including
changes and reductions in corridors, lobbies, parking facilities and other public areas and the installation of kiosks, planters, sculptures, displays, escalators, mezzanines, and other structures, facilities, amenities and features therein, and
changes for the purpose of connection with or entrance into or use of the Property in conjunction with any adjoining or adjacent building or buildings, now existing or hereafter constructed). In connection with such matters, or with any other
repairs, maintenance, improvements or alterations, in or about the Property, Landlord may erect scaffolding and other structures reasonably required, and during such operations may enter upon the Premises and take into and upon or through the
Premises, all materials required to make such repairs, maintenance, alterations or improvements, and may close public entry ways, other public areas, restrooms, stairways or corridors. 

  
 46 

 25.3 LANDLORD’S RIGHT TO MAINTAIN. Except as expressly otherwise provided in this Lease,
Landlord shall have no liability to Tenant by reason of any inconvenience, annoyance, interruption, or injury to business arising from Landlord’s making any repairs or changes which Landlord is required or permitted to make by this Lease, by
any other lease or agreement affecting the Property, or by Law, in or to any portion of the Property, Complex, or the Premises, including the Systems and Equipment and appurtenances of the Property or the Premises, provided that Landlord shall use
due diligence with respect thereto and shall perform such work, except in case of emergency, at times reasonably convenient to Tenant and otherwise in such manner as will not materially diminish Tenant’s beneficial enjoyment of the Premises for
their intended use. 
 25.4 REASONABLE NOTICE. In connection with entering the Premises to exercise any of the foregoing rights, Landlord
shall: (a) provide reasonable advance written or oral notice to Tenant’s on-site manager or other appropriate person (except in emergencies, or for routine cleaning or other routine matters), and
(b) take reasonable steps to avoid any unreasonable interference with Tenant’s business. 
 26 BUILDING PLANNING 

26.1 RELOCATION RIGHT. In the event Landlord requires the Premises for use in conjunction with another suite or for other reasons connected with
Landlord’s planning program for the Building, upon notifying Tenant in writing, Landlord shall have the right to move Tenant to other space in the Building or in the Complex, provided such space is not more than ten percent (10%) smaller or
larger than the Premises. If Landlord elects to move Tenant to such other space, Landlord shall give Tenant at least thirty (30) days’ prior written notice of Landlord’s intention to relocate the Premises, Landlord shall pay for
(a) all direct, out-of-pocket, reasonable expenses of Tenant in moving from the Premises to the new space and (b) the cost of improving the new space so that
the level of improvements in the new space is comparable to the level of improvements in the Premises, and as nearly as practicable, the physical relocation of the Premises shall take place on a weekend and shall be completed before the following
Monday. All the terms and conditions of the original Lease shall remain in full force and effect, except that (i) a revised Exhibit B shall become a part of this Lease and shall reflect the location of the new space; and
(ii) Tenant agrees to execute promptly upon notice from Landlord an amendment to this Lease amending the Table and corresponding sections of the Lease in order to reflect all correct data for the new space. 

27 HOLDING OVER 
 27.1
HOLDOVER. Unless Landlord expressly agrees otherwise in writing, Tenant shall pay Landlord one hundred fifty percent (150%) of the amount of Rent then applicable prorated on per diem basis for each day Tenant shall retain possession of the
Premises or any part thereof after expiration of the Term or earlier termination of this Lease, together with all damages sustained by Landlord on account thereof. In the case of any such holdover, the Lease shall be converted to a month-to-month tenancy which either party may terminate upon written notice of not less than thirty (30) days to the other. Tenant shall remain bound to comply with all
provisions of this Lease until Tenant vacates the Premises and shall be subject to the provisions of§ 11.1 above. 
 27.2 PERMISSIVE MONTH-TO-MONTH TENANCY. Notwithstanding the foregoing to the contrary, at any time before or after expiration or earlier termination of the Term of the Lease, Landlord may
serve notice advising Tenant of the amount of Rent and other terms required, should Tenant desire to enter a month-to-month tenancy. If Tenant shall hold over more than one full calendar month after such
notice, Tenant shall thereafter be deemed a month-to-month tenant, on the terms and provisions of this Lease then in effect, as modified by Landlord’s notice,
except that Tenant shall not be entitled to any renewal or expansion rights contained in this Lease or any amendments hereto. 

  
 47 

 28 PARKING 

28.1 AVAILABLE PARKING. Subject to the terms and conditions contained in the balance of this Article 28, Landlord agrees to make available to
Tenant during the Term of this Lease and any renewal term up to a maximum of seventeen (17) parking spaces on a non-exclusive basis in the area(s) designated by Landlord for parking in the Building’s
parking lots and/ or facility (the “Parking Facility”). Said parking spaces shall be in locations designated by Landlord, and parking shall be on a first-come-first-served, unassigned, nonreserved basis. Landlord reserves the right to
designate different locations or different parking areas for Tenant’s use without any liability to Tenant and Tenant agrees that any change shall not give rise to any claims or offset against Landlord hereunder. Tenant shall abide by any and
all parking regulations and rules established from time to time by Landlord or Landlord’s parking operator. Landlord reserves the right in its sole and absolute discretion to restrict or prohibit the use of the Parking Facility for any vehicles
other than passenger automobiles, such as full-sized vans or trucks. Tenant shall not permit any vehicles belonging to Tenant or Tenant’s employees, agents, customers, contractors, or invitees to be
loaded, unloaded, or parked in areas other than those designated by Landlord for such activities and shall not permit any such vehicles to be parked overnight in the Parking Facility; provided, Tenant may apply for an Overnight Parking Permit from
Landlord’s Property Manager for limited periods for good cause relating to Tenant’s business, subject to such rules and regulations governing such overnight parking as Landlord’s Property Manager may establish from time to time. A
failure to comply with the foregoing provisions shall afford Landlord the right without notice to remove any vehicles involved and to charge the cost to Tenant, which cost shall be immediately due and payable upon demand by Landlord. 

28.2 USE AT TENANT’S OWN RISK. Landlord shall have no obligation to monitor the use of the Parking Facility. Tenant’s and its
employees’ use of the Parking Facility shall be at the sole risk of Tenant and its employees. Unless caused by the gross negligence or willful harmful act of Landlord, Landlord shall have no responsibility or liability for any injury or damage
to any person or property by or as a result of the use of the Parking Facility (or substitute parking) by Tenant and its employees, whether by theft, collision, criminal activity, or otherwise, and Tenant hereby assumes, for itself and its
employees, all risks associated with any such occurrences in or about the Parking Facility. 
 29 MISCELLANEOUS PROVISIONS. 

29.1 GENERAL DEFINITIONS. The definitions which follow shall apply generally to the provisions of this Lease. 

(a) The term business days means Monday through Friday inclusive, excluding Holidays as defined in§ 8.1.1 above.
Throughout this Lease, wherever days is used the term shall refer to calendar days. Wherever the term business days is used the term shall refer to business days as defined hereunder. 

(b) The term mortgage shall include any mortgage or deed of trust, and the term mortgagee shall include a
trustee. 
 (c) The terms include, including, and such as shall each be construed as if
followed by the phrase “without limitation.” The rule of eiusem generis shall not be applicable to limit a general statement following or referrable to an enumeration of specific matters to matters similar to the matters
specifically mentioned. 
 (d) The term obligations under this Lease and words of like import shall mean the covenants
to pay Rent and Additional Rent under this Lease and all of the other covenants and conditions contained in this Lease. Any provision in this Lease that one party or the other or both shall do or not do or shall cause or permit or not cause or
permit a particular act, condition, or circumstance shall be deemed to mean that such party so covenants or both parties so covenant, as the case may be. 

  
 48 

 (e) The term Tenant’s obligations hereunder and words of like
import and the term Landlord’s obligations hereunder and words of like import shall mean the obligations under this Lease which are to be performed or observed by Tenant, or by Landlord, as the case may be. Reference to
performance of either party’s obligations under this Lease shall be construed as “performance and observance.” 

(f) Reference to Tenant being or not being in default hereunder or words like import shall mean that Tenant is in default
in the performance of one or more of Tenant’s obligations hereunder, or that Tenant is not in default in the performance of any of Tenant’s obligations hereunder, or that a condition of the character described in § 20.1 above has
occurred and continues or has not occurred or does not continue, as the case may be. 
 (g) References to Landlord as having no
liability to Tenant or being without liability to Tenant shall mean that Tenant is not entitled to terminate this Lease or to claim actual or constructive eviction, partial or total, or to receive any credit, allowance, setoff,
abatement, or diminution of Rent, or to be relieved in any manner of any of its other obligations hereunder, or to be compensated for loss or injury suffered or to enforce any other kind of liability whatsoever against Landlord under or with respect
to this Lease or with respect to Tenant’s use or occupancy of the Premises. 
 (h) The term requirements of insurance
bodies and words of like import shall mean rules, regulations, orders, and other requirements of the California Board of Fire Underwriters and/ or the California Fire Insurance Rating Organization and/or any other similar body performing the
same or similar functions and having jurisdiction or cognizance of the Property and/or the Premises. 
 (i) The term
repair shall be deemed to include restoration and replacement as may be necessary to achieve and/ or maintain good working order and condition. 

(j) Reference to termination of this Lease includes expiration or earlier termination of the Term of this Lease or
cancellation of this Lease pursuant to any of the provisions of this Lease or to Law. Upon a termination of this Lease, the Term and estate granted by this Lease shall end at noon of the date of termination as if such date were the date of
expiration of the Term of this Lease, and neither party shall have any further obligation or liability to the other after such termination, except as shall be expressly provided for in this Lease and except for any such obligation as by its nature
or under the circumstances can only be, or by the provisions of this Lease may be, performed after such termination; and in any event, unless expressly provided to the contrary in this Lease, any liability for a payment or obligation which shall
have accrued to or with respect to any period ending at the time of termination shall survive the termination of this Lease. 
 (k)
The term in full force and effect when herein used in reference to this Lease as a condition to the existence or exercise of a right on the part of Tenant shall be construed in each instance as including the further condition that at
the time in question no default on the part of Tenant exists, and no event has occurred which has continued to exist for such period of time (after the notice, if any, required by this Lease), as would entitle Landlord to terminate this Lease or to
dispossess Tenant. 
 (l) The term Tenant shall mean Tenant herein named or any assignee, heir, distributee, executor,
administrator, legal representative, or other successor in interest (immediate or remote) of Tenant herein named, while such Tenant or such assignee or other successor in interest, as the case may be, is in possession of the Premises as owner of the
Tenant’s estate and interest granted by this Lease and also, if Tenant is not a single individual or a corporation, all of the persons, firms, and corporations then comprising Tenant; and their liability hereunder shall be joint and several.

  
 49 

 29.2 LIGHT AND AIR. No diminution of light, air or view by any structure which may hereafter
be erected (whether or not by Landlord) shall entitle Tenant to any reduction of Rent under this Lease, result in any liability of Landlord to Tenant, or in any other way affect this Lease. 

29.3 WAIVER OF TERMS. If either Landlord or Tenant waives the performance of any term, covenant, or condition contained in this Lease, such
waiver shall not be deemed to be a waiver of the term, covenant, or condition itself or a waiver of any subsequent breach of the same or any other term, covenant, or condition contained herein. Furthermore, the acceptance of Rent by Landlord shall
not constitute a waiver of any preceding breach by Tenant of any term, covenant, or condition of this Lease, regardless of Landlord’s knowledge of such preceding breach at the time Landlord accepts such Rent. Failure by Landlord or Tenant to
enforce any of the terms, covenants, or conditions of this Lease for any length of time shall not be deemed to waive or to decrease the right of Landlord or Tenant to insist thereafter upon strict performance by Landlord or Tenant, as the case may
be. Waiver by Landlord or Tenant of any term, covenant, or condition contained in this Lease may only be made by a written document signed by Landlord. 

29.4 FAILURE TO DELIVER STATEMENTS. Landlord’s failure during the Term of this Lease to prepare and deliver any of the Statements,
estimates, notices, or bills contemplated or required under this Lease, or Landlord’s failure to make a demand, shall not in any way cause Landlord to forfeit or surrender its rights to collect any of the foregoing items of Rent which may have
become due during the Term of this Lease. 
 29.5 ATTORNEY’S FEES. In the event that any action or proceeding (including arbitration) is
brought to enforce or interpret any term, covenant, or condition of this Lease on the part of Landlord or Tenant, the prevailing party in such action or proceeding (whether after trial or upon appeal) shall be entitled to recover from the party not
prevailing its expenses therein, including reasonable attorneys’ fees and all allowable costs as fixed by the court. 
 29.6 CORPORATE REVIEW
FEES. Notwithstanding anything to the contrary in this Lease, Tenant agrees to reimburse Landlord for its reasonable costs and/ or attorneys’ fees incurred in the review of (i) any transaction with respect to which Tenant is required
to give notice under § 17.13 of the Lease and/ or (ii) any other change of name, registration, corporate status or merger, acquisition, consolidation, transfer, loan, security, or collateral transaction, or other matter related to
Tenant’s legal or corporate status or the financing of any loan or collateral or security associated with the same requiring Landlord’s attention and need to seek legal advice. 

29.7 JURY TRIAL. Tenant and Landlord each hereby waive their respective rights to a trial by jury under applicable Laws in the event of any
litigation or dispute between Landlord and Tenant arising out of or in connection with this Lease and the parties’ performance thereunder. 

29.8 MERGER. Notwithstanding the acquisition (if same should occur) by the same party of the title and interests of both Landlord and Tenant
under this Lease, there shall never be a merger of the estates of Landlord and Tenant under this Lease, but instead the separate estates, rights, duties, and obligations of Landlord and Tenant, as existing hereunder, shall remain unextinguished and
continue, separately, in full force and effect until this Lease expires or otherwise terminates in accordance with the express provisions herein contained. 

29.9 NO MERGER ON VOLUNTARY SURRENDER. A voluntary or other surrender of this Lease by Tenant or the mutual cancellation of this Lease shall not
work a merger and shall, at the option of Landlord, terminate all or any existing subleases or subtenancies, or may, at the option of Landlord, operate as an assignment to it of any or all such subleases or subtenancies. 

  
 50 

 29.10 CONSENT. Notwithstanding anything contained in this Lease to the contrary, Tenant shall
have no claim and hereby waives the right to any claim against Landlord for money damages by reason of any refusal, withholding, or delaying by Landlord of any consent, approval, statement, or satisfaction; and in such event, Tenant’s only
remedies therefor shall be an action for specific performance, injunction, or declaratory judgement to enforce any right to such consent, approval, statement, or satisfaction. 

29.11 COUNTERPARTS. This Lease may be executed in multiple counterparts, each of which shall be deemed an original and all of which together
shall constitute one and the same instrument. 
 29.12 FINANCIAL STATEMENTS. In order to induce Landlord to enter into this Lease, Tenant
agrees that it shall promptly furnish Landlord, from time to time, upon Landlord’s written request, with financial statements reflecting Tenant’s current financial condition. Tenant represents and warrants that all financial statements,
records, and information furnished by Tenant to Landlord in connection with this Lease are and shall be true, correct, and complete in all respects. Landlord shall hold all such financial statements in confidence and shall not disclose any portion
of such financial statements to any party other than its financial and legal advisors, who shall also be bound by the confidentiality provision set forth in this§ 29.12. 

29.13 GENDER AND NUMBER. Words used in neuter gender include the feminine and masculine, where applicable, and words used in the singular or
plural shall include the opposite number if appropriate. 
 29.14 JOINT AND SEVERAL OBLIGATION. If more than one person executes this Lease as
Tenant, each of them is jointly and severally liable for the keeping, observing, and performing of all of the terms, covenants, conditions, provisions, and agreements of this Lease to be kept, observed, and performed by Tenant. The term
Tenant as used in this Lease shall mean and include each of such signatories jointly and severally. The act of or notice from, or notice or refund to, or the signature of, any one or more of such signatories with respect to the tenancy
or this Lease, including any renewal, extension, expiration, termination, or modification of this Lease, shall be binding upon each and all of the persons executing this Lease as Tenant with the same force and effect as if each and all of them had
so acted or so given or received such notice or refund or so signed. 
 29.15 HEADINGS AND SECTION NUMBERS. The headings and titles of the
articles and sections of this Lease are used for convenience only and shall have no effect upon the construction or interpretation of this Lease. Wherever a reference is made in this Lease to a particular article or section, such reference shall be
deemed to include all subsections following such section reference, unless the contrary is expressly provided in connection with such reference. All references in this Lease to numbered articles, numbered sections, and lettered exhibits are
references to articles and sections of this Lease and exhibits annexed to (and thereby made part of) this Lease, as the case may be, unless expressly otherwise designated in the context. 

29.16 TIME. Time is of the essence of this Lease and all of its provisions. 

29.17 APPLICABLE LAW. This Lease shall in all respects be governed by and interpreted in accordance with the laws of the State of California
without reference to its conflicts of law principles. If suit is brought by a party to this Lease, the parties agree that jurisdiction of such action shall be vested exclusively in the state courts of the State of California, County of San Mateo, or
in the United States District Court for the Northern District of California, and with its execution and delivery of this Lease Tenant waives any defense it might otherwise have against the jurisdiction of such courts. 

  
 51 

 29.18 SEVERABILITY. If any provision of this Lease or the application thereof to any person or
circumstance shall be invalid or unenforceable to any extent, the remainder of this Lease and the application of such provision to other persons or circumstances shall not be affected thereby and shall be enforced to the greatest extent permitted by
law. 
 29.19 SIGNS. Tenant shall not place or permit to be placed in or upon the Premises where visible from outside the Premises or any part
of the Building, any signs, notices, drapes, shutters, blinds or window coatings, or displays of any type without the prior written consent of Landlord. Landlord shall consent to the location at the cost of Tenant of a building standard sign on or
near the entrance of the Premises and shall include Tenant in the Building and Complex directories located in the Building at no cost to Tenant. Landlord reserves the right in Landlord’s sole discretion to place and locate on the roof and
exterior of the Building and Complex and in any area of the Building and the Complex not leased to Tenant, such signs, notices, displays and similar items as Landlord deems appropriate in the proper operation of the Building and the Complex. 

29.20 EXECUTION BY LANDLORD. The submission of this document for examination and negotiation does not constitute an offer to lease, or a
reservation of, or option for, the Premises. This document becomes effective and binding only upon execution and delivery hereof by Tenant and by Landlord. No act or omission of any employee or agent of Landlord or of Landlord’s broker shall
alter, change or modify any of the provisions hereof. 
 29.21 USE OF NAME. Tenant shall not use the name of the Building or Complex for any
purpose other than the address of the business to be conducted by Tenant in the Premises. Tenant shall not use any picture of the Building or Complex in its advertising, stationery or in any other manner so as to imply that the entire Building or
Complex is leased by Tenant. Landlord expressly reserves the right at any time to change the name or street address of the Building and/ or Complex without in any manner being liable to Tenant therefor. 

29.22 NONRECORDABILITY OF LEASE. Tenant agrees that in no event shall this Lease or a memorandum hereof be recorded without Landlord’s
express prior written consent, which consent Landlord may withhold in its sole discretion. 
 29.23 CONSTRUCTION. All provisions hereof,
whether covenants or conditions, shall be deemed to be both covenants and conditions. The definitions contained in this Lease, shall be used to interpret the Lease. All rights and remedies of Landlord and Tenant shall, except as otherwise expressly
provided, be cumulative and non-exclusive of any other remedy at law or in equity. 
 29.24 FORCE MAJEURE
DELAYS. This Lease and the obligations of Landlord or Tenant, as the case may be, hereunder shall be excused during the period that such party is unable to fulfill any of its obligations hereunder or is delayed in doing so, if such inability or
delay is caused by reason of force majeure, strike, labor troubles, acts of God, acts of government, unavailability of materials or labor, or any other cause beyond the reasonable control of such party (collectively “Force Majeure
Delays”); provided, however, that Force Majeure Delay shall not excuse any obligation to pay money. 
 29.25 AUTHORITY. If Tenant is a
corporation, Tenant represents and warrants that Tenant is qualified to do business in California and that each individual executing this Lease on behalf of Tenant is duly authorized to execute and deliver this Lease on behalf of Tenant and shall
deliver appropriate certification to that effect if requested. If Tenant is a limited liability company, partnership, joint venture, or other unincorporated association, Tenant represents and warrants that each individual executing this Lease on
behalf of Tenant is duly authorized to execute and deliver this Lease on behalf of Tenant and that this Lease is binding on Tenant. Furthermore, Tenant agrees that the execution of any written consent hereunder, or any written modification or
termination of this Lease, by any general partner or member of Tenant or any other authorized agent of Tenant, shall be binding on Tenant. 

  
 52 

 29.26 NONDISCLOSURE. Tenant agrees that it shall not disclose any of the matters set forth in
this Lease or disseminate or distribute any information concerning the terms, covenants, or conditions thereof to any person, firm, or entity, other than a prospective assignee or subtenant of the Premises, without first obtaining the express
written approval of Landlord; provided, however, that Tenant may disclose the contents of this Lease to any director, officer, or employee of Tenant, to Tenant’s lawyers, accountants, or other third party consultants or professionals, to any
lenders, investors, or others to whom Tenant provides financial statements, or in response to any legally effective demand for disclosure pursuant to court order or from any other properly constituted legal authority. 

29.27 QUIET ENJOYMENT. So long as Tenant is not in default under this Lease, Tenant shall have quiet enjoyment of the Premises for the Term,
subject to all the terms and conditions of this Lease and all liens and encumbrances prior to this Lease. 
 29.28 ACCESS INSPECTION
DISCLOSURE. Pursuant to California Civil Code § 1938, Landlord hereby notifies Tenant that, as of the date of this Lease, the Premises have not undergone inspection by a “Certified Access Specialist” to determine whether the
Premises meet all applicable construction-related accessibility standards under California Civil Code § 55.53, and the Premises have not been determined to meet all applicable construction-related accessibility standards pursuant to Civil Code
§ 55.53. In addition, Civil Code§ 1938(e) requires that the following language be inserted into this Lease: 

A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply
with all of the applicable construction-related accessibility standards under state law. Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant
from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant. The parties shall mutually agree on the arrangements for the time and manner of the CASp
inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises. 

Landlord is acting in compliance with applicable Laws by inserting the foregoing paragraph into this Lease, but Landlord thereby expresses no opinion as to
the meaning or applicability of§ 1938 and offers no legal advice as to its meaning or applicability. Tenant is informed and agrees that it will seek its own legal counsel if it has questions regarding the meaning of§ 1938 or its
applicability to this Lease. 
 29.29 [*] 

29.30 EXHIBITS AND ATTACHMENTS. All exhibits and attachments referred to in the body of this Lease are deemed attached hereto and incorporated
herein by reference. The parties have attached the following exhibits to the Lease prior to execution: 
 Exhibit A
      Site Plan 
 Exhibit B       Floor Plan of Premises 

Exhibit C       Rules and Regulations 

Exhibit D       Athletic Facility Use Agreement 

Exhibit E       Commencement Date Agreement 

  
 53 

 29.31 ENTIRE AGREEMENT. This Lease, together with its exhibits, contains all the agreements of
the parties hereto and supersedes any previous negotiations. There have been no representations made by the Landlord or understandings made between the parties other than those set forth in this Lease and its exhibits. This Lease may not be modified
except by a written instrument duly executed by the parties hereto. 
 IN WITNESS WHEREOF, the parties have executed this Lease as of the date first
above written. 
  

									
	Landlord:	 		 	Tenant:
			
	KASHIW A FUDOSAN AMERICA, INC.,
a California corporation	 		 	DAY ONE THERAPEUTICS, INC.,
a Delaware corporation

									
					
		 		 		 	By:	 	/s/ Julie Grant
			
	[*]	 		 	 CEO

		 		 	[name typed]
	By:	 	/s/ Tomoki Miura	 		 		 	
		 	Tomoki Miura, Senior Manager	 		 	Its:	 	 

  
 54EX-10.5

 Exhibit 10.5 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT
THE 
 REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. 

Execution Version 

Confidential 

ASSET TRANSFER AND LICENSE AGREEMENT 

This Asset Transfer and License Agreement (“Agreement”) is made effective as of December 16, 2019 (the
“Effective Date”) by and between DOT THERAPEUTICS-1, INC. (“Day One”), a Delaware corporation and an Affiliate of Day One Holdings, LLC, having a place of business at
2765 Sand Hill Road, Menlo Park, CA 94025, and MILLENNIUM PHARMACEUTICALS, INC. (“Takeda”), a Delaware corporation and an Affiliate of Takeda Pharmaceutical Company Limited, having a place of business at 40 Landsdowne Street,
Cambridge, MA 02139. 
 RECITALS 

WHEREAS, pursuant to a Collaboration Agreement (the “Original Agreement”), effective as of August 27, 2004, by
and between Sunesis Pharmaceuticals, Inc. (“Sunesis”) and Biogen Idec MA Inc. (“Biogen Idec”), as amended, Sunesis and Biogen Idec collaborated on the discovery and development of small molecules that modulated
certain targets, and discovered and commenced development of several compounds, including the compound designated as BIIB024; 

WHEREAS, pursuant to a Termination and Transition Agreement, dated as of March 31, 2011, Sunesis, Biogen Idec and Takeda agreed
that (a) Takeda succeeded to the rights of Biogen Idec under the Original Agreement with respect to the Compound and certain other compounds and, in order to effectuate the foregoing, (b) effective of as March 31, 2011, (i) Sunesis
and Takeda entered into that certain License Agreement (the “License Agreement”), pursuant to which, among other things, Sunesis granted Takeda license to its interest in the jointly owned intellectual property to develop and
commercialize such Compound, (ii) Sunesis and Biogen Idec entered into an amendment and restatement of the Original Agreement and (iii) Takeda and Biogen Idec entered into an asset transfer agreement (the “Takeda-Biogen
Agreement”); 
 WHEREAS, effective as of January 8, 2014, Takeda and Sunesis amended and restated the License Agreement
(the “Amended and Restated License Agreement”), pursuant to which Takeda grants Sunesis rights to develop and commercialize compounds binding human 3-phosphoinositide-dependent protein kinase-1 (the “PDK Target”), but not compounds binding the Raf Target, and certain other rights with respect to such compounds; 

WHEREAS, pursuant to the License Agreement and the Amended and Restated License Agreement, Takeda, among other things, developed TAK-580 (also known as BIIB024); 
 WHEREAS, to facilitate the Contemplated Transactions, Takeda
and Sunesis are amending and restating the terms of the Amended and Restated License Agreement into two separate agreements (a) an agreement which contains the terms and conditions pursuant to which, among other things, Takeda (or its assignee)
will have a license under certain intellectual property rights of Sunesis to develop and commercialize compounds binding the Raf Target (but not compounds binding the PDK Target), and 

 
certain other rights with respect to such compounds (the “Sunesis License”), and (b) an agreement, which contains the terms and conditions pursuant to which, among other
things, Sunesis will have a license under certain intellectual property rights of Takeda to develop and commercialize compounds binding the PDK Target (but not compounds binding the Raf Target), and certain other rights with respect to such
compounds; 
 WHEREAS, Takeda owns the Assigned Technology and Controls certain Know-How and
Patent Rights related solely to, or otherwise necessary to Exploit, one or more Products or the Compound in the Day One Field in the Territory; 

WHEREAS, pursuant to this Agreement, among other things, Takeda will sell, assign, or otherwise transfer to Day One, and Day One will
purchase or otherwise acquire from Takeda, the Acquired Assets; 
 WHEREAS, Takeda has confidence in Day One’s ability to
Develop and Commercialize the Products in the Day One in the Territory and make such product available to patients and accordingly, under specific circumstances in which all Development of Products has been discontinued, rights under the Assigned
Technology and Licensed Intellectual Property would revert to Takeda on the terms and conditions set forth herein; 
 WHEREAS, Day
One desires to obtain, and Takeda wishes to grant, certain licenses under the Licensed Intellectual Property on the terms and conditions set forth herein; and 

WHEREAS, Takeda desires to obtain, and Day One wishes to grant, certain licenses for the Exploitation of Takeda Products under the
Assigned Technology in the Takeda Field, on the terms and conditions set forth herein. 
 NOW THEREFORE, the Parties, intending to be
legally bound hereby, agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 1.1
“Acquired Assets” has the meaning set forth in Section 2.1. 
 1.2 “Acquiring Party” has the
meaning set forth in Section 1.26. 
 1.3 “Adverse Event” or “AE” has the meaning set forth in
21 C.F.R. § 312.32 and generally means any untoward medical occurrence associated with the use of a product in human subjects, whether or not considered related to such product. An AE does not necessarily have a causal relationship with a
product, that is, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of such product. 

1.4 “Affiliate” means, with respect to any Person, any other Person that directly or indirectly controls, is
controlled by, or is under common control with such Person, for so long as such relationship continues to exist. For purposes of this definition only, “controls” and, with correlative meanings, the terms “controlled by” and
“under common control with” another Person will mean: 
 (a) direct or indirect ownership of more than 50% of the outstanding
voting securities or other voting interest of the other Person; or 
 (b) direct or indirect possession of the power to elect or appoint
more than 50% of the members of the governing body of the other Person; 

  
 2 

 provided that in the case of jurisdictions in which the maximum percentage ownership permitted by
Applicable Law for a foreign investor is less than 50%, such lower percentage will be substituted in clause 1.4(a) of the preceding sentence. Neither of the Parties will be deemed to be an “Affiliate” of the other solely as a result
of their entering into this Agreement. 
 1.5 “Agreement” has the meaning set forth in the Preamble. 

1.6 “Applicable Law” means applicable laws, statutes, rules, regulations, and other pronouncements having the effect
of law of any Governmental Authority that may be in effect from time to time, including disclosure obligations required by any stock exchange or securities commission having authority over a Party and any applicable rules, regulations, guidances, or
other requirements of any Regulatory Authority that may be in effect from time to time. 
 1.7 “Assigned Agreements”
means those certain agreements to which Takeda or its Affiliates is a party that are set forth on Schedule 1.7. 
 1.8
“Assigned Inventory” has the meaning set forth in Section 2.1. 
 1.9 “Assigned Know-How” means the Know-How set forth on Schedule 1.9, which lists the Know-How Controlled by Takeda or its Affiliates that
is related solely to one or more Products or the Compound and not to any other product Controlled by Takeda or any of its Affiliates. 

1.10 “Assigned Patent Rights” means the Patent Rights set forth on Schedule 1.10. 

1.11 “Assigned Regulatory Submissions” means the Regulatory Submissions set forth on Schedule 1.11, which lists the
Regulatory Submissions that are Controlled by Takeda or its Affiliates and relate solely to one or more Products or the Compound and not to any other product Controlled by Takeda or any of its Affiliates. 

1.12 “Assigned Technology” means the Assigned Know-How and the Assigned Patent
Rights. 
 1.13 “Basket” has the meaning set forth in Section 7.4(c). 

1.14 “Calendar Year” means any calendar year beginning on January 1st and ending on December 31st. 

1.15 “Cap” means [*]. 

1.16 “Change of Control” means, with respect to a Party or any of its Affiliates: [*]. 

1.17 “Claims” means collectively, any and all demands, claims, actions, and proceedings (whether criminal or civil, in
contract, tort, or otherwise) for Losses. 
 1.18 “Clinical Trial” means any clinical trial conducted in humans,
including any phase I clinical trial, phase II clinical trial, phase III clinical trial, or post-Regulatory Approval clinical trial; provided, further, that treatment of patients for compassionate use, including in an expanded access program, single
patient program, named patient program or a single patient IND shall not be included in determining whether a patient has been dosed thereunder. 

1.19 “Code” means the Internal Revenue Code of 1986, as amended. 

  
 3 

 1.20 “Commercialization” means any and all activities directed to
the marketing, promotion, distribution, offering for sale, sale, having sold, importing, having imported, exporting, having exported, or other commercialization of a pharmaceutical product, but excluding activities directed to Manufacturing,
Development, or Medical Affairs. “Commercialize,” “Commercializing,” and “Commercialized” will be construed accordingly. 

1.21 “Commercially Reasonable Efforts” means, with respect to the Exploitation of a Product by Day One, [*]. 

1.22 “Common Stock” means shares of the Day One’s common stock, par value $0.0001 per share. 

1.23 “Compound” means TAK-580 and any metabolites, salts, esters, hydrates,
solvates, isomers, enantiomers, crystalline forms, co-crystalline forms, amorphous forms, free acid forms, free base forms, pro-drug (including any ester pro-drug) forms, racemates, polymorphs, chelates, stereoisomers, or tautomers of TAK-580, and all optically active forms thereof. 

1.24 “Confidential Information” means with respect to each Party, all Know-How
or other information, including proprietary information and materials (whether or not patentable) regarding or embodying such Party’s technology, products, business information, or objectives, that is communicated by or on behalf of the
Disclosing Party to the Receiving Party or its permitted recipients, including the terms and conditions of this Agreement. 
 1.25
“Contemplated Transactions” means, collectively, the transactions contemplated by this Agreement, other than the Series A Preferred Stock Transaction Agreements, including (a) the sale and purchase of the Acquired Assets and
(b) the license of the Licensed Intellectual Property. 
 1.26 “Control” or “Controlled” means
the possession by a Person (whether by ownership, license, or otherwise other than pursuant to this Agreement) of, (a) with respect to any tangible Know-How, the legal authority or right to physical
possession of such tangible Know-How, with the right to provide such tangible Know-How to the other Party on the terms set forth herein, (b) with respect to Patent
Rights, Regulatory Approvals, Regulatory Submissions, intangible Know-How, or other Intellectual Property, the legal authority or right to grant a license, sublicense, access, or right to use (as applicable)
to the other Party under such Patent Rights, Regulatory Approvals, Regulatory Submissions, intangible Know-How, or other Intellectual Property on the terms set forth herein, or (c) with respect to any
product, the legal authority to grant a license or sublicense (other than pursuant to this Agreement) of exclusive rights under Patent Rights that Cover such product or proprietary Know-How that is used in
connection with the Manufacture, use, or Commercialization of such product, in each case ((a), (b) and (c)), without breaching or otherwise violating the terms of any arrangement or agreement with a Third Party in existence as of the time such Party
or its Affiliate would first be required hereunder to grant the other Party such access, right to use, licenses, or sublicense. Notwithstanding the foregoing, in the case of any Intellectual Property that is acquired by or licensed to a Party after
the Effective Date (the “Acquiring Party”) that (i)(A) with respect to any tangible Know-How within such Intellectual Property, the acquiring Party has the legal authority or right to physical
possession of such tangible Know-How, with the right to provide such tangible Know-How to the other Party on the terms set forth herein, (B) with respect to Patent
Rights, Regulatory Approvals, Regulatory Submissions, intangible Know-How, or other Intellectual Property within such Intellectual Property, the Acquiring Party has the legal authority or right to grant a
license, sublicense, access, or right to use (as applicable) to the other Party under such Patent Rights, Regulatory Approvals, Regulatory Submissions, intangible Know-How, or other Intellectual Property on
the terms set forth herein, or (C) with respect to any product within such Intellectual Property, the Acquiring Party has the legal authority to grant a license or sublicense (other than pursuant to this Agreement) of exclusive rights under
Patent Rights that Cover 

  
 4 

 
such product or proprietary Know-How that is used in connection with the Manufacture, use, or Commercialization of such product, in each case ((A), (B),
and (C)), without breaching or otherwise violating the terms of any arrangement or agreement with a Third Party in existence as of the time such Party or its Affiliate would first be required hereunder to grant the other Party such access, right to
use, licenses, or sublicense, and (ii) the practice of which by the other Party solely with respect to the Compound or any Product would give rise to any payment obligation to the applicable Third Party, then such Intellectual Property will be
deemed Controlled by the Acquiring Party for the purposes of the licenses granted hereunder only if such other Party agreed to pay and does in fact pay to such Third Party or the Acquiring Party, at the Acquiring Party’s election, the
applicable payment obligations that are directly attributable to the use of such Intellectual Property in the Development, Manufacture, or Commercialization of the Compound or any Product by or on behalf of such other Party, its Affiliates or
(sub)licensees. 
 1.27 “Cover”, “Covers” or “Covered” means, with respect to a
particular subject matter at issue and a relevant Patent Right or individual claim in such Patent Right, as applicable, that the manufacture, use, sale, offer for sale, or importation of such subject matter would fall within the scope of one or more
claims in such Patent Right or the individual claim of such Patent Right. 
 1.28 “Day One Field” means all fields
of use for the prevention, diagnosis, or treatment of all diseases or conditions, other than the fields of use included in the Takeda Field, subject to Section 9.4. 

1.29 “Day One Developed Technology” means (a) [*], and (b) [*]. 

1.30 “Day One Indemnitees” has the meaning set forth in Section 7.2. 

1.31 “Day One Therapeutics” means any or all of Day One Therapeutics, Inc. or Day One Holdings, LLC. 

1.32 “Development” means all internal and external research, development, and regulatory activities related to
pharmaceutical products, including (a) research, toxicology testing and studies, non- clinical and preclinical testing, studies, and other activities, and Clinical Trials, and (b) preparation,
submission, review, and development of data or information for the purpose of submission to a Regulatory Authority to obtain authorization to conduct Clinical Trials and to obtain, support, or maintain Regulatory Approval of a pharmaceutical product
and interacting with Regulatory Authorities following receipt of Regulatory Approval in the applicable country or region for such pharmaceutical product regarding the foregoing, but excluding activities directed to Manufacturing, Medical Affairs, or
Commercialization. Development will include development and regulatory activities for additional forms, formulations, or indications for a pharmaceutical product after receipt of Regulatory Approval of such product (including label expansion),
including Clinical Trials initiated following receipt of Regulatory Approval or any Clinical Trial to be conducted after receipt of Regulatory Approval that was mandated by the applicable Regulatory Authority as a condition of such Regulatory
Approval with respect to an approved formulation or indication (such as post-marketing studies, observational studies, implementation and management of registries and analysis thereof, in each case, if required by any Regulatory Authority in any
region in the Territory to support or maintain Regulatory Approval for a pharmaceutical product in such region). “Develop,” “Developing,” and “Developed” will be construed accordingly. 

1.33 “Disclosing Party” has the meaning set forth in Section 8.1(a). 

1.34 “Dispute” has the meaning set forth in Section 9.6. 

1.35 “Effective Date” has the meaning set forth in the Preamble. 

  
 5 

 1.36 “EMA” means the European Medicines Agency, or any successor
agency with similar responsibilities. 
 1.37 “Excluded Assets” has the meaning set forth in Section 2.3. 

1.38 “Exploit” means to Develop, Manufacture, perform or have performed Medical Affairs, Commercialize, or otherwise
exploit. “Exploitation” and “Exploiting” will be construed accordingly. 
 1.39
“FDA” means the United States Food and Drug Administration, or any successor agency thereto. 
 1.40
“FFDCA” means the United States Federal Food, Drug and Cosmetic Act, as amended or supplemented from time to time. 

1.41 “Fully-Diluted Basis” means, as of a specified date, (a) the number of shares of Common Stock
then-outstanding, plus (b) the number of shares of Common Stock issuable upon exercise or conversion of then-outstanding convertible securities or warrants, options, or other rights to subscribe for, purchase or acquire from Day One any
capital stock of Day One (which will be determined without regard to whether such securities or rights are then vested, exercisable or convertible), plus (c) all shares of Common Stock reserved for issuance pursuant to any equity
incentive plan of the Day One, and plus (d) all shares of Common Stock issuable pursuant to the Series A Purchase Agreement at all closings thereunder, in each case measured on an as-converted to
Common Stock basis; provided that, for clarity, “other rights to subscribe for, purchase or acquire” will not include (i) preemptive or other rights to participate in new offerings of securities by Day One,
(ii) anti-dilution provisions that have not been triggered, and (iii) anti-dilution provisions that would not be triggered by the issuance of equity securities to Takeda pursuant to or in connection
with the provisions of this Agreement. 
 1.42 “Fundamental Breaches” has the meaning set forth in
Section 7.4(b)(i). 
 1.43 “Governmental Authority” means any court, tribunal, arbitrator, agency, commission,
department, ministry, official, authority or other instrumentality of any national, state, county, city or other political subdivision. 

1.44 “Grant Back License” has the meaning set forth in Section 2.5(a). 

1.45 “Gross Up Taxes” has the meaning set forth in Section 3.4. 

1.46 “ICH” means International Conference on Harmonization. 

1.47 “IND” means, in the United States, an Investigational New Drug Application filed with the FDA as more fully
defined in 21 C.F.R. §312.3, and, with respect to every other country in the Territory, the clinical trial notification, clinical trial application or other equivalent application (i.e., a filing that must be made prior to commencing clinical
testing of any Product in humans) filed with the applicable Regulatory Authority in such country. 
 1.48 “Indemnified
Party” has the meaning set forth in Section 7.3. 
 1.49 “Indemnifying Party” has the meaning set
forth in Section 7.3. 

  
 6 

 1.50 “Intellectual Property” means all Patent Rights, rights to
inventions, copyrights, design rights, trademarks, Know-How, and all other intellectual property rights (whether registered or unregistered), and all applications and rights to apply for any of the foregoing,
anywhere in the world. 
 1.51 “IO Combo Study” means that certain clinical study under the study ID C28003. 

1.52 “IRS” means the Internal Revenue Service. 

1.53 “JDC” has the meaning set forth in Section 4.5. 

1.54 “Know-How” means any (a) proprietary information or materials,
including records, improvements, modifications, techniques, assays, chemical or biological materials, designs, protocols, formulas, data (including physical data, chemical data, toxicology data, animal data, raw data, clinical data, and analytical
and quality control data), dosage regimens, control assays, product specifications, marketing, pricing and distribution costs, inventions, algorithms, technology, forecasts, profiles, strategies, plans, results in any form whatsoever, know-how, and trade secrets (in each case, whether or not patentable, copyrightable, or otherwise protectable), and (b) any physical embodiments of any of the foregoing. 

1.55 “Labeling” means the healthcare professional information or patient information used in the Territory that is
part of an MAA for a Product including the package insert, medication guides, company core safety information (“CCSI”), and company core data sheet (“CCDS”). 

1.56 “Liability” means any obligation or liability (direct or indirect, matured or unmatured, absolute, accrued,
contingent or otherwise), whether or not required by United States generally accepted accounting principles to be reflected in financial statements or disclosed in the notes thereto. 

1.57 “Licensed Intellectual Property” means the Licensed Know-How and the
Licensed Patents. 
 1.58 “Licensed Know-How” means the Know-How, other than the Assigned Know-How, that is Controlled by Takeda or its Affiliates (a) on the Effective Date and set forth on Schedule 1.58 or (b) otherwise
disclosed in writing by Takeda to Day One during the Term for the purpose of Exploiting the Compound or the Products in the Day One Field in the Territory. 

1.59 “Licensed Patents” means (a) all Patent Rights Controlled by Takeda on the Effective Date and set forth on
Schedule 1.59 and (b) with respect to any patent set forth on Schedule 1.59, any patent applications from which such patent issued, and with respect to any such patent application (including any provisional application) in any country or
international or regional patent authority, the following items, collectively: (i) all divisionals, continuations and continuations-in-part of such patent
application; (ii) any patents (including certificates of correction) issuing from such patent application or any patent application described in clause (i); (iii) all patents and patent applications, in any country or international or regional
patent authority, based on, corresponding to or claiming the priority date(s) of, or common priority with, such patent application or any of the patents and patent applications described in clauses (i) or (ii); (iv) all rights derived from any
of the items described in clauses (i), (ii) or (iii) including any substitutions, extensions (including supplemental protection certificates), registrations, confirmations, reissues, re- examinations and
renewals of any of the patents described in clauses (ii) or (iii). 
 1.60 “Losses” means losses, damages,
Liabilities, costs, charges, and expenses (including reasonable attorneys’ fees). 

  
 7 

 1.61 “MAA” means a (a) New Drug Application or supplemental New
Drug Application as contemplated by Section 505(b) of the FFDCA, submitted to the FDA pursuant to 21 C.F.R. § 314, including any amendments thereto, or (b) any comparable applications filed in or for countries or jurisdictions outside
of the United States to obtain Regulatory Approval to Commercialize a pharmaceutical product in that country or jurisdiction. 
 1.62
“Manufacture” or “Manufacturing” means activities directed to manufacturing, processing, formulating, packaging, labeling, filling, finishing, assembly, quality assurance, quality control, testing, and release,
shipping, or storage of any pharmaceutical product (or any components or process steps involving any product or any companion diagnostic), placebo, or comparator agent, as the case may be, including process development, qualification, and
validation, scale-up, pre-clinical, clinical, and commercial manufacture and analytic development, product characterization, and stability testing, but excluding
activities directed to Development, Commercialization, or Medical Affairs. “Manufacturing” and “Manufactured” will be construed accordingly. 

1.63 “Medical Affairs” means activities conducted by a Party’s medical affairs departments (or, if a Party does
not have a medical affairs department, the equivalent function thereof), including communications with key opinion leaders, medical education, symposia, advisory boards (to the extent related to medical affairs or clinical guidance), and other
medical programs and communications, including educational grants, research grants (including conducting investigator-initiated studies), and charitable donations to the extent related to medical affairs and not to other activities that do not
involve the Commercialization of Products and are not conducted by a Party’s medical affairs (or equivalent) departments. 

1.64 “Notifying Party” has the meaning set forth in Section 4.8(d)(ii). 

1.65 “Original Agreement” has the meaning set forth in the recitals. 

1.66 “Party” means Day One or Takeda. 

1.67 “Patent Rights” means any and all (a) patents, (b) patent applications, including all provisional and non-provisional applications, patent cooperation treaty (PCT) applications, substitutions, continuations, continuations-in-part,
divisions and renewals, and all patent rights granted thereon, (c) all patents-of-addition, reissues, re-examinations and
extensions or restorations by existing or future extension or restoration mechanisms, including supplementary protection certificates and equivalents thereof, (d) inventor’s certificates, letters patent, or (e) any other substantially
equivalent form of government issued right substantially similar to any of the foregoing described in subsections (a) through (d) above, anywhere in the world. 

1.68 “Person” means any individual, firm, corporation, partnership, limited liability company, trust, business trust,
joint venture, Governmental Authority, association or other entity. 
 1.69 “Pharmacovigilance Agreement” has the
meaning set forth in Section 4.9(a). 
 1.70 “Point of Contact” has the meaning set forth in Section 4.13.

 1.71 “Product Trademarks” has the meaning set forth in Section 5.8. 

1.72 “Products” means all products incorporating or comprising the Compound in any dosage, form or formulation,
including any and all modes of administration. 

  
 8 

 1.73 “Prosecution” means the filing, preparation, prosecution
(including any interferences, reissue proceedings, reexaminations, oppositions and similar proceedings), post-grant reviews, requests for patent term adjustments, and maintenance of Patent Rights. For the avoidance of doubt, Prosecution excludes any
applications or requests for Patent Term Extension. When used as a verb, “Prosecute” means to engage in Prosecution. 

1.74 “Raf Target” means the human Raf protein together with the Raf protein family members Raf-1, A-Raf, B-Raf, and C-Raf. 

1.75 “Recall” means removal or correction of a Product following (a) notice or request of any Regulatory
Authority or (b) the good faith determination by a Party that an event, incident, or circumstance has occurred that required such a recall of such Product. A Recall does not include a market withdrawal or a stock recovery. 

1.76 “Receiving Party” has the meaning set forth in Section 8.1(a). 

1.77 “Regulatory Approval” means any and all approvals, licenses, registrations, or authorizations of the relevant
Regulatory Authority, including any pricing and/or reimbursement approval or determination necessary for the Development, Manufacture, use, import, transport, or Commercialization of Product in a particular country or jurisdiction. 

1.78 “Regulatory Authority” means (a) in the US, the FDA or (b) in any other jurisdiction anywhere in the
world, any regulatory body with similar regulatory authority over pharmaceutical products (including without limitation, the EMA). 

1.79 “Regulatory Submissions” means any filing, application, or submission with any Regulatory Authority in support of
the Development, Manufacture, Commercialization, or other Exploitation of a pharmaceutical product (including to obtain, support, or maintain Regulatory Approval from that Regulatory Authority), and all correspondence or communication with or from
the relevant Regulatory Authority, as well as minutes of any material meetings, telephone conferences, or discussions with the relevant Regulatory Authority. Regulatory Submissions include all INDs, MAAs, and other applications for Regulatory
Approval and their equivalents. 
 1.80 “Related Party” means (a) any Person to which Day One grants a
sublicense under the rights granted to Day One under Section 2.4(a) or (b) any other Person to which Day One grants a license under any of the Assigned Technology. For the purposes of this Agreement, Takeda will not be considered a Related
Party of Day One. 
 1.81 “Related Party Developed Technology” means all
Know-How developed or invented by or on behalf of a Related Party in the performance of activities under this Agreement or using the Assigned Technology or Licensed Intellectual Property, and that is related
to the Products or the Compound in the Day One Field, and all Patent Rights with a priority date after the Effective Date that Cover any such Know- How that, in each case, is necessary or useful to Exploit the Takeda Products in the Takeda Field in
the Territory, including any such Know-How that comprises any improvement to the Compound as an active product ingredient, but, in each case, excluding any such Know-How
related to, or Patent Rights Covering, [*]. 
 1.82 “Review Material” has the meaning set forth in Section 8.6.

 1.83 “SEC” means the U.S. Securities and Exchange Commission, or any successor thereto. 

  
 9 

 1.84 “Series A Preferred Stock” means the Series A Preferred Stock
of Day One, $0.0001 par value per share. 
 1.85 “Series A Preferred Stock Transaction Agreements” has the meaning
set forth in Section 3.2. 
 1.86 “Series A Purchase Agreement” means that certain Series A Preferred Stock
Purchase Agreement, dated as of the Effective Date, by and between Day One and the purchasers of Series A Preferred Stock party thereto. 

1.87 “Serious Adverse Event” or “SAE” has the meaning set forth in 21 C.F.R. § 312.32, and
generally means any Adverse Event that (a) results in death, (b) is life-threatening, (c) requires inpatient hospitalization or prolongation of existing hospitalization, (d) results in persistent or significant disability or
incapacity, (e) is a congenital anomaly or birth defect, or (f) based upon appropriate medical judgment is considered an important medical event that may jeopardize the patient or subject and may require medical or surgical intervention to
prevent one of the outcomes listed in this definition. 
 1.88 “Stock Issuance Agreement” means the agreement
attached hereto as Exhibit A. 
 1.89 “Sunesis” has the meaning set forth in the recitals. 

1.90 “Sunesis License” has the meaning set forth in the recitals. 

1.91 “TAK-580” means the pan-RAF
kinase inhibitor previously known as BIIB024 and MLN 2480. 
 1.92 “TAK-580
IND” means the IND for the Product, which is number 108,340. 
 1.93 “Takeda-Biogen Agreement” has the
meaning set forth in the recitals. 
 1.94 “Takeda Developed Technology” means (a) [*], and (b) [*]. For clarity,
the Takeda Developed Technology excludes the Assigned Technology and the Licensed Patents. 
 1.95 “Takeda Development
Notice” has the meaning set forth in Section 4.5(a). 
 1.96 “Takeda Field” means the prevention,
diagnosis, or treatment of diseases or conditions that are set forth on the attached Schedule 1.96 but expressly excluding the prevention, diagnosis, or treatment of [*]. 

1.97 “Takeda Indemnitees” has the meaning set forth in Section 7.1. 

1.98 “Takeda Licensee Developed Technology” means [*]. 

1.99 “Takeda Product” means any Product Developed or Commercialized by or on behalf of Takeda, its Affiliates or any
of Takeda or its Affiliates respective licensees or sublicensees under this Agreement for use in the Takeda Field. 
 1.100
“Tax” means (a) all federal, provincial, territorial, state, municipal, local, foreign or other taxes, imposts, rates, levies, assessments and other charges in the nature of a tax, including all income, excise, franchise,
gains, capital, real property, goods and services, transfer, value added, gross receipts, windfall profits, severance, ad valorem, personal property, production, sales, use, license, stamp, documentary stamp, mortgage recording, employment, payroll,
social security, unemployment, disability, 

  
 10 

 
escheat and unclaimed property, estimated or withholding taxes, and all customs and import duties, in each case, whether disputed or not; (b) interest, penalties, fines, additions to tax, or
additional amounts imposed by any Governmental Authority in connection with (i) any item described in clause (a) or (ii) the failure to comply with any requirement imposed with respect to any Tax Returns, (c) any Liability for the
payment of any amounts of the type described in clause (a) or clause (b) as a result of being or having been a member of an affiliated, consolidated, combined or unitary group; and (d) any Liability for the payment of any amounts as a
result of being party to any tax sharing agreement or arrangement or as a result of any express or implied obligation to indemnify any other person with respect to the payment of any amounts of the type described in clause (a), (b), or (c). 

1.101 “Territory” means all of the countries of the world, and their territories and possessions. 

1.102 “Third Party” means any Person other than a Party or an Affiliate of a Party. 

1.103 “Third Party Action” has the meaning set forth in Section 5.5(a). 

1.104 “Third Party Claim” has the meaning set forth in Section 7.1. 

1.105 “Third Party Infringement” has the meaning set forth in Section 5.4(b). 

1.106 “Third Party IP Agreement” means any agreement pursuant to which Day One licenses or otherwise acquires rights
under any Know-How or Patent Rights controlled by a Third Party that is necessary or useful to Exploit any Product in the Day One Field in the Territory, other than the Sunesis License. 

1.107 “Third Party Obligations” has the meaning set forth in Section 6.2(a). 

1.108 “Trademark” means any trademark, trade name, service mark, service name, brand, domain name, trade dress, logo,
slogan, or other indicia of origin or ownership, including the goodwill and activities associated with each of the foregoing. 

1.109 “Transfer Plan” has the meaning set forth in Section 4.1. 

1.110 “Up-Front Payment” has the meaning set forth in Section 3.1. 

1.111 “Withholding Tax Action” means an assignment of all or any portion of this Agreement by Day One, Change of
Control of Day One, change of jurisdiction of payments by Day One, or change of domicile by Day One that in and of itself without regard to any other circumstance causes a withholding tax obligation to arise or which increases a withholding tax
obligation with respect to an amount payable to Takeda pursuant to this Agreement, except to the extent a Change of Control of Day One or change of domicile of Day One is caused by the direct or indirect ownership of Day One by Takeda or any of
Takeda’s direct or indirect owners or Affiliates. 
 ARTICLE 2 

TRANSFER OF ASSETS; GRANT OF RIGHTS 

2.1 Transfer of Assets. Subject to the terms and conditions hereof, upon the Effective Date, Takeda hereby grants, sells,
transfers, conveys, assigns, and delivers to Day One, and Day One agrees to purchase and receive from Takeda all of Takeda’s and its Affiliates’ rights, title, and interest in and to the following assets (the assets set forth in the
following clauses (a) – (e), collectively, the “Acquired Assets”): 
 (a) the Assigned Patent Rights; 

  
 11 

 (b) the Assigned Know-How; 

(c) the Assigned Agreements; 

(d) the Assigned Regulatory Submissions; and 

(e) inventory of the Compound set forth on Schedule 2.1(e) (the “Assigned Inventory”). 

Upon the Effective Date, Takeda will execute and deliver to Day One the Bill of Sale assigning the Acquired Assets to Day One, substantially in the form
attached hereto as Schedule 2.1. 
 2.2 Further Assurances. After the Effective Date, each Party will promptly take such
actions as may be reasonably necessary to effect the sale, conveyance, assignment, and transfer of all Acquired Assets to Day One in a manner consistent with the assignment and delivery terms of this Agreement, and any other document or instrument
contemplated hereby or thereby. Without limiting the generality of the foregoing, each Party will, from time to time (but not to exceed the date that is [*] after the Effective Date), take such actions as may be reasonably necessary to perfect the
transfer of the Assigned Patent Rights to Day One, including the execution of (a) any documents needing inventor signature, a patent assignment agreement substantially in the form attached hereto as Schedule 2.2, and (b) any other patent
assignments that may be reasonably required in any jurisdiction in the Territory in connection with the transfer and assignment to Day One of the Assigned Patent Rights, all in forms reasonably acceptable to Takeda and Day One. Any fees associated
with the recording and other filing of assignment documents will be the sole and exclusive responsibility of Day One. 
 2.3
Excluded Assets. Except as expressly set forth in the licenses granted under Section 2.4, Day One is not acquiring any rights, title, or interests in, to or under the Licensed Intellectual Property (except as set forth in
Section 5.1) or acquiring any assets, properties or rights, in each case, that are not Acquired Assets (collectively, the “Excluded Assets”). 

2.4 License Grant to Day One. 

(a) Exploitation License. Subject to the terms and conditions of this Agreement, Takeda hereby grants and agrees to grant to Day One an
irrevocable, perpetual license (or sublicense to the extent applicable), with the right to grant sublicenses through multiple tiers as set forth in Section 2.4(b), in the Territory under the Licensed Intellectual Property and the Takeda
Developed Technology to Exploit the Compound and the Products in the Day One Field in the Territory. The foregoing license will be exclusive with respect to the Licensed Intellectual Property and non-exclusive
with respect to the Takeda Developed Technology. Day One will not, and will cause its Related Parties not to, Exploit the Compound or any Product outside of the Day One Field or Exploit any Takeda Product in the Territory for so long as the Grant
Back License remains in effect. 
 (b) (Sub)licenses. Day One may grant to Day One Therapeutics or to any Third Party any sublicenses
of the rights granted under Section 2.4(a) or any licenses or other rights to Exploit any Product, in each case, without Takeda’s prior written consent. Each sublicense of the rights granted under Section 2.4(a) or license or other
grant of rights to any other Related Party to Exploit any Product, in each case, will (i) refer to and be consistent with the terms and conditions of this Agreement, (ii) will require assignment or sublicensable license (through multiple
tiers) to Day One of rights to all Related Party Developed Technology, which rights will be licensed or sublicensed, and will be sufficient to so license or 

  
 12 

 
sublicense, to Takeda pursuant to the Grant Back License as part of the Day One Developed Technology if such Related Party Developed Technology is Controlled by Day One (as provided in the
proviso to the definition of Control), and (iii) contain confidentiality terms and conditions at least as restrictive as those set forth in this Agreement. Day One will remain responsible for the failure of its Related Parties to comply with
the relevant obligations under this Agreement. Unless otherwise agreed in writing by Takeda and prior to the first Change of Control of Day One that occurs after the Effective Date, Day One may not grant to any Affiliate (other than Day One
Therapeutics) any sublicense of the rights granted under Section 2.4(a) or any licenses or other rights to Exploit any Product and may not engage any Affiliate (other than Day One Therapeutics) to exercise any of Day One’s rights or
perform any of Day One’s obligations, in each case, under this Agreement or otherwise with respect to the Exploitation of any Compound or any Product. 

(c) Assays. Takeda hereby grants and agrees to grant to Day One a fully-paid, royalty- free, worldwide,
non-exclusive, perpetual, irrevocable and sublicenseable through multiple tiers license under Takeda’s rights to the assays described in Schedule 2.4(c) to use, import and Manufacture (and have
Manufactured) such assays for purposes of performing its obligations and exercising its rights this Agreement and the Sunesis License. 

(d) Covenant Not to Sue. Subject to Day One’s compliance with the terms and conditions of this Agreement, Takeda will not, and
will cause its Affiliates to not, anywhere in the Territory, assert any legal or equitable cause of action, suit, or claim against Day One, its Affiliates, or any of its Related Parties asserting infringement of any Patent Rights Controlled by
Takeda or its Affiliates as a result of Day One’s, its Affiliates, or its Related Parties’ Exploitation of the Compound or the Products. 

2.5 License Grants to Takeda. 

(a) Takeda Field. Subject to the terms and conditions of this Agreement, Day One hereby grants and agrees to grant to Takeda and its
Affiliates an irrevocable (subject to Section 2.6), perpetual (subject to Section 2.6), license (or sublicense to the extent applicable), with the right to grant sublicenses through multiple tiers, in the Territory under the Assigned
Technology and the Day One Developed Technology, solely to Exploit the Takeda Products in the Takeda Field in the Territory (the “Grant Back License”). The Grant Back License will be exclusive with respect to the Assigned Technology
and the Licensed Intellectual Property and non-exclusive with respect to the Day One Developed Technology. Takeda will not, and will cause its Affiliates and sublicensees not to, Exploit the Compound or the
Products outside of the Takeda Field in the Territory or any Product that is not a Takeda Product in the Territory. Each sublicense under the Grant Back License will (i) refer to and be consistent with the terms and conditions of this
Agreement, (ii) will require assignment or sublicensable license (through multiple tiers) to Takeda of rights to all Takeda Licensee Developed Technology, which rights will be licensed or sublicensed, and will be sufficient to so license or
sublicense, to Day One pursuant to Section 2.4(a) as part of the Takeda Developed Technology if such Takeda Licensee Developed Technology is Controlled by Takeda (as provided in the proviso to the definition of Control), and (iii) contain
confidentiality terms and conditions at least as restrictive as those set forth in this Agreement. Takeda will remain responsible for the failure of its Affiliates and sublicensees hereunder to comply with the relevant obligations under this
Agreement. 
 (b) Internal Research. Subject to the terms and conditions of this Agreement, Day One hereby grants and agrees to grant
to Takeda and its Affiliates a fully paid-up, royalty free, perpetual, irrevocable, non-exclusive license to practice under the Assigned Technology solely for the
purpose of conducting Takeda’s and its Affiliates’ internal, non-clinical research activities in any field, but excluding clinical Development or Commercialization of the Compound or any research
activities undertaken specifically in support of clinical Development or Commercialization of the Compound. 

  
 13 

 2.6 Termination of License to Takeda. 

(a) If Takeda has not dosed at least one patient with a Takeda Product in a Clinical Trial in the Takeda Field on or before the date that is
[*] after the Effective Date, then the Grant Back License will automatically terminate. 
 (b) If Takeda has dosed at least one patient with
a Takeda Product in a Clinical Trial in the Takeda Field on or before the date that is [*] after the Effective Date, and if, prior to the first commercial sale of any Takeda Product by or on behalf of Takeda, its Affiliates, licensees or
sublicensees, Takeda, its Affiliates or licenses or sublicensees do not conduct any Development activities with respect to at least one Takeda Product for a continuous period of longer than [*], and such suspension of activity is not: (i) by
written agreement of the Parties, or (ii) a result of Takeda’s reasonable response to guidance from or action by a Regulatory Authority in the Territory (such as a clinical hold, or a Recall or withdrawal), then Day One may, at its
election, terminate the Grant Back License upon [*] prior written notice to Takeda. 
 2.7 No Implied Licenses, Rights or
Covenants; Intent of the Parties. Except as expressly set forth in this Agreement, neither Party grants to the other Party any licenses, rights, or covenants in, to, or under any intellectual property rights owned or Controlled by such Party and
each Party expressly retains all rights under such intellectual property owned or Controlled by such Party not licensed to the other Party hereunder, including, in the case of Takeda, the grant to Day One of a license to practice the Licensed Know-How to Exploit any compounds or products other than the Products and the Compound. It is the intent of the Parties that neither the entry into this Agreement, nor the terms set forth herein, will cause Takeda
or any of its Affiliates to be in breach under any agreement with any Third Party in existence as of the Effective Date, including Sunesis Pharmaceuticals, Inc. and Biogen Idec MA Inc. 

2.8 Negative Covenants. 

(a) Day One will not, and will cause its Affiliates and direct its Related Parties not to, practice any Licensed Intellectual Property for any
purpose other than as expressly authorized in this Agreement. 
 (b) Takeda will not, and will cause its Affiliates and direct its licensees
and sublicensees not to, practice any intellectual property rights Controlled by Day One or its Affiliates (including the Assigned Technology) for any purpose other than as expressly authorized in this Agreement. 

(c) If Takeda identifies any compounds binding the Raf Target, other than the Compound, that it or any of its Affiliates owns solely pursuant
to, or as a result of its activities under, the Takeda-Biogen Agreement or the Sunesis License (each, an “Excluded Raf Compound”), then Takeda will not, and will cause its Affiliates and direct its licensees and sublicensees not to,
Exploit any Excluded Raf Compound or any pharmaceutical product containing or comprising any Excluded Compound for any purpose. 

2.9 Agreements Relating to Transfer of Acquired Assets. Takeda and Day One agree that all Intellectual Property included in the
Acquired Assets will be transmitted or otherwise provided to Day One in accordance with the Transfer Plan. 
 ARTICLE 3 

COMPENSATION 
 3.1
Up-Front Payment. As partial consideration for the licenses granted and assets transferred pursuant to this Agreement, within thirty (30) days following the Effective Date, Day One will pay to
Takeda by certified bank check or wire transfer to an account designated by Takeda in U.S. Dollars the amount of [*] (the “Up-Front Payment”). 

  
 14 

 3.2 Series A Preferred Stock Issuance. Subject to and upon the terms and
conditions of this Agreement, and as partial consideration for the license grants and transfers of assets contemplated by this Agreement, on the Effective Date Day One will issue to Takeda, and Takeda will acquire from Day One 9,857,143 duly
authorized and validly issued shares of Series A Preferred Stock which is equal to [*] of the issued and outstanding capital stock of Day One on a Fully-Diluted Basis as of immediately following the consummation of the transactions contemplated by
the Series A Purchase Agreement and the Stock Issuance Agreement. Takeda will, as a condition to such issuance become a party the Stock Issuance Agreement, voting agreement, right of first refusal and co-sale
agreement, and investors’ rights agreement (collectively, with the Series A Purchase Agreement, such agreements, the “Series A Preferred Stock Transaction Agreements”) with Day One and/or the other purchasers of Series A
Preferred Stock in connection with such financing on substantially the same terms and conditions as such other purchasers. Immediately following the closing of the issuance of Series A Preferred Stock to Takeda in accordance with this
Section 3.2 and the closing pursuant to the Series A Purchase Agreement, the Series A Preferred Stock acquired by Takeda hereunder will represent no less than [*] of Day One’s outstanding capital stock on a Fully-Diluted Basis, after
giving effect to the transactions contemplated by the Stock Issuance Agreement and the Series A Purchase Agreement. 
 3.3
Currency. All payments to Takeda hereunder will be made by deposit of USD in the requisite amount to such bank account as Takeda may from time to time designate by written notice to Day One. The Parties may vary the method of payment set
forth herein at any time upon written agreement, and any change will be consistent with the Applicable Law at the place of payment or remittance. 

3.4 Tax Withholding. If Day One or any of its agents is required by Applicable Law to deduct or withhold Taxes from any payment
to Takeda under this Agreement, then Day One will make such deductions or withholdings as so required, will pay over such amounts to the proper Governmental Authority on Takeda’s behalf in a timely manner, and will provide Takeda with written
evidence of payment of such amounts no later than [*] following such payment. If any such payment is payable (in whole or in part) in consideration other than cash and if the cash portion of any such payment is insufficient to satisfy all required
Tax withholding obligations, then Day One shall retain an amount of the non-cash consideration otherwise payable equal in value to the amount required to satisfy any applicable withholding Taxes (as reasonably
determined by Day One). The applicable payment under this Agreement will be decreased by such amounts; provided, however, if the Tax withholding is required as a result of a Withholding Tax Action, then Day One will increase the amount of the
payment due to Takeda such that the net amount actually received by Takeda is equal to the payment due after taking into account the withholding of Tax with respect to such payment and the withholding of Tax with respect to any additional payment
required to be made pursuant to this Section 3.4 (such Taxes for which additional amounts are required to be paid by Day One, the “Gross Up Taxes”). The Parties will reasonably cooperate with each other in order to reduce or
eliminate applicable withholding Tax, including by providing such forms the Parties are legally able to complete and file to qualify for the benefits of a bilateral income tax treaty. Notwithstanding the foregoing, no Gross Up Tax is payable to the
extent Takeda determines in good faith that it would receive a credit, refund, or other Tax attribute that would offset the economic burden of applicable withholding Taxes. 

ARTICLE 4 
 EXPLOITATION
OF THE PRODUCTS 
 4.1 Know-How. Takeda will provide to Day One copies of the
Assigned Know-How and Licensed Know-How in accordance with the transfer plan set forth on Schedule 4.1 (the “Transfer Plan”).

  
 15 

 
Following the completion of the activities set forth in the Transfer Plan, during the [*] period following the Effective Date, Takeda will reasonably consider any requests from Day One to provide
any additional Know-How not included in the Transfer Plan and that is reasonably necessary for the continued Development of the Compound or any Product, to the extent such
Know-How remains within Takeda’s or any of its Affiliate’s possession and Control at the time of such request. Any such Know-How provided by Takeda (following
agreement by each Party) will be included as Licensed Know-How and licensed to Day One pursuant to Section 2.4(a). 

4.2 Transferred Inventory. Takeda will transfer to Day One the Assigned Inventory in accordance with the Transfer Plan. Except
as set forth in Section 4.7, Takeda will have no further obligation to make any further physical inventory of the Compound or any Product available to Day One. Except as set forth in the quality materials provided with the Assigned Inventory,
the Assigned Inventory transferred to Day One by Takeda under this Section 4.2 is transferred on an “as is” basis, and notwithstanding any provision to the contrary set forth in this Agreement Takeda will have no liability for any
losses, claims, or damages arising from or related to Day One’s use of such Assigned Inventory. 
 4.3 Access to
Personnel. Day One will have access, as set forth in the Transfer Plan and reasonably requested by Day One, [*], to Takeda and its Affiliates employees at reasonable times during normal business hours and upon reasonable prior notice for
discussion related to the use of the Assigned Technology and the Licensed Intellectual Property in the Day One Field and for reasonable assistance with respect to the transfer of the Assigned Technology and Licensed
Know-How. If Takeda agrees to provide to Day One any additional assistance beyond that which is set forth in the Transfer Plan, then Day One will reimburse any costs and expenses incurred by Takeda or any of
its Affiliates in providing such access to personnel, support, and assistance beyond that set forth in the Transfer Plan. 
 4.4
Development Plans. 
 (a) Day One will have sole control over and decision-making authority with respect to Development of the
Compound and the Products, other than the Development and Manufacture of Takeda Products for the use in the Takeda Field in the Territory and the Compound for use in such Takeda Products, subject to Section 9.4. Day One will establish a written
development plan for each Product that contemplates all Clinical Trials and other material Development activities to be performed by or on behalf of Day One with respect to such Product in the Day One Field, including all such Development activities
required to seek and obtain Regulatory Approval for such Product in the Day One Field throughout the Territory (for each Product, a “Day One Development Plan”). Day One will update each Day One Development Plan at least annually no
later than [*] of each Calendar Year for so long as Day One is undertaking material Development efforts with respect to such Product, and otherwise as frequently as may be required during such period. Day One will provide each initial Day One
Development Plan and update thereto to Takeda as soon as reasonably practicable following the finalization thereof. 
 (b) Subject to
Section 9.4, Takeda will have sole control over and decision-making authority with respect to the Development and Manufacture of Takeda Products for the use in the Takeda Field in the Territory and the Compound for use in such Takeda Products.
Following delivery of the Takeda Development Notice, Takeda will establish a written development plan for each Takeda Product that contemplates all Clinical Trials and other material Development activities to be performed by or on behalf of Takeda
with respect to such Takeda Product in the Takeda Field, including all such Development activities required to seek and obtain Regulatory Approval for such Takeda Product in the Takeda Field throughout the Territory (for each Takeda Product, a
“Takeda Development Plan”). Takeda will update each Takeda Development Plan at least annually no later than [*] of each Calendar Year for so long as Takeda is undertaking material Development efforts with respect to such Takeda
Product, and otherwise as frequently as may be required during such period. Takeda will provide each initial Takeda Development Plan and update thereto to Day One as soon as reasonably practicable following the finalization thereof. 

  
 16 

 4.5 Joint Development Committee. 

(a) Formation and Purpose. Promptly following Takeda’s written notice to Day One that Takeda or its Affiliates intend to Develop
the Takeda Products in the Takeda Field (the “Takeda Development Notice”), the Parties will establish a Joint Development Committee (“JDC”). The purpose of the JDC will be to share information related to each
Party’s Development of the Compound and the applicable Products. 
 (b) Membership. Each Party shall designate three
representatives to serve on the JDC, each of whom will have the appropriate experience and expertise based on the stage of Development of the Products to perform its responsibilities on the JDC. The Parties may elect to vary the number of
representatives from time to time; provided that, unless otherwise agreed by the Parties in writing, each Party shall have the right to designate an equal number of representatives from each Party to serve on the JDC. Either Party may
designate substitutes for its JDC representatives if one or more of such Party’s designated representatives is unable to be present at a meeting. From time to time each Party may replace its JDC representatives by written notice to the other
Party specifying the prior representative(s) and their replacement(s). 
 (c) Meetings. For so long as Takeda is undertaking material
Development efforts with respect to any Takeda Product, unless otherwise agreed by the Parties, the JDC shall meet at least [*] per [*]. Additional meetings of the JDC may be held with the consent of each Party (such consent not to be unreasonably
withheld, delayed or conditioned). At each meeting of the JDC, the Parties’ representatives will review and discuss each Day One Development Plan and Takeda Development Plan and the material Development activities conducted by each Party with
respect to the Development of the Products or Takeda Products, as applicable, in their respective fields since the prior meeting of the JDC. The JDC will have no decision-making power, but Day One will consider in good faith any recommendations from
the JDC regarding the Development of the Products in the Day One Field and Takeda will consider in good faith any recommendations from the JDC regarding the Development of the Takeda Products in the Takeda Field. 

(d) Non-Member Participation. Additional representatives of each Party who are not members of
the JDC having relevant experience may from time to time be invited to participate in a JDC meeting. Non-member participants who are not employees of a Party or its Affiliates shall only be allowed to attend
if: (i) the other Party’s representatives have consented to the attendance (such consent not to be unreasonably withheld, delayed or conditioned); and (ii) such non-member participant is subject
to confidentiality and non-use obligations at least as restrictive as those set forth in this Agreement. 

(e) Disbandment of the JDC. The JDC will be dissolved effective upon the completion of all Development activities of each Party in
their respective fields, or upon termination of the Grant Back License pursuant to Section 2.6. 
 4.6 Commercialization
Activities. Subject to Section 9.4, Day One will have sole control over and decision-making authority with respect to the Commercialization of Products in the Territory, other than the Commercialization of Takeda Products in the Takeda
Field in the Territory, and Takeda shall have sole control over and decision-making authority with respect to the Commercialization of Takeda Products in the Takeda Field in the Territory, in each case, including: (a) developing and executing a
commercial launch and pre-launch plan; (b) marketing and promotion; (c) booking sales and distribution and performance of related services; (d) handling all aspects of order processing,
invoicing and collection, inventory and receivables; (e) publications; (f) providing customer support, including handling medical 

  
 17 

 
queries, and performing other related functions; (g) conforming its practices and procedures in all material respects to Applicable Law relating to the marketing, detailing and promotion of
Products in such Party’s field in the Territory; and (f) reviewing and approving all promotional materials for compliance with Applicable Law, including submission, where appropriate, to the applicable Regulatory Authority. Takeda and its
Affiliates and sublicensees, will use reasonable efforts to ensure that each Takeda Product Commercialized by or on behalf of Takeda is in a different form or formulation from any Product Commercialized by or on behalf of Day One or its Affiliates
or Related Parties. 
 4.7 Manufacturing. 

(a) From and after the Effective Date, Day One will Manufacture (either itself or through one or more of its Affiliates or Third Party
contract manufacturers) and have sole control over and decision-making authority with respect to the Manufacturing and distribution of all clinical and commercial supplies of the Compound and the Products in the Territory, other than the
Manufacturing and distribution of all clinical and commercial supplies of the Takeda Products for use in the Takeda Field and the Compound for the use in the Manufacture of such Takeda Products, subject to Section 9.4. Takeda will specify in
the Takeda Development Notice whether (a) Takeda desires Day One to Manufacture drug substance for use in the Manufacture of Takeda Products for use in the Takeda Field, in which case, Day One will negotiate in good faith an agreement with
Takeda on customary and commercially reasonable terms providing for the supply to Takeda of drug substance for use in the Manufacture of Takeda Products in the Takeda Field, or (b) Takeda will itself Manufacture (or have Manufactured) Takeda
Products for use in the Takeda Field and the Compound for use in the Manufacture of Takeda Products in the Takeda Field. 
 (b) From and
after the Effective Date, Takeda will continue to supply and distribute Product as necessary to maintain and support those clinical trials existing as of the Effective Date and identified in the Transfer Plan, in accordance with and on the timelines
set forth therein. 
 (c) Takeda shall provide Day One access to Takeda’s employees and consultants, and those of its contractors
(including its contract manufacturers), in each case, as set forth in the Transfer Plan, to assist in technology transfer to Day One or its contract manufacturer the Assigned Know-How and Licensed Know-How that is useful or necessary to Manufacture the Compound or the Products. Such assistance shall be provided remotely. Following the completion of the activities set forth in the Transfer Plan, during the [*]
period following the Effective Date, Takeda will reasonably consider any requests from Day One to provide any additional Know-How not included in the Transfer Plan and that is reasonably necessary for the
Manufacture of the Compound or any Product, to the extent such Know-How remains within Takeda’s possession and Control at the time of such request. Any such
Know-How provided by Takeda will be included as Licensed Know-How and licensed to Day One pursuant to Section 2.4(a). 

4.8 Regulatory Matters. 

(a) Transfer of Regulatory Submissions and Other Data. 

(i) TAK-580 IND. Takeda will transfer to Day One copies (in electronic or other format) of the
documents comprising the TAK-580 IND and all other Assigned Regulatory Submissions in accordance with the Transfer Plan. No later than [*] after Takeda’s receipt of written notice from Day One requesting
the transfer of sponsorship of the TAK-580 IND to Day One, and in any event within [*] after the Effective Date, Takeda will submit to the FDA written notice of the transfer of sponsorship of the TAK-580 IND to Day One. 
 (ii) Interim Responsibility. Until the transfer of sponsorship of the TAK- 580 IND to Day One is effective, Takeda shall be solely responsible for maintaining the TAK-580 IND and 

  
 18 

 
Takeda shall have responsibility for all communications with the FDA and all other Regulatory Authorities relating to the Compound and the Products, and Takeda will consult with Day One regarding
all such communications and shall promptly provide Day One with copies of all communications to or from any Regulatory Authority with respect to the Compound or any Product, including the Manufacture thereof; provided that for so long as
Takeda remains responsible for the TAK-580 IND, Takeda shall be responsible for preparing all Regulatory Submissions that are due for submission to any Regulatory Authority within such period in accordance
with the Transfer Plan. Takeda shall promptly provide Day One with copies of any communications or contacts it sends to or receives from any other Governmental Authority concerning the Compound or any Product. Upon the transfer of sponsorship of the
TAK-580 IND, Day One shall assume responsibility for maintaining the TAK-580 IND and for all communications with the FDA and all other Regulatory Authorities relating to
the Compound and the Products, subject to Takeda’s rights under Section 4.8(c). 
 (iii) Costs and Cooperation. Day One
will bear all Third Party expenses in connection with the transfer and assignment of all Assigned Regulatory Submissions. Subject to the terms and conditions of this Agreement, upon Day One’s written request, each Party will execute and
deliver, or will cause to be executed and delivered, to the other Party such endorsements, assignments, and other documents as may be reasonably necessary to assign, convey, transfer, and deliver to Day One all of Takeda’s rights, title, and
interests in and to the Assigned Regulatory Submissions, including submitting to each applicable Regulatory Authority a letter or other necessary documentation (in form and substance satisfactory to Day One), with copy to Day One, notifying such
Regulatory Authority of the transfer of ownership of each TAK-580 IND assigned to Day One pursuant to Section 4.8(a)(i). Each Party will provide to the other Party a copy of their respective letters of
transfer no later than [*] following submission thereof. Following the completion of the activities set forth in the Transfer Plan, during the [*] period following the Effective Date, Takeda will reasonably consider any requests from Day One to
transfer, convey, assign, and deliver any Regulatory Submission that (a) is related solely to one or more Products or the Compound and not to any other product that is Controlled by Takeda or any of its Affiliates, (b) remains in
Takeda’s possession and Control, and (c) is reasonably necessary for the continued Development or Regulatory Approval of the Compound or any Product, to the extent such Regulatory Submission remains within Takeda’s or any of its
Affiliate’s possession and Control at the time of such request. Any such Regulatory Submission provided by Takeda (following agreement by each Party) will be included in the Assigned Regulatory Submissions. 

(b) Day One Responsibilities. Subject to Applicable Law and this Section 4.8(b), Day One will, at its sole expense, oversee,
monitor, and manage all regulatory interactions, communications, and filings with, and submissions to, Regulatory Authorities with respect to the Products and the Compound in the Day One Field in the Territory; provided that Day One will
provide Takeda with a copy of all proposed material Regulatory Submissions filed with or submitted to any Regulatory Authority for Takeda’s review and comment sufficiently in advance of Day One’s filing or submission thereof, and Day One
will reasonably consider in good faith incorporating comments received from Takeda into such Regulatory Submissions, subject to Section 9.4. Subject to Section 4.11, Day One will have final decision making authority regarding all
regulatory activities, including the Labeling strategy and the content of submissions with respect to the Compound and all Products, subject to the terms and conditions of this Agreement, other than the Takeda Products and the Compound for the use
in the Manufacture of Takeda Products in the Takeda Field. 
 (c) Takeda Responsibilities. Subject to Applicable Law,
Section 9.4 and this Section 4.8(c), Takeda will, at its sole expense, oversee, monitor, and manage all regulatory interactions, communications, and filings with, and submissions to, Regulatory Authorities with respect to the Takeda
Products and the Compound for use in the Manufacture of Takeda Products in the Takeda Field in the Territory; provided that Takeda will provide Day One with a copy of all proposed material Regulatory

  
 19 

 
Submissions filed with or submitted to any Regulatory Authority for Day One’s review and comment sufficiently in advance of Takeda’s filing or submission thereof, and Takeda will
reasonably consider in good faith incorporating comments received from Day One into such Regulatory Submissions. Subject to Section 4.11 and Section 9.4, Takeda will have final decision making authority regarding all regulatory activities,
including the Labeling strategy and the content of submissions with respect to the Takeda Products and the Compound for the use in the Manufacture of Takeda Products in the Takeda Field, subject to the terms and conditions of this Agreement.
Notwithstanding any provision to the contrary set forth in this Agreement, Takeda shall have sole control over and decision making authority with respect to the IO Combo Study and any Regulatory Submissions relating thereto, provided that
Takeda will provide to Day One a copy of the final clinical study report for the IO Combo Study, which report Takeda may redact to the extent not related to TAK-580. 

(d) Cooperation, Meetings, and Sharing Final Materials. 

(i) Ongoing Cooperation. The Parties will cooperate with each other to achieve the regulatory objectives contemplated herein in a
timely, accurate, and responsive manner, including using reasonable efforts to coordinate the regulatory strategy in the Day One Field and Takeda Field such that it is consistent with the overall objective of facilitating Regulatory Approvals of one
or more Products in the Day One Field and one or more Takeda Products in the Takeda Field in the Territory. Each Party will assist the other Party, as is reasonably necessary, in order for such Party to obtain and maintain each applicable IND and
MAA for the Compound and the Products for which such Party bears responsibility under this Agreement, including in connection with the preparation and filing of such Party’s Regulatory Submissions. Each Party will assist the other Party as
reasonably requested in connection with chemistry, manufacturing, and controls data and the preparation and filing of Regulatory Submissions related to the Manufacture of the Compound and the Products in the Territory, at the requesting Party’s
expense (without limiting Takeda’s obligations under Sections 4.1, 4.3, or 4.7(c)). Upon a Party’s reasonable request, the other Party will provide or otherwise make available to the requesting Party relevant internal regulatory documents,
such as notes and preparation materials, and any materials documenting any clarifications (whether orally or otherwise) regarding any Regulatory Submissions transferred to the requesting Party from the other Party hereunder or with respect to which
the requesting Party has a right of reference, at the requesting Party’s expense (without limiting Takeda’s obligations under Sections 4.1, 4.3, or 4.7(c)). 

(ii) Meetings. Each Party (the “Notifying Party”) will promptly notify the other Party of any request made by or on
behalf of such Notifying Party for a meeting or substantive telephone conference call with a Regulatory Authority with respect to the Compound or any Product. Upon such other Party’s written request, the Notifying Party will request that the
Regulatory Authority permit at least one (1) employee or regulatory consultant (who is bound by written confidentiality terms and conditions at least as restrictive as those set forth in this Agreement) from such other Party with relevant
regulatory experience to observe and participate in any such meeting or conference call; provided that Day One’s right to observe and participate in such meetings or calls where Takeda is the Notifying Party will be limited to activities
related to the Day One Field, and Takeda’s right to observe and participate in such meetings or calls where Day One is the Notifying Party will be limited to activities related to the Takeda Field. To the extent permitted by such Regulatory
Authority and Applicable Law, such other Party will have the right to observe and, as applicable, participate in any such meeting or conference call. The foregoing rights and obligations will apply with respect to meetings or conferences initiated
by the Notifying Party or by a Regulatory Authority. The Notifying Party will promptly furnish the other Party with copies of all substantive contact reports concerning substantive conversations or minutes from any substantive meetings with a
Regulatory Authority with respect to any Product. 

  
 20 

 (iii) Sharing of Regulatory Submissions and Approvals. Each Party will keep the
other Party reasonably informed regarding the status and progress of material Regulatory Submissions with respect to the Products in such Party’s field, including (i) providing the other Party with a copy of all written correspondence from
a Regulatory Authority involving a Regulatory Submission for any Product; (ii) notifying the other Party of major topic made by oral correspondence from a Regulatory Authority involving a Regulatory Submission; (iii) providing the other
Party with a copy of each Regulatory Submission to be submitted to the FDA or EMA in advance of submission to the relevant Regulatory Authority; (iv) providing the other Party with a copy of all final Regulatory Submissions promptly after
submission to the relevant Regulatory Authority; and (v) promptly informing the other Party regarding the receipt or denial of Regulatory Approval for any Product obtained or denied; provided, however, that in all circumstances,
each Party will inform the other Party of such event prior to its public disclosure. 
 (iv) Each Party’s rights and obligations under
this Section 4.8(d) are subject to Section 9.4. 
 (e) Day One’s Right of Reference. Subject to the terms and
conditions of this Agreement and without expanding any of the rights granted to Day One under Section 2.4, Takeda hereby grants to Day One (or its Affiliates or its Related Parties) access to, and a right of reference with respect to, any
Regulatory Submissions and corresponding documentation to the extent related to the Product in the Day One Field and Controlled by Takeda, solely for the purposes of Exploiting the Compound and the Products in the Day One Field in the Territory.
Takeda agrees to execute, acknowledge, and deliver any further documents or instruments and to perform all such other acts as may be necessary or appropriate in order to effect such right of reference. 

(f) Takeda’s Right of Reference. Subject to the terms and conditions of this Agreement, including Section 9.4, and without
expanding any of the rights granted to Takeda under Section 2.5, Day One hereby grants to Takeda (or its Affiliates or its designees) access to, and a right of reference with respect to, any Regulatory Submissions and corresponding
documentation to the extent related to the Takeda Products in the Takeda Field and Controlled by Day One at any time during the Term, solely for the purposes of Exploiting the Takeda Products in the Takeda Field in the Territory and the Compound for
the use in the Manufacture of such Takeda Products. Day One agrees to execute, acknowledge, and deliver any further documents or instruments and to perform all such other acts as may be necessary or appropriate in order to effect such right of
reference. 
 4.9 Pharmacovigilance Agreement and Safety Data Exchange. 

(a) Pharmacovigilance Agreement. Not later than [*] following the receipt of a Takeda Development Notice, the Parties will execute a
pharmacovigilance agreement on reasonable and customary terms that will provide, among other things, guidelines and responsibilities for (i) the receipt, investigation, recording, review, communication, reporting, and exchange between the
Parties of Adverse Event reports and other safety information relating to the Products and the Compound in their respective fields, (ii) appropriate reconciliation procedures to ensure adequate and compliant exchange of safety data,
(iii) contact with Regulatory Authorities with respect to the foregoing, and (iv) the maintenance of a global safety database with respect to the Products, in each case ((i) – (iv)), in accordance with Applicable Law (the
“Pharmacovigilance Agreement”). The Pharmacovigilance Agreement will contain terms no less stringent than those required by ICH or other applicable guidelines in order to allow the Parties to meet the applicable regulatory and legal
requirements regarding the management of safety data in their respective territories. 
 (b) Safety Data Exchange. Until the
Pharmacovigilance Agreement is entered into by the Parties, the Parties will exchange any and all relevant safety data relating to the Products and the 

  
 21 

 
Compound in their respective fields within appropriate timeframes and in an appropriate format to ensure compliance with the reporting requirements of all applicable Regulatory Authorities on a
worldwide basis. Without limiting the generality of the foregoing, each Party will provide written notification to the other Party within [*] for Serious Adverse Events, and within [*] for non-Serious Adverse
Events. In addition, to the extent requested by a Party, the other Party will promptly provide to such Party any other information or materials that such Party may require to provide to any Regulatory Authority with respect to any such Serious
Adverse Event or Adverse Event. Each Party’s rights and obligations under this Section 4.9(b) are subject to Section 9.4. 

4.10 Clinical Trial Holds; Recalls. 

(a) Clinical Trial Holds. Each Party will promptly (but in any event within [*]) inform the other Party in the event that any Clinical
Trial for a Product is suspended, put on hold, or terminated in its respective field prior to completion thereof as a result of any action by a Regulatory Authority or such Party voluntarily. 

(b) Recalls. Each Party will promptly notify the other Party upon its determination that any event, incident, or circumstance has
occurred that may result in the need for a Recall, market withdrawal, or stock recovery of a Product (but in no event later than [*] and in all cases prior to the execution of such Recall, market withdrawal, or stock recovery). For all such Recalls,
the Parties will reasonably consult with each other with respect to the actions to be taken to address such Recall. Subject to the foregoing, as between the Parties, Day One will be responsible for execution of all Recalls, market withdrawals, and
stock recoveries that are taken with respect to any Product Commercialized by or on behalf of Day One or its Related Parties (a “Day One Recall”), and Takeda will be responsible for execution of all Recalls, market withdrawals, and
stock recoveries that are taken with respect to any Takeda Product Commercialized by or on behalf of Takeda or any of its Affiliates or (sub)licensees (a “Takeda Recall”). As between the Parties, all expenses incurred in connection
with any Day One Recall (including expenses for notification, destruction, and return of the affected Product and any refund to customers of amounts paid for such Product) will be the sole responsibility of Day One unless otherwise agreed by the
Parties in a separate definitive agreement and all expenses incurred in connection with any Takeda Recall (including expenses for notification, destruction, and return of the affected Takeda Product and any refund to customers of amounts paid for
such Product) will be the sole responsibility of Takeda unless otherwise agreed to in writing by the Parties. 
 4.11 Labeling
Information Exchange. Subject to Section 9.4, the Parties will cooperate to develop methods and procedures for sharing information related to Labeling for each Product; provided that Day One will have final decision making authority
with respect to the development and management of Labeling information for each Product Commercialized by Day One at its expense and Takeda will have final decision making authority with respect to the development and management of Labeling
information for each Takeda Product Commercialized by Takeda in the Takeda Field at its expense. 
 4.12 Diligence. Day One
will use Commercially Reasonable Efforts to Develop and seek Regulatory Approval for at least [*] in the Day One Field in either the United States or one of the United Kingdom, Germany, Italy, France, or Spain. Following receipt of Regulatory
Approval for a Product in the Day One Field in such country in the Territory, Day One will use Commercially Reasonable Efforts to Commercialize such Product in such country. 

4.13 Point of Contact. Promptly following the Effective Date, Day One and Takeda shall each appoint an individual to be its
point of contact (“Point of Contact”) with responsibility for (a) during the first year following the Effective Date, facilitating the performance and completion of the Transfer Plan, and (b) all other communication
between the Parties under this Agreement. The Point of Contact shall facilitate resolution of potential and pending issues and potential disputes to enable the parties to seek to reach consensus and avert escalation of such issues or potential
disputes. 

  
 22 

 4.14 Pass-Through Payment Obligations. 

(a) Sunesis License. Takeda shall pay to Day One or Sunesis, at Day One’s election, (i) any development milestones due to the
Sunesis License to the extent directly attributable to the Development of the Takeda Product and in a manner consistent with the applicable provisions of the Sunesis License, as set forth on Schedule 4.14(a), provided that, in the event
Development of the Product by Day One would cause such development milestones to come due, but for the Development of the Takeda Product, then Day One will reimburse Takeda any such amounts paid by Takeda, and (ii) any sales milestone or
royalty amounts due to Sunesis under the Sunesis License to the extent directly attributable to the sale of the Takeda Product and in manner consistent with the applicable provisions of the Sunesis License, as set forth on Schedule 4.14(a). 

(b) Future Third Party Intellectual Property. 

(i) If Day One intends to obtain rights to any Intellectual Property from a Third Party after the Effective Date that, if Controlled by Day
One, would be within the rights licensed or granted to Takeda hereunder, then Day One will provide Takeda written notice of its intent to acquire such rights. Following such written notice, the Parties will discuss (A) any milestone, royalty,
or sales-based payment obligations to such Third Party that would be payable solely as a result of the Development, Manufacture or Commercialization of the Compound or any Product by or on behalf of Takeda or its Affiliates or (sub)licensees,
(B) a reasonable allocation of any other payments required to be paid to such Third Party with respect to such Intellectual Property rights, and (C) and any other terms and conditions under which such Intellectual Property rights were
granted by such Third Party that would be applicable to the rights licensed or granted to Takeda hereunder. Such Intellectual Property rights will be deemed Controlled by Day One and included within the rights licensed or granted to Takeda hereunder
only if, within [*] after receipt of such written notice from Day One and prior to Day One entering into an agreement with such Third Party with respect to such Intellectual Property Rights, Takeda and Day One reach written agreement on the payment
obligations described in clauses (A) and (B) above and to the other terms and conditions described in clause (C) above. Takeda may, in its sole discretion, decline to agree to the payment and other obligations described in clauses
(A) through (C) above, in which case such Intellectual Property, if acquired or licensed by Day One, will not be deemed Controlled by Day One for the purposes of this Agreement. 

(ii) If Takeda intends to obtain rights to any Intellectual Property from a Third Party after the Effective Date that, if Controlled by
Takeda, would be within the rights licensed or granted to Day One hereunder, then Takeda will provide Day One written notice of its intent to acquire such rights. Following such written notice, the Parties will discuss (A) any milestone,
royalty or sales-based payment obligation to such Third Party that would be payable solely as a result of the Development, Manufacture or Commercialization of the Compound or any Product by or on behalf of Day One or its Affiliates or
(sub)licensees, (B) a reasonable allocation of any other payments required to be paid to such Third Party with respect to such Intellectual Property rights, and (C) and any other terms and conditions under which such Intellectual Property
rights were granted by such Third Party that would be applicable to the rights licensed or granted to Day One hereunder. Such Intellectual Property rights Takeda will be deemed Controlled by Takeda and included within the rights licensed or granted
to Day One hereunder only if, within [*] after receipt of such written notice from Takeda and prior to Takeda entering into an agreement with such Third Party with respect to such Intellectual Property rights, Day One and Takeda reach written
agreement on the payment obligations described in clauses (A) and (B) above and to the other terms and conditions described in clause (C) above. Day One may, in its sole discretion, decline to agree to the payment and other obligations
described in clauses (A) through (C) above, in which case such Intellectual Property, if acquired or licensed by Takeda, will not be deemed Controlled by Takeda for the purposes of this Agreement. 

  
 23 

 (iii) If Development of the Product by the
non-Acquiring Party causes a development milestone payment to become due under an agreement entered into pursuant to Section 4.14(b)(i) or Section 4.14(b)(ii) between the Acquiring Party and a Third
Party, which development milestone payment would have become due as a result of Development of the Product by the Acquiring Party but for the Development of the Product by the non-Acquiring Party, then the non-Acquiring Party will reimburse the Acquiring Party for the applicable development milestone payment to the extent required to achieve the agreement of the Parties reached pursuant to Section 4.14(b)(i) or
Section 4.14(b)(ii), as applicable. 
 4.15 Patent Assignments. Takeda covenants and agrees that as soon as practicable,
and in any event within [*] following the Effective Date, it will provide to Day One complete and accurate copies of the patent assignments set forth on Schedule 4.15. 

ARTICLE 5 
 INTELLECTUAL
PROPERTY 
 5.1 Ownership. Day One will own all Know-How developed or invented by
or on behalf of Day One in the performance of activities related to the Products or the Compound in the Day One Field and all Patent Rights with a priority date after the Effective Date that Cover any such
Know-How. Takeda will own all Know-How developed or invented by or on behalf of Takeda in the performance of activities related to the Takeda Products or the Compound
for use of the Manufacture of Takeda Products in the Takeda Field and all Patent Rights that Cover any such Know-How; provided that upon termination of the Grant Back License, to the extent requested by
Day One following such termination, Takeda will assign and transfer to Day One or its designee all such Know-How and all Patent Rights that Cover any such Know- How. All determinations of inventorship under
this Agreement will be made in accordance with U.S. patent law. 
 5.2 Know-How
Disclosure. Subject to Section 9.4, the Parties will as soon as reasonably practicable disclose to each other in writing any Know-How within the Day One Developed Technology or Takeda Developed
Technology, as applicable, conceived or reduced to practice, which disclosure may be made on a [*] basis after such conception or reduction to practice, but no later than [*] after the applicable Party’s intellectual property department or
patent prosecution counsel receives notice of such conception or reduction to practice. 
 5.3 Patent Prosecution. 

(a) Patent Prosecution and Maintenance. Immediately upon Takeda’s transfer of the Assigned Patent Rights to Day One, as between
the Parties, Day One will have the sole right to control Prosecution of the Assigned Patent Rights in the Territory in Day One’s name at Day One’s sole cost and expense. Subject to Section 9.4, Day One will keep Takeda reasonably
informed of all substantive matters relating to Prosecution of the Assigned Patent Rights and will consider in good faith the comments, requests, and suggestions of Takeda with respect to strategies for Prosecuting the Assigned Patent Rights. 

(b) Cooperation in Patent Prosecution. Takeda will, and will cause its Affiliates to, reasonably assist Day One or its designee and
cooperate in any Prosecution of the Assigned Patent Rights or Patent Rights Covering any of the Assigned Technology at Day One’s expense. Such cooperation includes executing all papers and instruments, or requiring its employees or contractors,
to execute such papers and instruments, so as to enable Day One to apply for and to prosecute Patent Rights in any country claiming any Assigned Technology. 

  
 24 

 5.4 Enforcement of Patent Rights. 

(a) Notice. If either Party receives notice of or otherwise becomes aware of any alleged or threatened infringement, misappropriation,
or any other violation of any Assigned Patent Rights granted by a jurisdiction within the Territory, then it will promptly notify the other Party thereof in writing, including providing evidence of infringement or the claim of invalidity or
unenforceability reasonably available to such Party. 
 (b) Enforcement of Assigned Patent Rights. As between the Parties, Day One
will have the sole right (but not the obligation), except as provided in this Section 5.4(b) and Section 5.4(c)(i), at its sole expense, to control enforcement of the Assigned Patent Rights against any actual or threatened infringement,
misappropriation, or other violation by a Third Party of any Assigned Patent Rights (“Third Party Infringement”), provided that Takeda will have the first right (but not the obligation), at its sole expense, to control
enforcement of the Assigned Patent Rights against any Third Party Infringement relating solely to one or more Takeda Products in the Takeda Field, except as provided in Section 5.4(c)(ii). The
non-enforcing Party will reasonably cooperate with the enforcing Party in any such Third Party Infringement action, at the enforcing Party’s expense. The enforcing Party will give the non-enforcing Party timely notice of any proposed settlement of any such action instituted by the enforcing Party and will not, without the prior written consent of the
non-enforcing Party, enter into any settlement that would (i) give rise to any financial liability or obligation of the non-enforcing Party or its Affiliates or
require an admission of liability, wrongdoing or fault or waiver of rights of the non-enforcing Party or its Affiliates; or (ii) impair the non-enforcing
Party’s rights under any Assigned Patent Rights or this Agreement. 
 (c) Step-in Right to
Enforce Assigned Patent Rights. 
 (i) With respect to any Third Party Infringement that does not solely relate to one or more Takeda
Products in the Takeda Field, Day One will have a period of [*] after its receipt of notice of such Third Party Infringement to elect to so enforce the Assigned Patent Rights (or to settle or otherwise secure the abatement of such infringement). If
Day One fails to commence a suit to enforce the applicable Assigned Patent Rights or to settle or otherwise secure the abatement of such infringement within such period, then Takeda may commence a suit or take action to enforce such Assigned Patent
Rights against such Third Party at its own cost and expense in accordance with this Section 5.4(c)(i), and Day One will reasonably cooperate with Takeda in such action at Takeda’s expense. Takeda will give Day One timely notice of any
proposed settlement of any such action instituted by Takeda and will not, without the prior written consent of Day One, enter into any settlement that would (A) give rise to any financial liability or obligation of Day One or its Affiliates or
require an admission of liability, wrongdoing or fault or waiver of rights of Day One or its Affiliates; or (B) impair Day One’s rights under any Assigned Patent Rights or this Agreement. 

(ii) With respect to any Third Party Infringement that solely relates to one or more Takeda Products in the Takeda Field, Takeda will have a
period of [*] after its receipt of notice of such Third Party Infringement to elect to so enforce the Assigned Patent Rights (or to settle or otherwise secure the abatement of such infringement). If Takeda fails to commence a suit to enforce the
applicable Assigned Patent Rights or to settle or otherwise secure the abatement of such infringement within such period, then Day One may commence a suit or take action to enforce such Assigned Patent Rights against such Third Party at its own cost
and expense in accordance with this Section 5.4(c)(ii), and Takeda will reasonably cooperate with Day One in such action at Day One’s expense. Day One will give Takeda timely notice of any proposed settlement of any such action instituted
by Day One and will not, without the prior 

  
 25 

 
written consent of Takeda, enter into any settlement that would (A) give rise to any financial liability or obligation of Takeda or its Affiliates or require an admission of liability,
wrongdoing or fault or waiver of rights of Takeda or its Affiliates; or (B) impair Takeda’s rights under any Assigned Patent Rights or this Agreement. 

(iii) The Parties acknowledge that, notwithstanding any provision to the contrary set forth in this Agreement, the rights granted to Takeda
with respect to the enforcement of the Assigned Patent Rights pursuant to this Section 5.4 are subject to Sunesis’ rights under the Sunesis License. 

(d) Cooperation. Each Party will provide to the Party enforcing any such rights under this Section 5.4 reasonable assistance in
such enforcement, at such enforcing Party’s request and expense, including joining such action as a party plaintiff if required by Applicable Law to pursue such action or providing the enforcing Party any reasonably requested documentation or
other materials. The enforcing Party will keep the other Party regularly informed of the status and progress of such enforcement efforts, including providing the other Party a reasonably opportunity to comment on the enforcing Party’s
determination of litigation strategy and the filing of important papers to the competent court and the enforcing Party will consider such comments in good faith. 

(e) Expenses. Subject to Section 5.4(f), the enforcing Party will be solely responsible for all expenses arising from a suit or
action with respect to a Third Party Infringement. The Party not bringing an action with respect to a Third Party Infringement in the Territory under this Section 5.4 will be entitled to separate representation in such matter by counsel of its
own choice and at its own expense, but such Party will at all times cooperate fully with the Party bringing such action. 
 (f)
Recoveries. Any recoveries resulting from an action or settlement relating to a claim of Third Party Infringement will first be applied to reimburse the initiating Party’s reasonable and documented out-of-pocket costs and expenses incurred in connection therewith and, with respect to any remaining recoveries, will be retained by the initiating Party. 

(g) Termination of Grant Back License. Each Party’s rights and obligations under this Section 5.4 are subject to
Section 9.4. 
 5.5 Defense of Patent Rights. 

(a) Notice. Each Party will promptly notify the other Party in writing if it receives notice or otherwise becomes aware of any Third
Party’s claim or assertion that any Product infringes any Patent Right granted by a jurisdiction within the Territory (a “Third Party Action”). 

(b) Defense. As between the Parties, (i) Day One will have the first right (but not the obligation), at its sole expense, to
control defense of any Third Party Action related to Day One’s Exploitation of any Product in the Day One Field, and (ii) Takeda will have the first right (but not the obligation), at its sole expense, to control defense of any Third Party
Action solely related to Takeda’s Exploitation of any Product in the Takeda Field. The non-controlling Party will reasonably cooperate with the controlling Party in any such Third Party Action, at the
controlling Party’s expense. The controlling Party will give the non-controlling Party timely notice of any proposed settlement of any such Third Party instituted by the controlling Party and will not,
without the prior written consent of the non-controlling Party, enter into any settlement that would (A) give rise to any financial liability or obligation of the
non- controlling Party or its Affiliates or require an admission of liability, wrongdoing or fault or waiver of rights of the non-controlling Party or its Affiliates; or
(B) impair the non-controlling Party’s rights under any Assigned Patent Rights or this Agreement. 

  
 26 

 (c) Takeda Step-in Right to Defend Assigned
Patent Rights. With respect to any Third Party Action that does not solely relate to the Takeda Field, if Day One does not take any steps to defend such Third Party Action within [*] after its receipt of notice thereof, then Takeda will have the
right and option to do so at its own cost and expense in accordance with this Section 5.5(c). Day One will reasonably cooperate with Takeda in the defense of any such Third Party Action controlled by Takeda, at Takeda’s expense. Takeda
will give Day One timely notice of any proposed settlement of any such Third Party Action and will not, without the prior written consent of Day One, enter into any settlement that would (a) give rise to any financial liability or obligation of
Day One or its Affiliates or require an admission of liability, wrongdoing or fault or waiver of rights of Day One or its Affiliates; or (b) impair Day One’s rights under any Assigned Patent Rights or this Agreement. 

(d) Cooperation. The non-defending Party will reasonably assist and cooperate with the Party
conducting the defense of a Third Party Action, including if required to conduct such defense, furnishing a power of attorney. 
 (e)
Termination of Grant Back License. Each Party’s rights and obligations under this Section 5.5 are subject to Section 9.4. 

5.6 Drug Price Competition and Patent Right Restoration Act. Each Party will promptly, and in any event at least [*] before any
time limit set forth in an Applicable Law or regulation, including the time limits set forth under the Hatch-Waxman Act (21 U.S.C. § 355), give written notice to the other Party of any certification of which it becomes aware filed pursuant to
21 U.S.C. Section 355(b)(2)(A) (or any amendment or successor statute thereto) claiming that any Assigned Patent Rights Covering any Product, or the Exploitation thereof, are invalid or unenforceable, or that infringement will not arise from
the Exploitation of a Product by a Third Party. 
 5.7 Listing of Patent Rights. Day One will have the sole right to determine
which of the Assigned Patent Rights, if any, will be listed for inclusion in the Approved Drug Products with Therapeutic Equivalence Evaluations pursuant to 21 U.S.C. Section 355, or any successor law in the United States, together with any
comparable laws in any other country in the Territory. The foregoing rights of Day One will be exercised only in consultation with Takeda, and Takeda will have the prior right to review and comment on any Patent Right listing. Day One will
incorporate Takeda’s reasonable comments into such listings. Each Party’s rights and obligations under this Section 5.7 are subject to Section 9.4. 

5.8 Trademarks. Each Party has the right to use any Trademark it Controls for the Commercialization of Products in its
respective field, and each Party and its Affiliates will retain all rights, title, and interest in and to its and their respective corporate names and logos. Each Party will have discretion over the Trademarks to be exclusively used in connection
with the Commercialization of such Product (the “Product Trademarks”) to be used by such Party in connection with the Commercialization of a Product in its respective field, subject to the other Party’s right to review and
comment on such Product Trademarks, other than any Trademarks comprising any corporate name or logo, prior to their use in any Commercialization of such Product. The Parties will coordinate to ensure that any Product Trademark proposed to be used by
a Party in Commercializing a Product are sufficiently distinctive from, and do not cause confusion with, the other Party’s existing or proposed Product Trademarks in its respective field. Each Party will solely own and be solely responsible for
applying for and maintaining registrations of the Product Trademarks, in its respective field (including payment of expenses associated therewith), and all goodwill associated therewith will inure to the benefit of such Party. Each Party will be
responsible for all expenses incurred by such Party to apply for and maintain such Product Trademarks and assume full responsibility, at its sole expense, for any infringement of its Product Trademarks by a Third Party. Each Party’s rights and
obligations under this Section 5.8 are subject to Section 9.4. 

  
 27 

 ARTICLE 6 

REPRESENTATIONS, WARRANTIES AND COVENANTS 

6.1 Mutual Representations and Warranties. Each Party represents and warrants to the other Party as of the Effective Date as
follows: 
 (a) Organization. It is a corporation duly organized, validly existing, and in good standing under the laws of the
jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver, and perform this Agreement. 

(b) Binding Agreement. This Agreement is a legal and valid obligation binding upon such Party and enforceable in accordance with its
terms, subject to the effects of bankruptcy, insolvency, or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance, and general principles of equity
(whether enforceability is considered a proceeding at law or equity). 
 (c) Authorization. The execution, delivery, and performance
of this Agreement by such Party have been duly authorized by all necessary corporate action and do not conflict with any agreement, instrument, or understanding, oral or written, to which it is a party or by which it is bound, nor violate any
Applicable Law or any order, writ, judgment, injunction, decree, determination, or award of any court or governmental body, or administrative or other agency presently in effect applicable to such Party. 

(d) No Further Approval. It is not aware of any government authorization, consent, approval, license, exemption of or filing or
registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any Applicable Law, currently in effect, necessary for, or in connection with, the transactions contemplated by
this Agreement or any other agreement or instrument executed in connection herewith, or for the performance by it of its obligations under this Agreement and such other agreements (save for Regulatory Approvals and similar authorizations from
Regulatory Authorities necessary for the Exploitation of the Compound and the Products as contemplated hereunder). 
 (e) No Inconsistent
Obligations. Neither Party is under any obligation, contractual or otherwise, to any Person that conflicts with or is inconsistent in any material respect with the terms of this Agreement, or that would impede the diligent and complete
fulfillment of its obligations hereunder. 
 6.2 Takeda Representations. Takeda represents and warrants to Day One as follows
as of the Effective Date: 
 (a) Third Party Payments. There are no agreements between Takeda or its Affiliates and any Third Party
granting rights in the Assigned Patent Rights, other than Sunesis’ ownership interest in any such Patent Rights pursuant to the Sunesis License. 

(b) Third Party Obligations. To Takeda’s knowledge, without any independent investigation, other than any payment obligations
under the Sunesis License, no financial or other obligations will arise under any written agreement between Takeda or any of its Affiliates and any Third Party as a result of the assignment to Day One of the Assigned Technology (“Takeda
Third Party Obligations”). 
 (c) Sufficient Rights. Takeda or its Affiliates is the sole and exclusive owner of the
Acquired Assets (and the inventions claimed in any Assigned Patent Right), other than Sunesis’ ownership interest in any such Patent Rights pursuant to the Sunesis License, with good and marketable title thereto,

  
 28 

 
all of which is free and clear of any claims, liens, charges, or encumbrances (other than those entered into in the ordinary course of business). Takeda has all rights necessary to grant the
rights and licenses under (i) the Licensed Intellectual Property and rights of reference to Regulatory Submissions, in each case, Controlled by Takeda or any of its Affiliates as of the Effective Date, that it grants to Day One in this
Agreement. 
 (d) Completeness of Assigned Patent Schedule. Schedule 1.10 is a complete and accurate list of all Patent Rights
Controlled by Takeda that Cover the Compound or one or more Products or the Exploitation thereof, and not any other product or compound Controlled by Takeda or any of its Affiliates. The Assigned Patent Rights include (i) Takeda’s interest
in all Patent Rights jointly owned by Takeda and Sunesis, (ii) all Patent Rights in the Development Technology (as defined in the Sunesis License), and (iii) all Patents Rights that Takeda Controls as of the Effective Date that were
assigned to Takeda under the Takeda-Biogen Agreement, in each case ((i) through (iii)), that Cover the Compound or one or more Products or the Exploitation thereof. 

(e) Registration and Maintenance. To Takeda’s knowledge, without any independent investigation, all registrations and applications
for the Assigned Patent Rights are valid, enforceable, and subsisting. Except as stated therein, no registration, or application therefor, for any of the Assigned Patent Rights has lapsed, expired, been abandoned, or been withdrawn, and no such
registrations, or applications therefor, are the subject of any opposition, interference, cancellation, inter partes review, post-grant review, or other legal or governmental proceeding pending before any Governmental Authority (other than standard
patent prosecution before a patent office). To Takeda’s knowledge, each of the Assigned Patent Rights properly identifies each and every inventor of the claims therein as determined in accordance with Applicable Law of the jurisdiction in which
such Assigned Patent Right is issued or such application is pending. There are no actions that are required to be taken within [*] of the Effective Date hereof with respect to the Assigned Patent Rights, including the payment of any registration,
maintenance or renewal fees or the filing of any response to the United States Patent and Trademark Office actions or foreign equivalents. Takeda has provided or otherwise made available to Day One current, true and complete copies of all Assigned
Patent Rights. 
 (f) Non-Infringement. There is no claim pending by Takeda alleging that a
Third Party is or was infringing, misappropriating, or otherwise violating the Assigned Technology or the Licensed Intellectual Property, and, to Takeda’s knowledge, as of the Effective Date, the Exploitation of the Compound or the Products
does not infringe or misappropriate any Patent Right or other Intellectual Property of any Third Party. 
 (g) Completeness of Assigned
Agreements Schedule. Schedule 1.7 is a complete and accurate list of all agreements to which Takeda or one or more of its Affiliates is a party that relate solely to the Exploitation of one or more Products or the Compound and not to any other
product Controlled by Takeda or any of its Affiliates. 
 (h) Absence of Litigation and Claims. To Takeda’s knowledge, without
any independent investigation, Takeda and its Affiliates have not received any notices or correspondence from the FDA or any other Governmental Authority requiring the termination, suspension, or material modification of any preclinical study or
Clinical Trial of a Product or Compound conducted by or on behalf of Takeda or its Affiliates. To Takeda’s knowledge, without any independent investigation, none of the Acquired Assets is subject to any order, writ, injunction, judgment,
decree, ruling, award, assessment or arbitration award of any Governmental Authority. 

  
 29 

 6.3 Mutual Covenants. 

(a) No Debarment. Neither Party nor any of its Affiliates will engage, in any capacity, in connection with this Agreement, any Person
who either has been debarred by such a Regulatory Authority, or is the subject of a conviction described in Section 306 of the FFDCA. Each Party will inform the other Party in writing promptly if it or any Person engaged by such Party or any of
its Affiliates who is performing any activities under or in connection with this Agreement is debarred or is the subject of a conviction described in Section 306 of the FFDCA, or if any action, suit, claim, investigation, or legal or
administrative proceeding is pending or, to such Party’s knowledge, is threatened, relating to the debarment or conviction of such Party, any of its Affiliates, or any such Person performing activities. 

(b) Specific Notifications Regarding Products. 

(i) Subject to Section 9.4, prior to Regulatory Approval of any Takeda Product in the Takeda Field in the Territory, Day One will, and
will cause its Affiliates and Related Parties to, promptly advise Takeda if such party is aware of any suspension, clinical hold, or other regulatory action by any Regulatory Authority relating to any Product where such action has had or would
reasonably be expected to have a material adverse impact on the Exploitation of any Takeda Product in the Takeda Field in the Territory. 

(ii) Subject to Section 9.4, prior to Regulatory Approval of any Product in the Day One Field in the Territory, Takeda will, and will
cause its Affiliates and sublicensees to, promptly advise Day One if such party is aware of any suspension, clinical hold, or other regulatory action by any Regulatory Authority relating to any Product where such action has had or would reasonably
be expected to have a material adverse impact on the further Exploitation of such Product in the Day One Field in the Territory. 
 (c)
Invention Assignment. To the extent permissible under Applicable Law, Day One will cause its and its Affiliates’ employees performing activities under this Agreement to be under an obligation to assign all rights, title, and interests in
and to their inventions and other Know-How, whether or not patentable, and Intellectual Property rights therein, to Day One or its Affiliates as the sole owner thereof. Takeda will have no obligation to
contribute to any remuneration of any inventor employed or previously employed by Day One or any of its Affiliates in respect of any such inventions, Know-How, or discoveries and Intellectual Property rights
therein that are so assigned to Day One or its Affiliates. Day One will pay all such remuneration due to such inventors with respect to such inventions and other Know- How, and Intellectual Property rights therein. 

(d) Foreign Corruption Compliance. In performing its obligations under this Agreement, each Party will, and will cause its
Affiliates to, comply with all Applicable Law, including any applicable anti-corruption or anti-bribery laws or regulations, of any Governmental Authority with jurisdiction over the activities performed by such Party or its Affiliates in furtherance
of such obligations. 
 (e) Notice of Adverse Events. 

(i) Subject to Section 9.4, Day One will notify Takeda promptly in writing of Day One’s becoming aware of any drug-related Serious
Adverse Event that arises in connection with the administration of any Product. All such notices (and any information related thereto) will be considered Confidential Information of Day One and will be maintained in confidence by Takeda. 

(ii) Subject to Section 9.4, Takeda will notify Day One promptly in writing of Takeda’s becoming aware of any drug-related Serious
Adverse Event that arises in connection with the administration of any Takeda Product. All such notices (and any information related thereto) will be considered Confidential Information of Takeda and will be maintained in confidence by Day One. 

  
 30 

 (f) Transparency Reporting. Each Party will be responsible for tracking and reporting
transfers of value initiated and controlled by its and its Affiliates’ employees, contractors, and agents pursuant to the requirements of the marketing reporting laws of any Governmental Authority in the Territory, including Section 6002
of the Patient Protection and Affordable Care Act, commonly referred to as the “Sunshine Act.” 
 6.4 No Other
Representations. THE EXPRESS REPRESENTATIONS AND WARRANTIES STATED IN THIS ARTICLE 6 ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED, OR STATUTORY, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, NON-INFRINGEMENT OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS. EACH PARTY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE EXPLOITATION
OF ANY PRODUCT PURSUANT TO THIS AGREEMENT WILL BE SUCCESSFUL OR THAT ANY PARTICULAR SALES LEVEL WITH RESPECT TO A PRODUCT WILL BE ACHIEVED. EXCEPT AS EXPRESSLY SET FORTH IN THE EXPRESS REPRESENTATIONS AND WARRANTIES IN THIS AGREEMENT, THE ACQUIRED
ASSETS ARE TRANSFERRED AND ASSIGNED TO DAY ONE ON AN “AS IS” BASIS. 
 ARTICLE 7 

INDEMNIFICATION AND INSURANCE 

7.1 Indemnification by Day One. Day One agrees to indemnify, hold harmless, and defend Takeda and its Affiliates, and their
respective officers, directors, employees, agents, and assigns (collectively, “Takeda Indemnitees”), from and against any Losses to the extent arising from: (a) any claim, demand, action or other proceeding by a Third Party
(each, a “Third Party Claim”) resulting from the Exploitation of the Compound or any Product by or on behalf of Day One, its Affiliates or Related Parties on or after the Effective Date, and (b) any breach, inaccuracy in or
failure to perform any representation or warranty, covenant or agreement in this Agreement by Day One. 
 7.2 Indemnification by
Takeda. Takeda agrees to indemnify, hold harmless, and defend Day One and its Affiliates, and their respective officers, directors, employees, agents, and assigns (collectively, “Day One Indemnitees”), from and against any
Losses to the extent arising from: (a) any Third Party Claim resulting from the Exploitation of the Compound or any Product prior to the Effective Date or on or after the Effective Date by or on behalf of Takeda, its Affiliates, licensees or
sublicensees (which licensees and sublicensees shall not include Day One or its Related Parties for the purposes of this Section 7.2), and (b) any breach, inaccuracy in or failure to perform any representation or warranty, covenant or
agreement in this Agreement by Takeda. 
 7.3 Indemnification Procedure for Claims. In connection with any Loss arising from a
Third Party Claim for which a Party (the “Indemnified Party”) seeks indemnification from the other Party (the “Indemnifying Party”) pursuant to this Agreement, the Indemnified Party will: (a) give the
Indemnifying Party prompt written notice of the Third Party Claim; provided, however, that failure to provide such notice will not relieve the Indemnifying Party from its liability or obligation hereunder, except to the extent of any
material prejudice as a direct result of such failure; (b) cooperate with the Indemnifying Party, at the Indemnifying Party’s expense, in connection with the defense and settlement of the Third Party Claim; and (c) permit the
Indemnifying Party to control the defense and settlement of the Third Party Claim; provided, however, that the Indemnifying Party will not without the Indemnified Party’s prior written consent, which will not be unreasonably
withheld or delayed, consent to or enter into any compromise or settlement of any such Third Party Claim that commits the applicable indemnitee to take, or to forbear to take, any action or does not provide for a full and complete written release by
the applicable Third Party of any applicable indemnitee. Further, the Indemnified Party shall have the right to participate (but not control) and be 

  
 31 

 
represented in any such suit or action by advisory counsel of its selection and at its own expense; provided that if an Indemnified Party determines in good faith that there is a
reasonable probability that such Third Party Claim would materially adversely affect it other than as a result of monetary damages for which it would be entitled to relief under this Agreement, then the Indemnified Party may, by giving written
notice to the Indemnifying Party, assume control of the defense of any Third Party Claim, but will not without the Indemnifying Party’s prior written consent, which shall not be unreasonably withheld or delayed, consent to enter into any
compromise or settlement of any such Third Party Claim if it involves a payment to be made on the part of the Indemnifying Party. 

7.4 Limitations. 

(a) Limitation of Liability. NEITHER PARTY WILL BE LIABLE UNDER ANY LEGAL THEORY (WHETHER TORT, CONTRACT OR OTHERWISE) FOR SPECIAL,
INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS UNDER THIS AGREEMENT, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE
OF SUCH DAMAGES, EXCEPT AS A RESULT OF A BREACH OF THE CONFIDENTIALITY AND NON-USE OBLIGATIONS IN ARTICLE 8. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 7.4 WILL LIMIT OR RESTRICT THE
INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY. 
 (b) Liability Caps. 

(i) In no event shall either Party’s Liability pursuant to Section 7.1 or Section 7.2 (as applicable) for breaches of any
representations or warranties contained in Section 6.2(c) (Sufficient Rights) (collectively “Fundamental Breaches”), exceed $[*]. 

(ii) Other than with respect to a Fundamental Breach, in no event will either Party’s liability pursuant to Section 7.1 or
Section 7.2 (as applicable) for breaches of the representations and warranties set forth in Section 6.1 and Section 6.2 exceed the Cap. 

(iii) The limitations on Liability set forth in this Section 7.4(b) shall not apply to any Liabilities arising from fraud by Takeda.

 (c) Basket. Other than with respect to a Fundamental Breach, a Party shall not be liable to the other Party for breaches of the
representations and warranties contained in this Agreement unless with respect to any such individual breach, the aggregate Losses arising from such individual breach exceed $[*] (the “Basket”), at which point the breaching Party
will indemnify the harmed party for the amount of such Losses in excess of the Basket, subject to the other limitations contained in this Article 7. Losses arising from any potential indemnification claims that arise out of or involve or relate to
similar facts or are based on related or similar occurrences, events or circumstances will be aggregated and treated as a single breach for purposes of this Section 7.4(c). 

(d) Survival. The representations and warranties contained in this Agreement shall survive the Effective Date until (i) [*] of the
Effective Date for Claims arising from or related to any Fundamental Breaches, and (ii) [*] following the Effective Date for all other Claims arising from or related to any other breach of any representation or warranty set forth in this Agreement,
and all rights to indemnification hereunder for any breach of any representation or warranty will terminate and expire on, and no action or proceedings seeking damages or other relief for breach of any representation or warranty or for
misrepresentation or inaccuracy may be commenced after, such applicable anniversary. The covenants and agreements contained herein shall survive until the expiration of the relevant statute of limitations period. 

  
 32 

 (e) Insurance Recovery. Notwithstanding the foregoing, the indemnifiable Losses shall
be net of the amount of any insurance proceeds actually received by the Indemnified Party, and each Indemnified Party agrees to file claims under each of its applicable insurance policies and to use commercially reasonable efforts to pursue all such
insurance claims (but shall not include an obligation to commence litigation), and any indemnity or contribution amounts actually recovered by such Indemnified Party for the applicable matter hereunder. 

(f) Exclusive Remedy. Each of the Parties acknowledges and agrees that from and after the Effective Date, the indemnification
provisions of Article 7 shall be the sole and exclusive remedy of the Takeda Indemnitees and Day One Indemnitees with respect to the Contemplated Transactions, except as set forth in Section 10.3. 

7.5 Insurance. Day One will maintain insurance during any time it is undertaking Development and Commercialization of any
Product or the Compound and for a period of at least [*] thereafter with a reputable, solvent insurer (carrier rating of AM Best A-VII (or equivalent or better)) in at least the following amounts: product
liability insurance with limits of liability not less than [*] per occurrence and [*] in the aggregate. Day One will provide Takeda with evidence of the existence and maintenance of such insurance coverage. Takeda and its Affiliates and its and
their respective employees, officers, directors, shareholders, consultants, authorized agents, and assigns will be named as additional insureds under all of the foregoing policies of insurance obtained by Day One. 

ARTICLE 8 

CONFIDENTIALITY AND PUBLICITY 

8.1 Nondisclosure. It is understood and agreed by the Parties that: 

(a) during the Term and for a period of [*] thereafter, a Party (the “Receiving Party”) receiving Confidential Information of
the other Party (the “Disclosing Party”) will (i) maintain in confidence such Confidential Information using at least the same degree of care with which such Receiving Party uses to maintain in confidence its own confidential
or proprietary information of similar kind and value (but in no event less than a reasonable degree of care), (ii) not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing Party, except for
disclosures expressly permitted below, and (iii) not use such Confidential Information for any purpose except those permitted by this Agreement (it being understood that this Section 8.1 will not create or imply any rights, licenses or
covenants not expressly granted under this Agreement). Notwithstanding any provision to the contrary in this Agreement, the obligations of confidentiality and non-use with respect to any trade secret within
such Confidential Information will survive such [*] period for so long as such Confidential Information remains protected as a trade secret under Applicable Law; 

(b) the Licensed Know-How will be considered the Confidential Information of Takeda; 

(c) the terms and conditions of this Agreement will be considered the Confidential Information of both Parties; and 

(d) as of the Effective Date, Day One will be deemed the Disclosing Party, and Takeda the Receiving Party, with respect to any and all Know-How or other proprietary information and materials within the Acquired Assets. 

  
 33 

 8.2 Exceptions. The obligations in Section 8.1 will not apply with
respect to any portion of the Confidential Information that the Receiving Party can show by competent evidence: 
 (a) is publicly disclosed
by the Disclosing Party, either before or after it is disclosed to the Receiving Party hereunder; 
 (b) is known to the Receiving Party or
any of its Affiliates, without any obligation to keep it confidential or any restriction on its use, prior to disclosure by the Disclosing Party, as evidenced by contemporaneous written records; provided that, as of the Effective Date, the
exception in this clause (b) shall not apply to Takeda or any of its Affiliates as the Receiving Party with respect any Confidential Information within the Acquired Assets; 

(c) is subsequently disclosed to the Receiving Party or any of its Affiliates on a non- confidential
basis by a Third Party that, to the Receiving Party’s knowledge, is not bound by a similar duty of confidentiality or restriction on its use; 

(d) is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party or any of its Affiliates, generally
known or available, either before or after it is disclosed to the Receiving Party; 
 (e) is independently discovered or developed by or on
behalf of the Receiving Party or any of its Affiliates without the use of Confidential Information belonging to the Disclosing Party; provided that, as of the Effective Date, the exception in this clause (e) shall not apply to Takeda or
any of its Affiliates as the Receiving Party with respect any Confidential Information within the Acquired Assets; or 
 (f) is the subject
of written permission to disclose provided by the Disclosing Party. 
 8.3 Authorized Disclosure. The Receiving Party may
disclose Confidential Information belonging to the Disclosing Party without the prior written approval of the Disclosing Party only to the extent such disclosure is reasonably necessary in the following instances: 

(a) Prosecuting Patent Rights as permitted by this Agreement; 

(b) preparing and submitting Regulatory Submissions and obtaining and maintaining Regulatory Approvals as permitted by this Agreement; 

(c) prosecuting or defending litigation, including responding to a subpoena in a Third Party litigation; 

(d) complying with Applicable Law or court or administrative orders; or 

(e) in communications with existing or bona fide prospective acquirers, merger partners, collaboration partners, lenders or investors, and
consultants and advisors of the Receiving Party in connection with transactions or bona fide prospective transactions with the foregoing, in each case on a
“need-to-know” basis and under confidentiality provisions at least as restrictive or protective of the Parties as those set forth in this Agreement or
otherwise customary for such type and scope of disclosure any such disclosure is limited to the maximum extent practicable for the particular context in which it is being disclosed; 

  
 34 

 (f) to allow the Receiving Party to exercise its rights and perform its obligations
hereunder, provided that such disclosure is covered by terms of confidentiality and non-use at least as restrictive as those set forth herein; 

(g) to comply with Applicable Law (whether generally or in pursuit of an application for listing of securities) including the SEC or
equivalent foreign agency or regulatory body, or otherwise required by judicial or administrative process, provided that in each such event, as promptly as reasonably practicable and to the extent not prohibited by Applicable Law or judicial or
administrative process, such Party will notify the other Party of such required disclosure and provide a draft of the disclosure to the other Party reasonably in advance of such filing or disclosure for the other Party’s review and comment. The
non- disclosing Party will provide any comments as soon as practicable, and the disclosing Party will consider in good faith any timely comments provided by the
non-disclosing Party; provided that the disclosing Party may or may not accept such comments in its sole discretion. Confidential Information that is disclosed in order to comply with Applicable Law or by
judicial or administrative process pursuant to this Section, in each case, will remain otherwise subject to the confidentiality and non-use provisions of this Article 8 with respect to the Party disclosing
such Confidential Information, and such Party will take all steps reasonably necessary, including seeking of confidential treatment or a protective order for a period of at least [*] (to the extent permitted by Applicable Law or Governmental
Authority), to ensure the continued confidential treatment of such Confidential Information, and each Party will be responsible for its own legal and other external costs in connection with any such filing or disclosure pursuant to this
Section 8.3(g); 
 (h) where Takeda is the Receiving Party, to its Affiliates for Takeda’s or its Affiliates’ internal
research and development of Products under this Agreement; and 
 (i) to its Affiliates, sublicensees or prospective sublicensees,
contractors, subcontractors or prospective contractors or subcontractors, consultants, agents, insurers, lenders and financial and other advisors on a
“need-to-know” basis in order for the Receiving Party to exercise its rights or fulfill its obligations under this Agreement, each of whom prior to disclosure
must be bound by obligations of confidentiality and restrictions on use of such Confidential Information that are at least as restrictive or protective of the Parties as those set forth in this Agreement or otherwise customary for such type and
scope of disclosure any such disclosure is limited to the maximum extent practicable for the particular context in which it is being disclosed; provided, however, that, the Receiving Party will remain responsible for any failure by any Person who
receives Confidential Information pursuant to Section 8.3(e) or this Section 8.3(i) to treat such Confidential Information as required under this Article 8. 

If and whenever any Confidential Information is disclosed in accordance with this Section 8.3, such disclosure will not cause any such information to
cease to be Confidential Information except to the extent that such disclosure results in a public disclosure of such information (other than by breach of this Agreement). In the event a Party is required to make a disclosure of the other
Party’s Confidential Information pursuant to clauses (a) through (d) of this Section 8.3, it will, except where impracticable, give reasonable advance notice to the other Party of such disclosure and use not less than the same efforts
to secure confidential treatment of such information as it would to protect its own confidential information from disclosure, permit the Disclosing Party to use its reasonable efforts to secure confidential treatment of such Confidential Information
prior to such disclosure (whether through protective orders or otherwise), cooperate with the Disclosing Party in the exercise of its right to protect the confidentiality of the Confidential Information, and disclose only that Confidential
Information which is required to be disclosed. 
 8.4 Public Disclosures. Neither Party may issue a press release or other
public statement, whether oral or written, disclosing the existence of this Agreement, the terms hereof, or any information relating hereto without the prior written consent of the other Party, except as otherwise provided for in this

  
 35 

 
Article 8, including pursuant to Section 8.3(g). Each Party agrees that any such announcement will not contain Confidential Information of the other Party or, if disclosure of such
Confidential Information is required by Applicable Law or the rules of the SEC, any stock exchange or listing entity, will make reasonable efforts to minimize such disclosure and obtain confidential treatment for any such information that is
disclosed to a government agency. Upon the request of Day One, the Parties may issue one or more press releases regarding the signing of this Agreement, each of which must be approved in writing by the other Party. After the issuance of such press
release or other public disclosure by a Party, the disclosing Party may make subsequent public disclosures reiterating such information without having to obtain the other Party’s prior consent and approval so long as the information in such
press release or other public announcement remains true, correct, and the most current information with respect to the subject matters set forth therein. 

8.5 Use of Names. Neither Party (nor any of its Affiliates or agents) will use the registered or unregistered Trademarks of the
other Party or its Affiliates in any press release, publication, or other form of promotional disclosure without the prior written consent of the other Party in each instance. 

8.6 Publications. The Parties recognize the desirability of publishing and publicly disclosing the results of, and scientific
information regarding, activities under this Agreement. Accordingly, each Party will be free to publish and present the results of and information regarding activities under this Agreement in such Party’s field as provided in this
Section 8.6 in a manner consistent with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 8.6, including International
Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Takeda and its Affiliates may, subject to the prior written consent of Day One (in its sole discretion), publish or present any results and
information initially submitted for publication or presentation prior to the Effective Date. Notwithstanding the foregoing, Takeda will not be required to seek Day One’s prior written approval to publish or present the publications set forth on
Schedule 8.6. Takeda and its Affiliates will not publish or present any results and information that were not initially submitted for publication or presentation prior to the Effective Date, without the prior written consent of Day One (in its sole
discretion). Each Party shall submit to the other Party for review and approval the portion of any proposed publication or public presentation under this Section 8.6 that contains such other Party’s Confidential Information (the
“Review Material”). Written copies of the Review Material will be submitted to the non-publishing Party no later than [*] before submission for publication or presentation, and the non-publishing Party will provide its comments with respect to the Review Material no later than [*] after its receipt of such written copy. 

ARTICLE 9 
 TERM AND
TERMINATION 
 9.1 Term. This Agreement will become effective on the Effective Date and unless earlier terminated pursuant
to this Article 9, will remain in effect until the expiration of all Assigned Patent Rights and Licensed Patent Rights on a country-by-country-basis in the Territory
(the “Term”). 
 9.2 Causes for Termination. 

(a) Termination for Failure to Issue Equity. Subject to the provisions of Section 9.6, Takeda may, at any time upon written notice
to Day One during the [*] period following the Effective Date, terminate this Agreement [*] after providing written notice to Day One, if Day One does not issue to Takeda the Series A Preferred Stock in accordance with Section 3.2 and cure such
default within [*] of the date of such notice from Takeda. In the event of any Dispute regarding the issuance of the Takeda the Series A Preferred Stock in accordance with Section 3.2, such [*] period during which Takeda has the right to
terminate this Agreement upon [*] written notice for Day One’s failure to issue to Takeda such Series A Preferred Stock in accordance with Section 3.2 will be tolled pending resolution of such Dispute pursuant to Section 9.6. 

  
 36 

 (b) Termination for Cessation of Development or Commercialization Activities. During
the Term, and prior to the first commercial sale of any Product by or on behalf of Day One, its Affiliates or Related Parties, if Day One, its Affiliates or Related Parties do not conduct any Development activities with respect to at least one
Product for a continuous period of longer than [*], and such suspension of activity is not: (i) by written agreement of the Parties, or (ii) a result of Day One’s reasonable response to guidance from or action by a Regulatory
Authority in the Territory (such as a clinical hold, or a Recall or withdrawal), then Takeda may, at its election, terminate this Agreement upon [*] prior written notice to Day One. 

(c) Termination for Bankruptcy. 

(i) This Agreement may be terminated by Takeda upon the filing or institution of bankruptcy, reorganization, liquidation or receivership
proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by Day One; provided, however, that in the event of any involuntary bankruptcy or receivership proceeding such right to terminate
will only become effective if Day One consents to the involuntary bankruptcy or receivership or such proceeding is not dismissed within [*] after the filing of such bankruptcy or receivership. 

(ii) All licenses and rights to licenses granted under or pursuant to this Agreement by each Party to the other Party are, and will otherwise
be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code (the “Bankruptcy Code”), licenses of rights to “intellectual property” as defined under Section 101(35A) of the Bankruptcy
Code. The Parties agree that each Party, as a licensee of certain rights under this Agreement, will retain and may fully exercise all of its rights and elections under the Bankruptcy Code. The Parties further agree that upon commencement of a
bankruptcy proceeding by or against a Party under the Bankruptcy Code, the other Party will be entitled to a complete duplicate of, or complete access to (as such other Party deems appropriate), all such Intellectual Property and all embodiments of
such Intellectual Property. Such intellectual property and all embodiments of such intellectual property will be promptly delivered to such other Party (A) upon any such commencement of a bankruptcy proceeding and upon written request by such
other Party, unless the Party subject to such bankruptcy proceeding elects to continue to perform all of its obligations under this Agreement, or (B) if not delivered under (A) above, upon the rejection of this Agreement by or on behalf of
the Party subject to such bankruptcy proceeding and upon written request by such other Party. Each Party (in any capacity, including debtor-in-possession) and its
successors and assigns (including any trustee) agrees not to interfere with the exercise by the other Party or its Affiliates of its rights and licenses to such Intellectual Property and such embodiments of Intellectual Property in accordance with
this Agreement, and agrees to assist the other Party and its Affiliates in obtaining such Intellectual Property and such embodiments of Intellectual Property in the possession or control of Third Parties as reasonably necessary or desirable for the
other Party to exercise such rights and licenses in accordance with this Agreement. The foregoing provisions are without prejudice to any rights Takeda or Day One may have arising under the Bankruptcy Code or other Applicable Law. 

9.3 Effects of Termination. Upon any termination of this Agreement, all rights and obligations of the Parties will terminate
except as provided in this Section 9.3 and Section 9.5. Upon the termination of this Agreement pursuant to Section 9.2: 

(a) Licenses. As of the effective date of termination of this Agreement, all licenses and all other rights granted by Takeda to Day One
under the Licensed Intellectual Property and Takeda Developed Technology will terminate and all sublicenses granted by Day One pursuant to Section 2.4(b) 

  
 37 

 
will also terminate; provided that, upon the request of any (sub)licensee of Day One not then in breach of its (sub)license agreement or the terms of this Agreement applicable to such
sublicensee, Takeda will enter into a direct license from Takeda to such sublicensee on the same terms as this Agreement, taking into account any difference in license scope, territory, and duration of such sublicense grant. In addition, upon the
termination of this Agreement, Takeda will have, and Day One hereby grants to Takeda, effective upon such termination, a worldwide, exclusive, royalty-bearing, perpetual, and irrevocable (subject to Takeda’s compliance with its payment
obligations, to be determined as further described below, including the applicable notice and cure period), and sublicensable (through multiple tiers) license under the Know-How developed or invented by or on
behalf of Day One in the performance of activities related to the Products or the Compound in the Day One Field and all Patents Rights with a priority date after the Effective Date that Cover any such
Know-How, in each case, to the extent Controlled by Day One, to Exploit Products in any and all fields of use, and for a period of [*] following the date of such Termination the Parties will negotiate in good
faith commercially reasonable economic terms, including a notice and cure period for the breach of any payment obligations under such economic terms, with respect to the foregoing license of rights; provided that, if the Parties fail to reach
agreement during such [*] period, such matter will be resolved in accordance with Section 9.6. In addition, Day One will assign to Takeda the Sunesis License and any Third Party IP Agreement pursuant to which Day One then Controls any
Intellectual Property necessary or useful to Exploit Products in the Day One Field, if permitted under such Third Party IP Agreement and, if such Third Party IP Agreement cannot be assigned to Takeda, to cooperate with Takeda’s reasonable
efforts to obtain a license directly from such Third Party. Following such termination, Day One will (i) transfer or assign, or have transferred or assigned, to Takeda or its designee Regulatory Submissions and Regulatory Approvals for the
Products then owned by Day One; (ii) transfer or assign, or have transferred or assigned, to Takeda or its designee Day One’s rights, title, and interests in and to all clinical trial agreements, manufacturing and supply agreements, and
distribution agreements (to the extent assignable and not cancelled), confidentiality and other agreements, data and other Know-How (including commercial information) that are owned by Day One or to which Day
One is a party, in each case, relating to any Product and that are necessary or useful for the Exploitation of such Products, to the extent that each such contract is assignable; (iii) transfer or assign, or have transferred or assigned, to
Takeda or its designee all of Day One’s or its Affiliate’s rights, title, and interests in and to any promotional materials, training materials, medical education materials, packaging and labeling, and all other literature or other
information related to the Products and copyrights and any registrations for the foregoing; (iv) transfer or assign, or have transferred or assigned, to Takeda or its designee some or all inventory of each Product (including all final product,
bulk drug substance, intermediates, works-in-process, formulation materials, reference standards, drug product clinical reserve samples, packaged retention samples, and
the like) then in the possession of Day One; (v) (A) provide a one-time technology transfer to Takeda or its designee of information and materials that are necessary or reasonably useful for Takeda or its
designee to Manufacture such Product in each formulation of such Product for which Takeda is granted rights under this Section 9.3, including providing reasonable assistance to Takeda or its designee in connection therewith upon request, and
(B) assign or have assigned to Takeda any agreement that exclusively relates to the Manufacture or supply of such Product in the Territory, to the extent that such contract is assignable; and (vi) if, as of the effective date of such
termination, Day One or its Affiliates are conducting any Clinical Trials for any Product, transfer or have transferred to Takeda or its designees the conduct of such Clinical Trials. 

(b) Assignment and Disclosure. To the extent requested by Takeda following the termination of this Agreement, Day One will promptly
upon request (and in any event within [*] after the effective date of such termination): 
 (i) assign and transfer to Takeda or its
designee all of Day One’s rights, title, and interests in and to all Assigned Agreements, other than the Sunesis License (which shall be assigned to Takeda pursuant to Section 9.3(a)); and 

  
 38 

 (ii) assign and transfer to Takeda or its designee all Assigned Know-How and Assigned Patent Rights. 
 (c) Return of Confidential Information. At the Disclosing
Party’s election, the Receiving Party will return (at Disclosing Party’s expense) or destroy all tangible materials comprising, bearing, or containing any Confidential Information of the Disclosing Party relating to any Product that are in
the Receiving Party’s or its Affiliates’ or sublicensees’ possession or control and provide written certification of such destruction (except to the extent any information is the Confidential Information of both Parties or to the
extent that the Receiving Party has the continuing right to use the Confidential Information under this Agreement); provided that the Receiving Party may retain one copy of such Confidential Information for its legal archives. Notwithstanding
any provision to the contrary set forth in this Agreement, the Receiving Party will not be required to destroy electronic files containing such Confidential Information that are made in the ordinary course of its business information back-up procedures pursuant to its electronic record retention and destruction practices that apply to its own general electronic files and information. 

9.4 Effects of Termination of Grant Back License. Effective as of the termination of the Grant Back License pursuant to
Section 2.6: (a) all licenses and all other rights granted by Day One to Takeda under the Assigned Technology, the Licensed Intellectual Property and the Day One Developed Technology will terminate and all sublicenses granted by Takeda will
also terminate; (b) the field of the exclusive license granted to Day One under Section 2.4(a) will be expanded to include the Takeda Field; (c) Day One will have, and Takeda hereby grants to Day One, effective upon such termination,
a worldwide, exclusive, royalty-bearing, perpetual and irrevocable (subject to Day One’s compliance with its payment obligations, to be determined as further described below, including the applicable notice and cure period), and sublicensable
(through multiple tiers) license under the Know-How developed or invented by or on behalf of Takeda in the performance of activities specifically related to the Takeda Products or the Compound in the Takeda
Field and all Patents Rights with a priority date after the Effective Date that Cover such Know-How, in each case to the extent Controlled by Takeda, to Exploit Takeda Products in any and all fields of use,
and for a period of [*] following the date of such termination the Parties will negotiate in good faith commercially reasonable economic terms, including a notice and cure period for the breach of any payment obligations under such economic terms,
with respect to the foregoing license of rights; provided that, if the Parties fail to reach agreement during such [*] period, such matter will be resolved in accordance with Section 9.6; (d) upon the request of any sublicensee of Takeda
not then in breach of its sublicense agreement or the terms of this Agreement applicable to such sublicensee, Day One will enter into a direct license from with such sublicensee on the same terms as this Agreement, taking into account any difference
in license scope, territory, and duration of the applicable sublicense grant and provided that Day One shall not be required to undertake any obligations in such direct license that are greater in scope than those set forth in this Agreement, unless
Day One otherwise agrees in writing; (e) Takeda will have no further control over or decision-making authority with respect to the Development and Manufacture of Takeda Products for the use in the Takeda Field in the Territory and the Compound
for use in such Takeda Products pursuant to Section 4.4 and Day One will have sole control over and decision- making authority with respect to Development and Manufacture of the Compound and the Products; (f) the JDC will terminate
pursuant to Section 4.5(e); (g) Takeda will have no further control over or decision-making authority with respect to the Commercialization of Takeda Products in the Takeda Field in the Territory pursuant
to Section 4.6 and Day One will have sole control over and decision-making authority with respect to the Commercialization of the Products in the Territory; (h) Takeda will have no further control over or decision-making authority with
respect to the Manufacture and distribution of all clinical and commercial supplies of the Takeda Products for use in the Takeda Field and the Compound for use in the Manufacture of such Takeda Products pursuant to Section 4.7 and Day One will
have sole control over and decision-making authority with respect to the Manufacturing and distribution of all clinical and commercial supplies of the Compound and the Products in the Territory; (i) Day One will have no further obligation to
provide 

  
 39 

 
Takeda with copies of proposed material Regulatory Submissions pursuant to Section 4.8(b); (j) Takeda will have no further responsibility for, control over, or decision-making authority with
respect to all regulatory activities for the Takeda Products pursuant to Section 4.8(c) and Day One will have final decision making authority regarding all regulatory activities, including the Labeling strategy and the content of submissions
with respect to the Compound and all Products; (k) Day One will have no further obligations and Takeda will have no further rights pursuant Section 4.8(d); (l) Day One’s obligations under Section 4.8(f) will terminate and
Takeda’s rights pursuant Section 4.8(f), including Takeda’s right of reference granted pursuant to Section 4.8(f); (m) the Pharmacovigilance Agreement will terminate; (n) the Parties’ will have no further rights or
obligations pursuant Section 4.9(b), including the obligation to exchange safety data relating to the Products and the Compound pursuant to Section 4.9(b); (o) the Parties will have no further obligation to share Labeling information and
Takeda will no longer have final decision-making authority with respect to Labeling for each Takeda Product pursuant to Section 4.11; (p) each Party will have no further Know-How disclosure obligation pursuant to Section 5.2; (q) Day One will have no further obligation to keep Takeda informed of all substantive matters relating to Prosecution of the Assigned Patent Rights and
to consider Takeda’s comments with respect thereto pursuant to Section 5.3(a); (r) Day One will have no obligations and Takeda will have no further rights pursuant to Section 5.4, including Takeda’s rights with respect to the
enforcement of the Assigned Patent Rights pursuant to Section 5.4; (s) Day One will have no obligations and Takeda will have no further rights pursuant to Section 5.5, including with respect to the defense of any Third Party Action
pursuant to Section 5.5; (t) Day One will have no obligations and Takeda will have no further rights pursuant to Section 5.7, including Takeda’s right to review and comment on any Patent Right listing pursuant to Section 5.7; (u)
Day One will have no obligations and Takeda will have no further rights pursuant Section 5.8, including Takeda’s right to review and comment on Day One’s Product Trademarks pursuant to Section 5.8; (v) each Party will have no
further obligations pursuant Section 6.3(b), including to notify the other party of any regulatory action by any Regulatory Authority relating to any Product pursuant to Section 6.3(b); and (w) each Party will have no further
obligations pursuant Section 6.3(e), including to notify the other party of any Serious Adverse Event relating to any Product pursuant to Section 6.3(e). 

9.5 Survival. The following provisions will survive any expiration or termination of this Agreement for the period of time
specified in such provision, or if not specified, then they will survive indefinitely: Article 1 (to the extent necessary for the interpretation of the other surviving Sections and Articles hereof), Article 2 (solely in the case of expiration in
accordance with Section 9.1), Section 3.4, Section 5.1 (solely in the case of expiration in accordance with Section 9.1), Section 5.5 (solely in the case of expiration in accordance with Section 9.1), Section 5.7
(solely in the case of expiration in accordance with Section 9.1), Section 5.8 (solely in the case of expiration in accordance with Section 9.1), Section 6.4, Article 7, Article 8, Article 9, and Article 10. Termination of this
Agreement will not relieve the Parties of any liability which accrued under this Agreement prior to the effective date of such termination nor preclude either Party from pursuing all rights and remedies it may have under this Agreement or at law or
in equity with respect to any breach of this Agreement. The remedies provided in this Article 9 are not exclusive of any other remedies a Party may have in law or equity. 

9.6 Dispute Resolution. If the Parties are unable to resolve any dispute arising out of or in connection with this Agreement
(each a “Dispute”), either Party may, by written notice to the other, have such Dispute referred to senior executive officers designated by each Party, or their respective designees for attempted resolution by good faith
negotiations within [*] after such notice is received. In such event, the Parties will cause their respective officers or their designees to meet (face-to-face or by
teleconference) and be available to attempt to resolve such issue. If the Parties should resolve such Dispute, a memorandum setting forth their agreement will be prepared and signed by both Parties at either Party’s request. If the Parties are
unable to resolve any Dispute, either Party may submit the matter for resolution pursuant to Section 9.7. 

  
 40 

 9.7 Litigation. Any unresolved Dispute that was subject to Section 9.6,
will be brought exclusively in a court of competent jurisdiction, federal or state, located in the State of Delaware, and in no other jurisdiction. Each Party hereby irrevocably consents to personal jurisdiction and venue in, and irrevocably agrees
to service of process issued or authorized by any such court in any such action or proceeding. The Parties hereby irrevocably waive any objection that they may now have or hereafter have to the laying of venue in the federal or state courts of
Delaware in any such action or proceeding, and hereby irrevocably waive and agree not to plead or claim in any such court that any such action or proceeding brought in any such court has been brought in an inconvenient forum. The Parties hereby
agree that any final judgment rendered by any such federal or state court of Delaware in any action or proceeding involving any Dispute, from which no appeal can be or is taken, may be enforced by the prevailing Party in any court of competent
jurisdiction. 
 9.8 Preliminary Injunctions. Notwithstanding any provision to the contrary set forth in this Agreement, in
the event of an actual or threatened breach of a Party’s obligations under this Agreement, a Party may seek a temporary restraining order or a preliminary injunction from any court of competent jurisdiction in order to prevent immediate and
irreparable injury, loss, or damage on a provisional basis. 
 9.9 Patent and Trademark Disputes. Notwithstanding any
provision to the contrary set forth in this Agreement, any and all issues regarding the scope, construction, validity, and enforceability of any Patent Rights or trademark relating to a Product that is the subject of this Agreement will be
determined in a court or other tribunal, as the case may be, of competent jurisdiction under the applicable patent or trademark laws of the country in which such Patent Rights or trademark rights were granted or arose. 

9.10 Confidentiality. Any and all activities conducted under this Article 9, including any and all proceedings and decisions
hereunder, will be deemed Confidential Information of each of the Parties, and will be subject to Article 8, to the extent applicable in accordance with Applicable Law. 

ARTICLE 10 

MISCELLANEOUS 
 10.1
Entire Agreement; Amendment. This Agreement, including the Exhibits and Schedules attached to and incorporated into this Agreement, sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements,
warranties, representations, conditions and understandings between the Parties with respect to the subject matter of this Agreement and supersedes and terminates all prior agreements and understandings between the Parties with respect to such
subject matter, including the Confidentiality Agreement, provided that all “Confidential Information” disclosed or received by Day One and Takeda thereunder is deemed “Confidential Information” hereunder and subject to the terms
and conditions of this Agreement. No subsequent alteration, amendment, change or addition to this Agreement will be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. 

10.2 Governing Law. This Agreement will be construed in accordance with, and governed in all respects by, the laws of the State
of Delaware (without giving effect to principles of conflicts of laws that would require the application of any other law); provided that matters of intellectual property law will be determined in accordance with the United States federal law. The
Parties hereby submit to the jurisdiction of the state courts in the State of Delaware and federal courts located in the District of Delaware, and waive any defense of inconvenient forum to the maintenance of any action or proceeding in such courts.

 10.3 Specific Performance. Subject Section 10.2, in addition to any and all other remedies that may be available at
law in the event of breach of this Agreement, the non-breaching Party will be entitled to seek specific performance of the agreements and obligations of the breaching Party hereunder and to such injunctive or
other equitable relief as may be granted by a court of competent jurisdiction. 

  
 41 

 10.4 Cumulative Remedies. No remedy referred to in this Agreement is intended
to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law or in equity. 

10.5 Force Majeure. Each Party will be excused from the performance of its obligations under this Agreement, except with respect
to any payment obligations, to the extent that such performance is prevented by a force majeure event and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse will be continued so long as the condition
constituting force majeure continues and the nonperforming Party uses reasonable efforts to remove the condition. For purposes of this Agreement, force majeure will include conditions beyond the reasonable control of the Parties, including an act of
God or terrorism, voluntary or involuntary compliance with any regulation, law or order of any government, war, civil commotion, labor strike or lock-out, epidemic, failure or default of public utilities or
common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe. 
 10.6
Notices. Any notice required or permitted to be given under this Agreement will be in writing, will specifically refer to this Agreement and will be deemed to have been sufficiently given for all purposes upon receipt if delivered (a) by
first class certified or registered mail, postage prepaid, (b) international express delivery service, (c) personally or (d) via facsimile or other electronic transmission with confirmation of receipt. Unless otherwise specified in
writing, the notice addresses of the Parties will be as described below. 
  

					
		 	 For Day One:
	 	 DOT Therapeutics-1, Inc.

[*]

			
		 	 With a copy to:
	 	 Cooley LLP

[*]

			
		 	 For Takeda:
	 	 Millennium Pharmaceuticals, Inc.

[*]

			
		 	 With copies to:
	 	 Millennium Pharmaceuticals, Inc.

[*]

 10.7 Assignment. Neither Party may assign or transfer this Agreement or any rights or
obligations under this Agreement without the prior written consent of the other Party, except that, subject to Section 10.8, a Party may make such an assignment or transfer without the other Party’s consent (a) if the assigning Party
is Takeda, to Takeda’s Affiliates or (b) to the successor upon the merger, consolidation, reorganization, acquisition of stock or other change of control transaction (each of the foregoing, a “Change of Control
Transaction”), or upon a sale of assets affecting substantially all of the assets of a Party (an “Asset Sale”). Except in connection with a Change of Control Transaction, Day One may not assign this Agreement or any of its
rights or obligations hereunder to any Affiliate, without the prior written consent of Takeda, which consent will not be unreasonably withheld, conditioned or delayed. Any permitted successor or assignee of rights or obligations under this Agreement
will expressly assume performance of such rights or obligations. Any permitted assignment will be binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this
Section 10.7 will be null and void. 
 10.8 Performance by Affiliates. Each of Takeda and Day One acknowledge that a
Party’s obligations under this Agreement may be performed by its Affiliates. Notwithstanding any delegation of obligations under this Agreement by a Party to its Affiliate, such Party will remain primarily liable and

  
 42 

 
responsible for the performance of all of its obligations under this Agreement and for causing its Affiliates to act in a manner consistent with this Agreement. Wherever in this Agreement a Party
delegates responsibility to its Affiliates or local operating entities, the Parties agree that such entities will not make decisions inconsistent with this Agreement, amend the terms of this Agreement or act in breach of its terms. 

10.9 Independent Contractors. It is understood and agreed that the relationship between the Parties is that of independent
contractors and that nothing in this Agreement will be construed as creating a partnership for tax purposes or as an authorization for either Party to act as the agent for the other Party. 

10.10 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other
acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 10.11
Severability. Each provision in this Agreement is independent and severable from the others, and no provision will be rendered unenforceable because any other provision may be invalid or unenforceable in whole or in part. If the scope of any
restrictive provision in this Agreement is too broad to permit enforcement to its full extent, then such restriction will be reformed to the maximum extent permitted by law. 

10.12 Headings. The headings for each Article and Section in this Agreement have been inserted for convenience of reference only
and are not intended to limit or expand on the meaning of the language contained in the particular Article or Section. 
 10.13 No
Waiver. Any delay in enforcing a Party’s rights under this Agreement, or any waiver as to a particular default or other matter, will not constitute a waiver of such Party’s rights to the future enforcement of its rights under this
Agreement, except with respect to an express written and signed waiver relating to a particular matter for a particular period of time. 

10.14 Interpretation. Except where the context otherwise requires, wherever used, the singular includes the plural, the plural
the singular, the use of any gender applies to all genders. The word “or” has the inclusive meaning that is typically associated with the phrase “and/or”; the word “and” is used in the conjunctive sense. The term
“including,” “include,” or “includes” means including, without limiting the generality of any description preceding such term. Unless the context requires otherwise, (i) any definition of or reference to any
agreement, instrument or other document will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or
modifications set forth herein or therein), (ii) any reference to any applicable laws will be construed as referring to such laws as from time to time enacted, repealed or amended, (iii) any reference to any person will be construed to include
the person’s successors and permitted assigns, (iv) the words “herein”, “hereof” and “hereunder”, and words of similar import, will be construed to refer to this Agreement in its entirety and not to any
particular provision hereof, (v) any reference to the words “mutually agree” or “mutual written agreement” will not impose any obligation on either Party to agree to any terms relating thereto or to engage in discussions
relating to such terms except as such Party may determine in such Party’s sole discretion, (vi) all references to Sections, Exhibits or Schedules will be construed to refer to Sections, Exhibits and Schedules to this Agreement,
(vii) the word “days” means calendar days unless otherwise specified, and (viii) the words “copy” and “copies” and words of similar import when used in this Agreement include, to the extent available,
electronic copies, files or databases containing the information, files, items, documents or materials to which such words apply. 

10.15 No Strict Construction. Each Party represents that it has been represented by legal counsel in connection with this
Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which drafted such terms and
provisions. 

  
 43 

 10.16 Counterparts. This Agreement may be executed in two (2) or more
counterparts, each of which will be deemed an original, but all of which together will constitute one (1) and the same instrument. For purposes of executing this Agreement, a facsimile copy of this Agreement, or .pdf copy, including the
signature pages, will be deemed an original. 
 [Signature page follows] 

  
 44 

 IN WITNESS WHEREOF the Parties have executed this Agreement in duplicate originals by
their duly authorized officers as of the Effective Date. 
  

									
	DOT THERAPEUTICS-1, INC.	 		 	MILLENNIUM PHARMACEUTICALS, INC.
					
	By:	 	/s/ Julie Papanek Grant	 		 	By:	 	/s/ [*]                    
					
	Name:	 	Julie Papanek Grant	 		 	Name:	 	[*]                        
					
	Title:	 	Chief Executive Officer	 		 	Title:	 	[*]                

  
 [Signature Page to
Asset Transfer and License Agreement] 

 Schedule 1.7 

Assigned Agreements 

 Schedule 1.9 

Assigned Know-How 

 Schedule 1.10 

Assigned Patent Rights 

 Schedule 1.10 

Assigned Regulatory Submissions 

 Schedule 1.58 

Licensed Know-How 

 Schedule 1.59 

Licensed Patents 

 Schedule 1.96 

Takeda Field 

 Schedule 2.1(e) 

Assigned Inventory 

 Schedule 2.1 

Bill of Sale 

 Schedule 2.2 

Patent Right Assignment 

 Schedule 2.4(c) 

Assays for Determination of Target Selectivity 

 Schedule 4.1 

Transfer Plan 

 Schedule 4.15 

Patent Assignments 

 Schedule 4.14(a) 

Sunesis License Payment Obligations 

 Schedule 8.6 

Publications 

 Exhibit A 

Stock Issuance Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}]]